Towards a Hand-Held Multi-Biomarker Point-of-Care Diagnostic to Quantify Traumatic Brain Injury by Cardinell, Brittney Ann (Author) et al.
Towards a Hand-Held Multi-Biomarker Point-Of-Care Diagnostic to Quantify  
Traumatic Brain Injury  
by 
Brittney Cardinell 
 
 
 
 
 
 A Dissertation Presented in Partial Fulfillment  
of the Requirements for the Degree  
Doctor of Philosophy  
 
 
 
 
 
 
 
 
 
 
Approved June 2017 by the 
Graduate Supervisory Committee:  
 
Jeffrey LaBelle, Chair 
Mark Spano 
Jeffrey Kleim 
Sarah Stabenfeldt 
Curtiss Cook 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
ARIZONA STATE UNIVERSITY  
August 2017  
  i 
ABSTRACT  
  
According to sources of the Centers for Disease Control and Prevention, approximately 1.7 million 
traumatic brain injury (TBI) cases occur annually in the United States. TBI results in 50 thousand 
deaths, nearly 300 thousand hospitalizations and 2.2 million emergency room visits causing a $76 
billion economic burden in direct and indirect costs. Furthermore, it is estimated that over 5 million 
TBI survivors in the US are struggling with long-term disabilities. And yet, a point-of-care TBI 
diagnostic has not replaced the non-quantitative cognitive and physiological methods used today. 
Presently, pupil dilation and the Glasgow Coma Scale (GCS) are clinically used to diagnose TBI. 
However, GSC presents difficulties in detecting subtle patient changes, oftentimes leaving mild TBI 
undiagnosed. Given the long-term deficits associated with TBIs, a quantitative method that enables 
capturing of subtle and changing TBI pathologies is of great interest to the field. 
 
The goal of this research is to work towards a test strip and meter point-of-care technology (similar 
to the glucose meter) that will quantify several TBI biomarkers in a drop of whole blood 
simultaneously. It is generally understood that measuring only one blood biomarker may not 
accurately diagnose TBI, thus this work lays the foundation to develop a multi-analyte approach to 
detect four promising TBI biomarkers: glial fibrillary acidic protein (GFAP), neuron specific enolase 
(NSE), S-100β protein, and tumor necrosis factor-α (TNF-α). To achieve this, each biomarker was 
individually assessed and modeled using sensitive and label-free electrochemical impedance 
techniques first in purified, then in blood solutions using standard electrochemical electrodes. Next, 
the biomarkers were individually characterized using novel mesoporous carbon electrode materials 
to facilitate detection in blood solutions and compared to the commercial standard Nafion coating. 
Finally, the feasibility of measuring these biomarkers in the same sample simultaneously was 
explored in purified and blood solutions. This work shows that a handheld TBI blood diagnostic is 
feasible if the electronics can be miniaturized and large quantity production of these sensors can 
be achieved. 
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PREFACE  
Some of the work in this dissertation document has been previously published in the 7th 
book chapter of Biosensors and Biodetection: Methods and Protocols, Vol. 2 [1], in an original 
article invited to the 2015 special issue of Biosensors and Bioelectronics [2], and in an original 
article published in 2013 by Analytica Chimica Acta [3].  These works are modified and expanded 
upon in this document.
  1 
CHAPTER 1 
INTRODUCTION 
1.1 Epidemiology and Pathophysiology of Traumatic Brain Injury (TBI) 
In 2013, approximately 2.8 million traumatic brain injury (TBI) cases occur in the United States; TBI 
resulted in 50 thousand deaths, nearly 300 thousand hospitalizations and 2.5 million emergency 
room visits, instigating an annual $76 billion economic burden in direct and indirect healthcare costs 
[4]–[6]. In 2010, the average estimated cost was $45,000 per injury in the US [7]. Moreover, it is 
estimated that over 40% of TBI survivors in the US are struggling with long-term cognitive, physical 
and/or sensory disabilities, further contributing to lifetime healthcare TBI costs estimated to be $400 
billion [7], [8]. 
 
Traumatic Brain Injury (TBI) occurs when an insult elicits focal or diffuse mechanical responses 
from brain cells which causes a pathophysiological response [9]–[11]. Focal, multifocal or diffuse 
primary damage occurs with nonspecific cell loss due to distortion of gray and white matter which 
instigates a cascade of secondary responses such as inflammation, blood-brain barrier 
compromise, cell death, excitotoxicity, and neurodegeneration [9], [11]. Several types of head 
injuries exist including closed, penetrating and blast injuries which present different 
pathophysiologies. 
 
Closed head trauma can cause brain damage if the head sustains sufficient forces, impact or rapid 
pressure changes often resulting from sudden deceleration, a fall, a blunt force trauma, or blast 
exposure [11]. Typically, the dura matter is not compromised or penetrated [9]. If the traumatic 
force is large enough, it can overcome the cushioning ability of the cerebral spinal fluid in the 
subarachnoid space and allow the brain to contact the hard and rough skull [9], [12]. However, if 
the traumatic force is not large enough to cause brain-skull contact, rotational, translational, or 
shearing forces can still disconnect axons from their cells bodies and cause pathway disruption [9], 
[11], [12]. Immediately following injury, there is damage to axons, increased neural activity due to 
the loss of regulation over neurotransmitter releases, altered blood flow in the brain, rise in 
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intracranial pressure, and sometimes breakdown of the blood-brain barrier [11]. Following primary 
injury, blood flow disruptions such as hemorrhaging and swelling cause vasospasms and loss of 
cerebral blood flow regulation causing ischemic microenvironments, negatively affecting neural 
cells [10], [13]. Immediate systemic responses to closed head injuries can vary (depending on 
severity) from changes in mental state, loss of consciousness, loss of memory, or reduced reflex 
responses [12]. Eventually, a glial scar is developed (7- 14 days post-injury) by reactive astrocytes 
which discourages future neural development [14], [15]. 
 
Moreover, studies have shown pathological differences between closed head injuries resulting from 
decelerations (typically car accidents), and blast exposure injuries [11], [16], [17]. This suggests 
that different biomarkers may be relevant depending on how the injury was sustained. In the field 
of TBI, other classifications of closed injury are emerging including Chronic Traumatic 
Encephalopathy (CTE), where multiple TBIs are sustained over time and is typically discovered 
post mortem after staining analysis of cleaved tau proteins [12]. Multiple studies have reported that 
those who repeatedly sustained TBIs and experienced repeated axon shearing often exhibited 
neurodegenerative physiologies (e.g. dementia, cognitive impairment) [12], [17]–[19]. 
 
Penetrating injuries occur when an object breaks through the skull and enters the brain’s soft tissue 
[11]. These injuries primarily arise from high velocity projectiles (e.g. shrapnel or bullet) entering 
the brain and exhibit a mixture of complex pathologies originating from the projectile’s properties 
(e.g. material, shape) and from the force required to put the projectile there (e.g. a blast) [11]. While 
the secondary damage cascade is typically similar between closed and penetrating injuries, the 
primary injury is typically greater in scale, increases the chance of infection, and depends on how 
far the projectile penetrates the brain and where the brain is damaged [11], [17], [20]. 
 
1.2 Biomarkers for TBI 
A biomarker is any observable or measurable trait which can indicate a physiological process such 
as vitals (e.g. pulse rate, pupil dilation). The diagnosis of TBI is typically based on observations 
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such as dizziness, duration of lost consciousness, nausea, headache and confusion [19]. 
Specifically, molecular biomarkers are bodily media (e.g. cerebral spinal fluid, tissue, urine, blood) 
components which can indicate some physiological process in a healthy or diseased state [11]. 
Examples of molecular biomarkers include DNA (gene sequences), proteins, metabolites, or ions 
[11]. For use in diagnostics, biomarkers should be robust in specificity and sensitivity for the 
physiological process they reflect [21]. In the case of TBI, several studied biomarkers can be more 
or less informative depending on how long after injury the sample is taken and depending on which 
physiological process is of interest.  
 
1.2.1 Observable Biomarkers of TBI 
 
The current method of TBI diagnosis, the Glasgow Coma Scale (GCS), developed in the 1970s, 
assess the degree of coma (loss of consciousness) induced by head injury. This scale is based 
upon observations such as motor, verbal and eye opening responses to stimuli [22], [23]. With 
regard to motor function, the preferred motor response is exhibited when the patient can perform a 
requested task. If the request cannot be completed, a painful pressure stimulation to a finger nail 
is applied to elicit an elbow motion (further classified as flexor, extensor or no response depending 
on the motion elicited). Abnormal and lack of response is indicative of brain injury if spinal damage 
can be eliminated as the potential cause. Responses to verbal tests of the patient’s ability to speak 
and orient themselves (e.g. know who and where they are), are classified as oriented, confused, 
inappropriate or incomprehensible. Verbal communication indicates the brain’s ability to integrate 
with the central nervous system if other conditions such as dysphasia can be ruled out as potential 
reasons for speech abnormalities. The brainstem’s arousal function can be shown to be intact if 
spontaneous eye openings in sleep and wake rhythms can be observed. Eye opening responses 
are ranked from spontaneous, to speech, to applied pain in limbs, to none [22], [23].  
 
Other observations which can help diagnose TBI include criteria in the Acute Concussion 
Evaluation (ACE): physical and cognitive abilities during exertion, changes in sleep patterns, in 
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addition to knowledge regarding previous conditions such as migraines or psychiatric disorders 
[19]. Other evaluation methods such as Automated Neuropsychological Assessment Metrics 
(ANAM) and Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) used in 
military and sport institutions conduct similar observations, but require a pre-injury baseline to 
determine differences in the physical and cognitive observations [19]. 
 
If initial observations of these biomarkers of physical and cognitive abilities suggests possible TBI, 
additional methods such as computer tomography (CT) and magnetic resonance imaging (MRI) 
techniques may be used to identify cerebral blood flow irregularities, damage to the skull, axonal 
injury, and even metabolism irregularities [19]. 
 
1.2.2 Molecular Biomarkers for TBI Diagnosis and Severity Determination of the Primary Injury 
 
Among the most studied TBI biomarkers include S-100β, glial fibrillary acidic protein (GFAP), 
neuron specific enolase (NSE), and myelin basic protein (MBP) [11], [21], [24]. GFAP is a filament 
protein in the cytoskeletons of astrocytes that spikes in blood concentration shortly after injury along 
with increased intracranial pressure and systemic hypotension [11], [21], [24]. The Operation Brain 
Trauma Therapy study identified GFAP as an effective TBI biomarker across preclinical injury 
models and severity, making GFAP a candidate biomarker for novel diagnostic methods [25]. NSE 
is a glycolytic enzyme found in neurons (γ-γ isoform) and neuroendocrine cells (α-γ isoform), and 
is known to increase in serum concentration relative to TBI severity after blood-brain-barrier 
breakdown (half-life over 20 hours after injury) [11], [21], [24]. S-100β is a calcium-binding protein 
involved in signal transduction that is found most often in astrocytes, which maintains high serum 
concentrations for over 48 hours after blood-brain barrier disruption and injury (half-life of 30-90 
minutes) [11], [21]. Moreover, high levels of S-100β have been shown to induce apoptosis [24]. 
Tumor necrosis factor alpha (TNF-α) is a pro-inflammatory molecule that helps to coordinate the 
response of inflammatory cell types to the site of brain damage [11], [26]. TNF-α is a short-lived 
molecule, but maintains large concentrations 1-4 hours after injury [11], [26] (could indicate when 
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secondary damage occurs if frequently monitored). MBP is the largest constituent of the myelin 
sheath and can be measured in blood as a result of demyelinating diseases or within hours of TBI 
for up to two weeks post-injury [21]. 
 
The catecholamines (epinephrine, norepinephrine and dopamine) have been shown to positively 
correlate with trauma such as TBI [27]–[29]. Normal levels of blood catecholamines ranges from 
0.19 nM to 11 nM [30], [31]. Post-trauma blood levels of catecholamines can exceed 29 nM, 
depending on severity [32]. These levels are often measured for other purposes besides TBI 
diagnosis in a clinical lab using the high-performance liquid chromatography (HPLC) method [31], 
[33]. However, blood levels of catecholamines may increase for various reasons, and cannot be 
used as the only biomarkers to diagnose TBI [31]. 
 
1.2.3 Molecular Biomarkers for Secondary Pathologies 
 
While most studies focus on identifying biomarkers for diagnosis and severity determination of TBI, 
some have worked to determine biomarkers that can indicate secondary damage such as 
intracranial pressure changes and blood-brain barrier compromise [11]. One study has shown that 
cleaved tau proteins can indicate when intracranial pressures [34] exceed the limits which have 
been shown to increase negative morbidity and mortality outcomes [35]. GFAP and S-100β have 
also been shown by Pelinka et al. to correlate to ICP readings from TBI patients [36]. Other serum 
biomarkers studied to indicate ICP include copper, ceruloplasmin, and retinol binding protein 4 [11].  
 
Breakdown of the blood-brain barrier (BBB) has been known to be followed by increased 
inflammation and ICP, difficulty maintaining homeostasis, among other pathological events [37]. 
Severe TBI serum levels of S-100β have been correlated to the degree of BBB damage [38], though 
the overall levels of S-100β were much lower than other reports [24], [39], [40]. 
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Secondary ischemia results from other negative effects on cerebral vasculature regulation including 
hemorrhaging and hypertension caused by elevated ICP which does diminishes blood flow to the 
injured tissue and in turn causes metabolic disturbances [11]. Antibodies to phospholipids typically 
studied in stroke models could indicate ischemic events after TBI [11], [41], [42]. 
 
Necrosis, or tissue death, is frequently seen in TBI where the brain has made contact with the skull 
[11]. Studies have found a molecule called calpain can be indicative of swelling changes, which is 
the greatest risk for additional necrosis after the primary injury [11]. Other anti-inflammatory 
interleukins and cytokines have been shown to potentially indicate inflammation changes after TBI 
such as interleukin-6 (IL-6), IL-10 and TGF-β, which have been known to counteract the pro-
inflammatory markers known to facilitate glial scarring [11]. The following growth factors and 
cytokines have been linked to the formation of glial scarring (non-functional tissue): tissue necrosis 
factor alpha (TNF-α), insulin-like growth factor-1 (IGF-1), transforming growth factor (TGF), 
fibroblast growth factor (FGF), various interleukins, and interferon-γ [12]. Depending on which part 
of the brain this glial scarring occurs, surrounding ipsilateral tissue or areas on the contralateral 
side may take over the lost function with rehabilitative therapy [12]. 
 
Post-mortem staining analysis for cleaved tau proteins in people who frequently sustained multiple 
TBIs (or CTE), showed that cleaved tau protein concentrations increased with repeated injuries 
[12]. Hyperphosphorylation of these microtubule-associated tau proteins has also been shown to 
indicate neurodegenerative disorders such as Alzheimer’s [24]. These proteins reside within the 
axon compartment and are abundant in the cleaved form when injury induces axonal damage, thus 
extensive presence of these cleaved proteins indicates either one extremely severe TBI (from 
which the patient did not likely recover), or cumulative axonal damage over time [24]. 
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1.2.4 Serum Biomarkers for Mild TBI 
 
Several studies have concluded that S-100β is indicative of mild TBI, indicating this biomarker has 
high sensitivity [11], [43]–[45]. However, one study found that serum levels of S-100β did not 
statistically differ between mild, moderate or severe TBI [46]. Several studies have failed to find 
significant evidence correlating S-100β concentrations to mild TBI intracranial damage indicated 
by CT scan (mostly due to specificity issues) [24], [39], [43], [47], but one study found that the 
absence of S-100β in early blood samples predicted a normal CT scan [48]. Several studies have 
struggled to find a correlation between NSE concentration and mild TBI despite its very high 
specificity, largely due to sensitivity problems since mild TBI levels are not much higher than healthy 
levels [24], [49]–[52]. NSE levels exceeding 21.7 µg/L have shown to indicate mortality and poor 
GOS [11]. In a study by Kavalci and coworkers, cleaved tau proteins were found to elevate as a 
result of mild TB!, but was not statistically correlated to CT indications of intracranial damage [24], 
[53]. However, other studies have found difficulty in correlating cleaved tau protein concentration 
with mild TBI outcomes [54] [55]. Mild TBI is difficult to find diagnostic biomarkers for due to the 
general lack of specificity many of the potential markers have, especially in multi-trauma cases [11]. 
TNF-α has been linked to cell death signaling and mediation of inflammation after injury [56], [57], 
if this molecule is constantly monitored, it may indicate when secondary swelling is increasing and 
steps can be taken to reduce the inflammation potentially reducing necrosis and secondary 
damage.  A summary of the literature’s reports regarding serum concentrations of these biomarkers 
can be found in Table 1.1. 
 
1.2.5 Serum Biomarkers for Moderate TBI 
 
Biomarkers specifically for moderate TBI were not found in the literature. Moderate TBI is 
diagnosed clinically using the GCS and GOS, or higher/lower levels of mild/severe biomarkers. 
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1.2.6 Serum Biomarkers for Severe TBI 
 
S-100β has been shown to correlate to GCS and CT abnormalities in severe TBI cases [24]. More 
than 90% of patients in one study exhibited pathological CT scans [58]. S-100β remained at high 
levels for days in fatal cases, whereas S-100β was reduced after 36 hours after moderate injury 
[24], [36]. Vos et al. found S-100β concentrations exceeding 1.13 ng/mL in severe TBI patients 
correlated with increased mortality and morbidity [59]. In one study, about half of the unfavorable 
outcome patients experienced a secondary rise in S-100β serum concentrations [60]. Serum NSE 
levels have been found to significantly increase due to severe TBI [51] and found to correlate to 
both GCS and CT abnormalities in fatal TBI cases [59]. One study has also correlated 3 month 
post-injury NSE serum concentrations to GCS, attributing these high levels to secondary damage 
such as hypoxia and hypotension [61]. GFAP has been shown to be elevated in days 1-3 after 
severe TBI before gradually decreasing, while patients with > 15 µg/L GFAP serum levels did not 
survive [62]. Another study also found GFAP to correlate with several types of diffuse injury CT 
scans, outcome, intracranial pressure, disability, and vegetative state outcome [36]. The extrinsic 
apoptosis signaling protein, TNF-α was found to increase in serum after severe TBI, but did not 
correlate with survival outcome [56]. A summary of severe TBI serum concentrations of these 
biomarkers can be found in Table 1.2. 
 
Serum levels of some of these biomarkers are also known to fluctuate as a result of non-head 
injuries, and consequently have less specificity than an ideal biomarker. Specifically, serum levels 
of S-100β have been shown to increase due to long bone fractures, burns and other extracerebral 
injuries; but with non-TBI injuries, S-100β decrease after 6 hours, thus after 6 hours the biomarker 
is more suitable for TBI specificity [11], [21], [24], [45], [63]. NSE has also been studied as a 
potential biomarker for lung cancer, neuroblastomas, ischemic stroke and neuroendocrine bladder 
tumors [11]. TNF-α levels can increase due to a number of injury types [11], [24]. It is therefore 
imperative that a diagnostic can quantify and distinguish between several biomarkers in the same 
blood sample to minimize false-positives. Unfortunately, quantifying these biomarkers typically 
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requires a clinical lab and a trained technician, stabilizing reagents, purification steps, etc [30], [31], 
[64], [65]. To this end, this work focuses on developing methods to characterize and quantify some 
of these biomarkers using electrochemical impedance techniques in purified and complex 
solutions.  
 
1.3 Methods of TBI Diagnosis 
A TBI can be classified into open or closed injuries, then further classified into mild, moderate or 
severe [18], [19]. Today, the most traditional method used clinically to diagnose TBI is the Glasgow 
Coma Scale (GCS) which ranks qualitative observations including duration of unconsciousness, 
verbal, eye and motion responses from 0 to 15 (where 15 is a very mild TBI). The GCS (defines 
primary endpoints based on injury characteristics) is often augmented with computer tomography 
imaging in moderate to severe cases to determine if the brain’s blood flow has been disrupted (e.g. 
hematoma or hemorrhage) [24], [66]–[68]. However, in mild TBI cases CT scans often do not reveal 
any pathologies [11], which perhaps contributes to a great number of mild TBIs not being 
diagnosed. Table 1.3 (adapted from Hawley, 2003) classifies TBI severity as a function of GCS 
ranking [69]. The Glasgow Outcome Score also classifies TBI severity into 5 secondary endpoints: 
1- death, 2- persistent vegetative state, 3- severe disability, 4- moderate disability, and 5- good 
recovery [24], [51], [70]. The CDC also developed the Acute Concussion Evaluation (ACE) which 
is another part self-reporting and part observation under exertion survey to assess changes in sleep 
patterns, cognitive, emotional and physical traits [19]. For blast-induced TBIs, the Military Acute 
Concussion Evaluation (MACE) is often used within 12 hours of injury and is based on 
consciousness and memory loss [11]. In penetrating TBI cases, an intracranial pressure sensor 
may be used to monitor secondary inflammation and damage [68]. However, it is difficult to detect 
subtle patient changes using the GCS and as such, mild TBI often remains undiagnosed. Given 
the long-term deficits associated with TBIs, a quantitative method that enables capturing of subtle 
and changing TBI pathologies is of great interest to the field. Although TBI awareness has 
increased with improved recognition of its signs and symptoms, the barrier to progress lies with the 
lack of innovation in diagnostic and treatment modalities for TBI patients [71], [72]. 
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1.3.1 Developing Methods to Diagnose TBI 
 
Devices currently in development to diagnose and quantify TBI include piezoelectric, acceleration, 
and biological optical or electrochemical sensors. For military and contact sports applications, 
piezoelectric pressure and acceleration sensors are integrated into helmets to calculate the force 
the head experiences in a traumatic event [73], [74]. While these devices may be helpful in reducing 
injury and in determining if a person should receive medical attention, the force data is an indirect 
quantification of the injury. Many efforts to develop biological sensors to measure many important 
biomarkers in media such as blood show more promise for indicating injury severity and 
pathophysiology [21]. In the previous section, 1.2 Biomarkers for TBI, strong evidence was given 
for that the most likely device to replace the current clinical diagnostic methods must measure 
several biomarkers, thus multiplexed sensors are discussed hereafter. At present, there are few 
techniques within a clinical lab’s arsenal, outside of ELISA, which can detect more than one 
biomarker in one experiment. However, ELISA requires a trained person to carry out multiple hours 
of steps and analysis to obtain a result. The sensors examined hereafter, though not necessarily 
meant for TBI diagnostics, could be customized for a TBI diagnostic and offer alternatives to 
complete with ELISA’s cost, sensitivity, and/or assay time. 
 
1.3.1.1 Developing Multiplexed Optical Biosensors 
 
Optical based sensor systems have shown lower limits of detection to be typically less than 1 
ng/mL, which is not sensitive enough to detect many of the CSF and serum biomarkers for TBI 
such as S-100β, MBP, and GFAP in mild TBI cases, but perhaps in severe TBI cases [19]. Other 
admirable qualities regarding these sensors are the time and cost of the assay. The best sensor 
examined was a magnetic immunochromatography test which costs less than $3 per assay (only 
$4k for the instrument), and can provide a result within 2-15 minutes [19]. All of the optical 
techniques explored here have lower limits of detection which can rival or surpass that of the ELISA, 
the standard in clinical labs for protein assays [75]. 
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Several studies have been innovating the traditional ELISA protocol. In a review article by Leng 
and colleagues, there is a comparison of ELISA and several multiplexed assays (using flow 
cytometry, chemiluminescence or electrochemiluminescence) to detect cytokines [75]. The flow 
cytometry multiplexed assays use a sandwich method where beads functionalized with antibodies 
bind to the antigen of interest, then labeled antibodies (fluorescent or streptavidin tagged) create 
the sandwich complex that can quantify up to 25 cytokines via emission spectroscopy [75]. 
Chemiluminescence detection can be used on a multiple-antibody coated plate to improve the 
sensitivity and throughputs of a traditional ELISA [75]. A similar microplate set up adds wires to 
create and electric field which excites a proprietary tag (on one of the sandwich antibodies) that is 
amplified by another molecule in the buffer allowing up to 9 cytokines to be measured in a sample 
[75]. The review by Leng et al. also warns about considerations regarding the nature of multiplexed 
assays including: increased potential for non-specific binding (antigen binding to multiple 
antibodies), potential for plasma and serum proteins to cause false-positives, and increased 
difficulty of data analysis and necessity to make reasonable assumptions. 
 
One plasmonic sensor developed by Yu et al. immobilizes antibodies onto gold nanorods which 
employs a colorimetric absorbance method to monitor binding of antibody to antigen in solution 
[76]. As binding occurs, there is a red shift which correlates to concentration. The investigators 
were successful in detecting three analytes in one test tube, however due to their choice of 
antibodies, they experienced non-specific binding where one antigen could bind to the other two 
antibodies [76]. Later that year, the same investigators had modified their functionalization protocol 
and were able to get quantifiable results [77]. Using the same three antibodies, the investigators 
changed the way these antibodies attached to the gold nanorods resulting in lower limits of 
detection of 10 nM - 90nM (1.5 - 13.5 µg/mL) in phosphate buffer saline (PBS) solutions, none of 
these experiments were conducted in complex solutions (e.g. blood or serum) [77]. 
 
In a similar opto-magnetic sensor validated in blood serum, blood plasma, and whole saliva, surface 
plasmon resonance (SPR) is used to detect analytes via an ELISA-like sandwich binding method 
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[78]. As is customary in SPR, antibodies are bound to a gold surface via flow channel, followed 
later by the antigen, then by magnetic nanoparticles also coated with antibodies to form the other 
half of the sandwich [78]. A laser is pointed at the bottom of the immobilized gold surface, and 
characteristics of the reflected light are a function of the number of magnetic nanoparticles bound 
to the other side which in turn can be correlated to analyte concentration. These investigators have 
produced low-cost cartridges to detect drugs such as morphine in saliva [78]. Five analytes and a 
control were successfully detected in a multiplexed use of this sensor with a lower limit of detection 
of 250 fM in 1 µL samples [78]. 
 
One novel sensor used silicon wires in a spiral configuration as a sensing surface, upon which 
antibodies were immobilized onto several of the spirals embedded in a micro-channel [79]. The 
initial attempts used antibodies to detect streptavidin [80], but a later multiplexed attempt used anti-
goat and anti-rabbit IgG’s on different spirals in the same system [79]. After antibody 
functionalization, a PBS sample containing the antigen(s) flows through the micro-channel and a 
saturated phase shift is optically measured using an infrared camera using serum albumin (BSA) 
as a control [79], [80]. 
 
1.3.1.2 Developing Multiplexed Electrochemical Biosensors 
 
Electrochemistry is extensively described in the next section (1.4 Electrochemistry in Medical 
Diagnostics). Briefly, electrochemistry is the measurement of electrical characteristics in a sample 
which can be used to quantify a component or characteristic of the sample. 
 
One publication utilized various “inorganic nanocrystal tracers” with square wave stripping 
voltammetry and magnetic separation (to minimize non-specific absorption) to quantify four 
biomarker-colloidal crystal pairs [81]. In this sandwich assay, the primary antibodies were 
conjugated to magnetic beads and the secondary antibodies were conjugated to a nanocrystal (via 
carbamate linkage). The antigens were added, while the primary antibodies were stirring. After 
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primary binding, the secondary antibodies were added, then the sandwich complex was rinsed then 
placed in nitric acid to encourage the bound nanocrystals to dissolve into solution (still magnetically 
stirred) followed by a transfer to a buffer solution where the electrochemical stripping technique 
measured the dissolved nanocrystals. This sensor was able to obtain a femtomolar detection limit 
while measuring up to 5-6 antigens simultaneously in non-complex solutions [81]. 
 
A sensor developed in the EIC Laboratories, Inc. to simultaneously detect two tumor biomarkers 
using electrochemical ELISA was reported [82]. An iridium substrate was silanized then prepared 
with glutaraldehyde for primary antibody immobilization (one antibody for each of the two working 
electrode surfaces). These sensors were exposed to samples containing one or both antigens, 
followed by exposure to the alkaline phosphatase-labelled secondary antibody. Next, hydroquinone 
diphosphate (substrate to the alkaline phosphatase conjugated to the secondary antibody) was 
incubated on the sensors surface, then an amperometric electrochemical technique was used to 
measure the resulting current from the oxidation of the enzyme product on one working electrode 
at a time [82]. The detection for one biomarker showed linearity over a 25-150 ng/mL range, while 
the other sensor showed linearity over a 10-200 ng/mL range [82]. 
 
A sensor to simultaneously detection two forms of HIV DNA oligonucleotides using square wave 
voltammetry was reported to quantify both markers without a label, with linearity over a 20 to 100 
nM range with a detection limit of 0.1 nM [83]. The investigators custom made multi-electrode array 
made of gold and silver (for reference electrode) with silver epoxy film for electrical contacts. Probe 
DNA (instead of capture antibody) was allowed to self-assemble onto the gold working electrode 
surface, followed by incubation in methylene blue incubation. After the target DNA was incubated 
for one hour, square wave voltammetry measured the current generated by the oxidation of 
methylene blue which was not in a hybridized DNA structure (more target DNA equates to less 
current measured) [83]. 
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A multiplexed electrochemical sensor reported detection of interleukin-8 (IL-8) mRNA and IL-8 
protein in saliva samples for oral cancer diagnosis [84]. The functionalization of this sensor greatly 
mimics the ELISA protocol (use of horse radish peroxidase, tetramethylbenzidine, etc) with an array 
of gold electrodes in place of a microplate and cyclic square wave voltammetry is used to 
encourage immobilization and binding instead of a long incubation periods. However, 
amperometric methods indirectly quantify one antigen at a time by measuring the current generated 
by the reduction of TMB/oxidation of HRP. This method obtained 3.9 fM IL-8 mRNA and 7.5 pg/mL 
of IL-8 detection limits in 56 human saliva samples with 83% sensitivity and 87% specificity [84]. 
 
In a study by Chen et al., two biomarkers (CEA and AFP) were simultaneously detected using 
differential pulse voltammetry [85]. This immunosensor was fabricated by functionalizing a glassy 
carbon electrode with chitosan-gold nanoparticle composites, followed by overnight co-absorption 
of both capture antibodies via EDC/NHS (carbodiimide crosslinking) immobilization. Next, BSA was 
incubated on the sensor surface to block any non-specific binding sites. Serum solutions containing 
both antigens were incubated on the functionalized sensor surface for 35 mins before the two 
probes were incubated for 45 minutes. The two probes consisted of carboxyl graphene nanosheets 
with toluidine blue and EDC/NHS immobilized labeled anti-CEA blocked with BSA, while the other 
probe consisted of carboxyl graphene nanosheets with Prussian blue and EDC/NHS immobilized 
labeled anti-AFP blocked with BSA. Differential pulse voltammetry measurements measured the 
reduction of toluidine blue and Prussian blue which correlated to CEA and AFP concentrations with 
0.1 ng/mL and 0.05 ng/mL detection limits, respectively. 
 
Shan and coworker used square wave voltammetry and electrochemical impedance spectroscopy 
(EIS) to detect 5 biomarkers for lung cancer [86]. First, gold was deposited onto the glassy carbon 
working electrode surface, followed by overnight incubation of all five capture antibodies onto the 
surface [86], [87]. Later, BSA was used to block unbound working electrode surface, followed by 
incubation of all the antigen on the functionalized sensor surface [86], [87]. Lastly, secondary 
antibodies to the antigens which were conjugated to different gold particle-dye tag probes were 
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incubated on the sensor surface [86], [87]. Square wave voltammetry was used to determine 
oxidation peaks for each antibody-antigen-antibody-conjugate set. These measurements were 
successfully compared to ELISA and validated in serum clinical samples [86].  
 
Previous efforts in my lab have also created a label-free and rapid multiplexed electrochemical 
sensor for interleukin-12 (IL-12) and tumor necrosis factor-alpha (TNF-α) capable of 4 pg/mL and 
60 pg/mL detection limits, respectively [88]. Gold nanoparticles (2-20 nm) were conjugated to the 
capture antibodies and immobilized via EDC/NHS carbodiimide linkage to a gold surface with a 
blacking agent of ethanolamine. Electrochemical impedance spectroscopy (EIS) measured purified 
solutions of antigens and showed that the antibody-antigen impedance signal could be changed 
based on nanoparticle size [88]. 
 
A multiplexed sensor and data approach would likely be the most effective way to diagnose and 
monitor treatment after TBI. It has been proposed the combination of biomarker data with imaging 
or GCS information could increase diagnostic accuracy and potentially overcome sensitivity and/or 
specificity issues with individual biomarkers [11]. Others have worked to develop analysis methods 
such as linear combinations using receiver operator curves and boosting algorithms to improve 
accuracy of diagnostic tools measuring multiple biomarker data [89]–[92]. Several works using 
electrochemistry and similar techniques have successfully detected some of the TBI biomarkers in 
serum and purified conditions, but none have shown promise in whole blood solutions [93]–[95]. 
 
1.4 Electrochemistry in Medical Diagnostics 
Electrochemistry aims to correlate electrical effects (e.g. current, impedance) to another 
phenomena, such as a chemical change [96]. In the fields of medical devices and biosensors, the 
most prevalent modes of measuring physiologically relevant molecules include potentiometric, 
amperometric and impedimetric techniques [96]. 
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1.4.1 Potentiometric Medical Diagnostics 
 
Cyclic voltammetry (CV) is a potentiometric technique which stimulates the sample solution with a 
saw-tooth voltage wave while current is measured (Fig 1.1) [1], [96]. Square wave voltammetry is 
another popular technique used in developing medical diagnostics which uses an increasing step-
like square wave at a defined frequency to stimulate the sample while forward (e.g. increasing 
voltage) and reverse (e.g. decreasing voltage) current is measured to yield a differential current 
(forward – reverse) (Fig 1.2) [96]. Several of the multiplexed electrochemical biosensors discussed 
in section 1.3 Methods of TBI Diagnosis included diagnostics while used potentiometric techniques 
to measure various proteins, HIV genes, and cancer biomarkers [81], [83], [85]–[87]. 
 
1.4.2 Amperometric Medical Diagnostics 
 
The self-monitoring blood glucose meter uses the more sensitive amperometric-it technique which 
applies a DC voltage (typically the oxidation potential informed by a CV) to the solution as current 
is measured over time (Fig 1.3) [3], [96], [97]. In our lab, we have successfully applied amperometric 
techniques to measure glucose and norepinephrine using low-cost materials [2], [3], [97]–[100]. 
 
1.4.3 Impedimetric Medical Diagnostics 
 
Two impedance techniques were used in this work: electrochemical impedance spectroscopy (EIS) 
and impedance-time (Z-t). The EIS technique uses an AC voltage signal which changes frequency 
over time to stimulate the solution and measures the resulting AC current, the phase and amplitude 
(complex impedance magnitude) differences between the applied AC voltage and the measured 
AC current creates the Nyquist plot (Fig 1.4) [1], [2], [96], [101]–[103]. These phase and amplitude 
changes in the current AC wave are observed as a result of the near-field chemical changes, such 
as biomarkers binding to antibodies immobilized to the working electrode surface. The Z-t 
technique works similarly, except the AC voltage maintains one defined frequency and yields a 
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complex impedance versus time plot (Fig 1.5) [1], [2]. While these two impedance techniques have 
similar sensitivity, Z-t requires less hardware to generate the stimulating signal, and is therefore 
more preferable for a handheld device. Both EIS and Z-t have been studied for biosensor use due 
to their rapid, robust and label-free approach that enables detection of very small analyte 
concentrations [1], [2], [101], [104], [105]. Impedance techniques have been used to detect 
salmonella, glycans and lectins, cytokines pertaining to multiple sclerosis, diabetes biomarkers, 
neurotransmitters and biomarkers for TBI [1], [2], [104]–[109]. 
 
1.4.4 Novel Materials to Improve Sensor Performance 
 
Other efforts regarding electrochemical biosensors include exploration of novel electrode materials 
and compositions to achieve lower sensitivity and/or higher specificity. As discussed in the methods 
of TBI diagnosis section (1.3), several studies have employed various nanoparticles, nanosheets, 
nanorods, beads, chitosan and other materials to improve sensor performance [75], [77], [78], [81], 
[86]–[88]. Among the most commonly utilized materials is carbon due to its conductive, inert, bio-
compatible and relatively low-cost characteristics [110]–[113]. It has been shown that increasing 
the surface area of the working electrode can greatly improve electrochemical sensitivity by 
increasing the double layer capacitance and encouraging organic absorption to the electrode 
surface [97], [114]–[119]. Ordered mesoporous carbons (MPCs) have shown to be less expensive 
than nanotubes but also capable of increasing surface area and sensitivity [3], [97], [115], [117], 
[120]–[123]. Moreover, mesoporous carbons can be created by carbonizing simple self-assembly 
products of commercially available surfactants and low-cost phenolic resins [97]. However, 
triconstituent assembly of phenolic resin, surfactant and a silica template (which are later etched 
out to leave mesopores, <1 nm) can increase and help to control resulting MPC surface area (760 
m2/g without silica template; >2000 m2/g using 46% silica) [3], [121], [124], [125]. An additional 
benefit to MPC is its ability to detect with high sensitivity and specificity even in complex media 
such as whole blood [3], [97], making it an ideal material for biosensors and a cost-effective 
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alternative to Nafion membranes [126]. Furthermore, these MPCs can also be functionalized with 
capture antibodies in a simple and one-step fashion to detect biomolecules of interest [127], [128]. 
 
1.5 Objective and Specific Aims 
An ideal TBI diagnostic would quantify multiple biomarkers with little to no sample preparation, 
would not require intricate assay techniques, and would yield a result in 30 minutes or less [129]. 
It is generally understood that measuring one biomarker may not accurately diagnose TBI, thus 
this work will lay the foundation to develop a multi-analyte approach to detect four promising TBI 
biomarkers: glial fibrillary acidic protein (GFAP), neuron specific enolase (NSE), S-100β protein, 
and tumor necrosis factor-α (TNF-α). The envisioned device for which this work lays a foundation 
is a low-cost handheld point-of-care (POC) monitor and test strip diagnostic that would rapidly 
quantify multiple TBI biomarkers in a drop of blood using novel nanomaterials, to revolutionize the 
diagnosis of TBI. The objective of this work is to develop novel electrochemical impedance 
diagnostic sensors and analysis methods to simultaneously quantify multiple TBI biomarkers in the 
same complex sample. To this end, the following aims have been set: 
1.5.1 Specific Aim 1:  
Develop impedance and impedance-time models for the four TBI biomarkers of interest (GFAP, 
NSE, S-100β, and TNF-α). 
 
1.5.2 Specific Aim 2: 
Optimize the mesoporous carbon (MPC) protocol to encapsulate individual and multiple antibodies 
and compare the filtering ability of MPC to the commercial standard, Nafion.  
 
1.5.3 Specific Aim 3: 
Determine feasibility for simultaneous multiplexed detection of TBI biomarkers using MPC in 
purified and complex solutions. 
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1.6 Figures 
Table 1.1: Literature summary of serum concentrations of most studied biomarkers of mild TBI. 
Serum Biomarker Healthy Concentrations Mild TBI Concentrations 
S-100β 
0.0001 µg/L [38] 
0.05 µg/L [130], [131] 
~ 0.25 µg/L [131] 
> 0.5 µg/L [132] 
~ 0.31 µg/L [131] 
~ 0.77 µg/L [47] 
NSE 
8.45 µg/L [51] 
9.6 µg/L [24], [131] 
< 12.5 µg/L [133] 
~ 6.95 µg/L [51] 
~ 10.2 µg/L [131] 
GFAP 0. 004 µg/L [40] > 0.033 µg/L [40] 
Cleaved Tau Protein 0.086 µg/L [54] 
~ 0.016 µg/L [53] 
~ 0.188 µg/L [54] 
TNF-α 15.5 pg/mL [56] > 14 pg/mL [57] 
 
Table 1.2: Literature summary of serum concentrations of most studied biomarkers of severe TBI. 
Serum Biomarker Healthy Concentrations Severe TBI Concentrations  
S-100β 
0.0001 µg/L [38] 
~ 0.05 µg/mL [24], [130] 
0.0015 - 0.0057 µg/L [38] 
> 0.12 µg/L [39] 
0.3 - 1.6 µg/L (GCS 4-5) [24] 
2.0 - 2.5 µg/L (GCS 1-3) [24] 
~ 1.5 µg/L [40] 
0.5 – 2.3 µg/L [60] 
NSE 
8.45 µg/L [51] 
9.6 µg/L [24], [131] 
>7-10 µg/L [24], [134], [135] 
~12.8 µg/L [51] 
GFAP 0. 004 µg/L [40] ~ 0.1 µg/L [40], [62] 
Cleaved Tau 
Protein 
0.03 µg/L* [34] ~3200 µg/L* [34] 
TNF-α 15.5 pg/mL [56] > 24.3 pg/mL [56] 
* Indicates Cerebral Spinal Fluid (CSF) sample rather than serum sample 
 
Table 1.3: Definitions of TBI severity based on duration of unconsciousness and GCS rank. 
Adapted from Hawley, 2003 [69]. 
TBI Severity Criteria 
Mild GCS 13-15; unconsciousness < 15 mins 
Moderate GCS 9-12; unconsciousness > 15 mins 
Severe GCS 3-8; unconsciousness > 6 hrs 
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Fig 1.1: A schematic of the potentiometric cyclic voltammetry technique including stimulating signal 
(part A) and an example of resulting raw data from which oxidation and reduction potentials can be 
determined (part B). 
Fig 1.2: A schematic of the potentiometric square wave voltammetry technique including 
stimulating signal (part A) and an example of resulting raw data (part B). 
Fig 1.3: A schematic of the amperometric-it technique including stimulating signal (part A) and an 
example of resulting raw data (part B). 
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Fig 1.4: A schematic of the electrochemical impedance spectroscopy technique including 
stimulating signal (part A) and an example of resulting raw data (part B). Showing NE 
concentrations of 1, 50, 500, and 5000 pg/mL. 
 
Fig 1.5: A schematic of the impedance-time technique including stimulating signal (part A) and an 
example of resulting raw data (part B). This is 500 pg/mL NE data 368, 321, 3676, 46300 Hz. 
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CHAPTER 2 
CHARACTERIZATION AND DEVELOPMENT OF IMPEDANCE MODELS FOR SELECTED TBI 
BIOMARKERS 
2.1 Introduction 
The EIS and Z-t techniques were first used to quantify the catecholamines, then used to quantify 
the four selected TBI biomarkers: GFAP, NSE, S-100β, and TNF-α. The goals of these experiments 
were to address the first specific aim: to characterize and develop models to quantify the 
biomarkers of interest in purified and complex solutions. Characterization of each biomarker on an 
individual basis in purified solutions using the gold standard electrochemical set up (gold disk, 
platinum wire, Ag/AgCl wire electrodes) was required since the impedimetric characteristics of 
these biomarkers was unknown. Additionally, this was important to ensure the capture antibodies 
or other molecular recognition elements (e.g. enzyme, aptamer) would yield a measurable 
electrochemical signal when bound to the target biomarker. The desired information included 
optimal binding frequency of the target biomarker to its capture antibody (acquired from EIS data) 
and minimal assay time (acquired from Z-t data) with corresponding biomarker concentration 
versus impedance calibration curves/models. Validation of this information in complex solutions 
(plasma and/or blood) would help determine the feasibility of detecting these biomarkers in real 
samples and help inform data analysis when multiple biomarkers are measured simultaneously. 
Moreover, two of the biomarkers (NSE and S-100β) were quantified in a small study using rat 
controlled cortical impact (CCI) rat plasma. The remainder of this chapter include adaptations from 
the Haselwood et al., 2015 and Cardinell et al., 2017 publications [1], [2]. 
 
2.2 Experimental Methods 
2.2.1 Equipment 
 
To conduct these experiments, the following equipment was required: a 660C CH Instruments 
Electrochemical Analyzer (CH Instruments, Austin, TX, USA), an analytical scale such as the 
Ohaus EX224 analytical balance, a VWR Digital Vortex Mixer (VWR, Randor, PA, USA), referred 
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to as vortexer, a Branson 2510 sonicator from Sigma Aldrich, and a Vulcon Technologies Clinaseal 
centrifuge. 
 
2.2.2 Chemical Reagents 
 
Unless otherwise specified, all chemical reagents were purchased form Sigma-Aldrich, St. Louis, 
MO, USA. Potassium hexacyanoferrate (III) dissolved to 1000 mM, 200 mM and 100 mM in 10 mM 
Phosphate Buffer Saline (EMD Chemicals, Billerica, MA, USA), is henceforth known as 
ferricyanide. The phenylethanolamine N-methyltransferase (PNMT) enzyme used to detect 
norepinephrine (NE) was purchased from Calzyme (Tulelake, CA, USA). The antibodies for the 
other four TBI biomarkers of interest included anti-GFAP (MAB360, EMD Millipore, Billerica, MA), 
anti-NSE (MBS530354, MyBiosource, San Diego, CA), anti-S-100β (SAB1402349, Sigma-Aldrich, 
St. Louis, MO), and anti-TNF-α (MAB210, R&D Systems, Minneapolis, MN). Immobilization of the 
enzyme and antibodies required 1 mM 16-mercaptohexadecanoic acid (16-MHDA) in ethanol, N-
hydroxysulfosuccinimide sodium salt (Toronto Research Chemicals, Toronto, Ontario, Canada) 
was dissolved to 80 mM in PBS and mixed with N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide to 
10 mM (known as EDC/NHS), and the final immobilization solution was 1% ethanolamine (in DI 
water). More detail regarding these solutions is provided in Cardinell et al., 2017 [1]. One part DL-
norepinephrine hydrochloride to two parts S-(5′-adenosyl)-L-methionine chloride dihydrochloride 
(SAM, co-factor of PNMT enzyme) were mixed in 10 mM PBS. All other antigens were purchased 
from the same source as their respective antibodies: GFAP (cat # 345996), NSE (cat # 
MBS537040), S-100β (cat # S6677), and TNF-α (cat # 210-TA-100). Bioreclamation LLC (New 
York, USA) provided the White New Zealand rabbit and Sprague Dawley rat whole blood stabilized 
with K2-EDTA. 
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2.2.3 Electrochemical Cell & Measurement Parameters 
 
A standard three-electrode electrochemical cell was used in these experiments (all purchased from 
CHI Instruments, Austin, TX, USA): a 2 mm gold disk working electrode (GDE), a Ag/AgCl wire (d 
= 0.05 mm) reference electrode, and a platinum wire (d = 0.05 mm) counter electrode. To form a 
well into which samples could be pipetted, the two wire electrodes were bent into the top of a cut 1 
mL pipette tip (tapered end removed) then scotch-taped around the outside of the pipette tip so a 
GDE could be snuggly placed into the bottom of the pipette tip where the pipettor would usually be 
inserted (Fig 2.1). From the electrochemical analyzer, alligator clips were connected to the brass 
connection of the GDE (green alligator clip), the Ag/AgCl reference electrode (white), and the Pt 
counter electrode (red). Once these connections were made, electrochemical techniques could be 
run on 100 µL samples making contact with all three electrodes in the pipette tip sample well. 
 
Three electrochemical methods were used to quantify the biomarkers of interest using the three-
electrode system: cyclic voltammetry (CV), electrochemical impedance spectroscopy (EIS), and 
impedance time (Z-t). CVs were run from -1 V to +1 V, using a scan rate of 0.1 V/s for 6 segments. 
If a reversible reaction occurred, the resulting current versus voltage curve contains an oxidation 
and reduction current peak. Averaging these two peaks provides the formal potential. EIS 
measurements used the calculated formal potential as the initial voltage with a 5 mV AC amplitude, 
sweeping 1 Hz to 100,000 Hz. Parameters for Z-t measurements also used the CV’s formal 
potential for the initial voltage with a 5 mV AC amplitude, a run time of 90 s (to approximately match 
EIS run time), and a specified frequency (usually the optimal binding frequency, discussed later). 
 
2.2.4 GDE Functionalization 
 
To perform EIS and Z-t on biomarker samples, the GDEs must be functionalized with the enzyme 
or capture antibody. The immobilization process described here has also been published in several 
works including La Belle et al., 2013 and is summarized in Fig 2.2 [1], [2], [101], [104], [105], [136]. 
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Each incubation or measured sample solution was 100 µL in volume and cut 1 mL pipette tips 
served as incubation wells for each GDE. First, each GDE was thoroughly polished using 0.05 µm 
Al2O3 powder wetted with DI water on a felt polishing pad, followed by sonication in DI water for 20 
mins. Following sonication, a CV was run on each GDE using 100 mM ferricyanide to determine 
the formal potential. Then the three-electrode system was disassembled and rinsed before a quality 
check EIS measurement was run on 100 mM ferricyanide using the determined formal potential. If 
the GDE was smooth and ready for immobilization, the resulting Nyquist curve had a Warburg 
(checkmark-like) shape with a real impedance of approximately 100 Ω. 
 
Next, the alkane-thiol self-assembling monolayer (1 mM 16-MHDA) was incubated on each GDE 
surface for 1 hr at room temperature. After a rinse with DI water, each GDE was placed in an empty 
1 mL pipette tip and stored in dark place overnight. On the following day, monolayer self-assembly 
was verified by running EIS on 100 mM ferricyanide. This time, each Nyquist curve had a Randles 
(semi-circle) shape with a much larger real impedance (104 - 105 Ω). After, the EDC/NHS solution 
(a zero-cross-linking primer) was incubated on each GDE for 1 hr at 4°C. Following a rinse with DI 
water, one of the following protein solutions in PBS was incubated for 1 hr at 4°C: 0.01 mg/mL 
PNMT enzyme, 5 µg/mL anti-GFAP, 20 µg/mL anti-NSE, 2.5 µg/mL anti-S-100β, or 5 µg/mL anti-
TNF-α. These protein concentrations had already been optimized for this purpose. After a rinse 
with PBS, each GDE was incubated with 1% ethanolamine in DI (non-specific binding blocker) for 
30 mins at 4°C. The functionalized GDEs were stored in PBS at 4°C for use later that day. 
 
2.2.5 Preparation of Purified Solutions of Biomarkers 
 
After GDE functionalization, a physiologically relevant 9-point titer of the corresponding substrate 
and co-factor or antigen in PBS was run with 3 blanks solutions first (50 µL of PBS + 50 µL of 100 
mM ferricyanide), followed by biomarker solutions from lowest to highest concentration with a PBS 
rinse between solution measurements. The final solutions for EIS or Z-t measurement were mixed 
immediately before being placed into the three-electrode sample well: 50 µL of biomarker in PBS 
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+ 50 µL of 100 mM ferricyanide. Since the biomarker solutions were diluted by a factor of two when 
mixed with equal part ferricyanide, the biomarker solutions in PBS were twice the desired end 
concentration, as detailed in Tables 2.1-2.5 for the NE+SAM co-factor, GFAP, NSE, S-100β, and 
TNF-α, respectively. 
 
2.2.6 Preparation of Blood and Plasma Solutions Spiked with Biomarkers 
 
To obtain plasma, whole blood was centrifuged (1205 RCF) for 10 minutes with all items and 
equipment kept at 4°C. The supernatant was centrifuged again for 1 minute, then syringe filtered 
(0.45 µm). Some of the blood and plasma remained undiluted while other solutions were diluted 
with PBS to 10%, 25%, and 50% blood/plasma. All blood and plasma solutions were aliquoted into 
sterile Eppendorf tubes for storage at -20°C (whole blood) and -80°C (plasma) until use. 
 
The 5%, 12.5% and 25% blood/plasma solutions were mixed in a similar way. Final solutions for 
5% blood/plasma: 25 µL of 200 mM ferricyanide + 25 µL of biomarker in PBS + 50 µL of 10% 
blood/plasma in PBS. Biomarker solutions for 5%, 12.5% and 25% blood/plasma data were created 
to be four times the desired end concentration, as detailed in Tables 2.6-2.10 for the NE+SAM co-
factor, GFAP, NSE, S-100β, and TNF-α, respectively. Final solutions for 90% blood/plasma were 
mixed differently: 5 µL of 1000 mM ferricyanide + 5 µL of biomarker in PBS + 90 µL of 100% 
blood/plasma. Biomarker solutions for 90% blood/plasma data were created to be twenty times the 
desired end concentration, as detailed in Tables 2.11-2.15. 
 
As a note, NE+SAM measurements were conducted in 5%, 10%, 25% and 90% blood. This is 
reflected in the calculations and data, but all else (measurement method, data analysis, etc.) was 
the same. 
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2.2.7 Controlled Cortical Impact (CCI) Injuries and Rat Plasma Preparation 
 
The rat injuries and plasma preparation were conducted by the Stabenfeldt Lab in accordance with 
the Institutional Animal Care and Use Committee at Arizona State University. The controlled cortical 
impact model (CCI) was used to impart mild or moderate/severe unilateral frontoparietal cortical 
contusions [137] in adult male Long Evans Hooded rats (n=18 total, Envigo, Indianapolis, IN). The 
rats were anesthetized with isoflurane, placed into a stereotaxic frame (Leica, Wetzlar, Germany), 
followed by performance of a 3.0 mm diameter craniotomy using a Dremel engraving cutter 
(Dremel, Racine, WI) centered 2.0 mm posterior of bregma and 2.0 mm lateral of midline, while 
keeping dura intact. Next, a 2.0 mm diameter electromagnetically driven piston was discharged into 
the cortical tissue (N = 8 mild with depth of 0.5 mm; N = 8 moderate/severe with depth of 2.0 mm) 
at a velocity of 4 m/s for a duration of 200 ms (ImpactOne, Leica). A cellulose sponge was used to 
stop bleeding before the skull was replaced using UV-curing hard dental acrylic (SDI, Inc., Itasca, 
IL) and the incision was closed. Rat sham surgeries (N = 2) included craniotomy, but excluded 
piston discharge prior to replacing skull and closing the incision. All animals received post-operative 
analgesia. On day 1, 3, 7, or 14 after CCI, whole blood was collected into heparinized collection 
tubes (BD, Franklin Lake, NJ) during perfusion. Centrifugation at 4°C (2000g for 15 minutes) was 
used to isolate plasma before storage at -80°C until use. Rat CCI plasma samples were diluted to 
25% using PBS and no biomarker titers were used in measurement of these samples. Each plasma 
collection was from a separate rat (biological replicates). As with the spiked blood/plasma 
measurements, each GDE measured 3 blank solutions and 1 rat sample (50 µL of 25% rat CCI 
plasma and 50 µL of 200 mM ferricyanide). 
 
2.2.8 Electrochemical Impedance Spectroscopy (EIS) Measurements 
 
For each GDE, EIS was measured on 12 purified solutions for each biomarker (a gradient): 3 blank 
and the 9-point titer solutions. For the blood and plasma data, each GDE still measured EIS on 12 
solutions (a gradient): 1 purified blank solution (50 µL of PBS + 50 µL of 200 mM ferricyanide), 2 
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blood/plasma blank solutions (50 µL of blood/plasma + 50 µL of 200 mM ferricyanide), and the 9-
point titer solutions. 
 
2.2.9 EIS Data Analysis 
 
Purified biomarker gradients were measured using EIS on at least 10 functionalized GDEs for each 
of the five biomarkers. Measurements of NE+SAM in 5%, 10%, 25% and 90% blood were each 
conducted on one GDE. Gradients for 5%, 12.5% and 90% blood and plasma were run on 3 GDEs, 
while 12.5% blood and plasma data was collected on 6 GDEs for the other four biomarkers. 
 
The raw data from the EIS measurements consisted of 5 columns: frequency (Hz), real impedance 
Z’ (Ω), imaginary impedance Z” (Ω), the magnitude of complex impedance Z (Ω), and phase (deg). 
Only the magnitude of the complex impedance (Z) data and the corresponding frequencies were 
used for analysis. One biomarker was analyzed at a time; the frequency column was copied to a 
new Excel sheet, followed by the complex impedance magnitude column data for each biomarker 
solution measured on 1 GDE (12 sets of Z data). This was repeated for each GDE. For each GDE’s 
data set, two columns were calculated for natural logarithmic (LN) slope and R2 at each frequency 
to create LN fits where y: complex impedance magnitudes for all concentrations at a given 
frequency (Ω) and x: LN of biomarker concentrations measured (pg/mL). The slope calculations 
indicate the sensor’s general responsivity, while the R2 calculations indicate the sensor’s 
reproducibility.  
 
An optimal binding frequency for the biomarker-capture protein pair ideally occurs where the 
highest LN slope and R2 coincide, and is ideally the same frequency over replicated GDEs. 
However, it has been discovered that the highest LN slope and R2 rarely coincide at the same 
frequency. Thus, the optimal frequencies were determined through a tradeoff between high 
response (slope) and reproducibility (R2). Reproducibility was favored as long as the slope was not 
very small compared to the slopes at other frequencies. Experience with several biomarker systems 
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has shown that optimal frequencies generally should favor an R2 that is greater than 0.7 and a 
slope that is greater than 10% of highest slope value over all frequencies measured. Moreover, the 
selection of an optimal frequency was further complicated by the fact that the optimal frequency for 
one GDE rarely coincided with the optimal frequency of another GDE. However, the cluster of 
potential optimal frequencies across GDEs were often within a range of ~10 of the measured 
frequencies. From here, a calibration curve for each potential optimal frequency was created with 
error bars: a plot with a least squares LN trendline fitting the average complex impedance of all 
GDEs at each potential frequency (Ω) versus the natural log of the biomarker concentrations 
(pg/mL). Additionally, RSD (relative standard deviation) and SD (standard deviation) calculations 
were performed on the collective GDE data for each potential frequency. Based on this additional 
analysis, one optimal frequency was selected according to the best LN fits, smallest RSD and SD 
calculations. 
 
Once an optimal frequency and corresponding calibration curve were selected, detection limits (DL) 
were calculated based on a formula provided by the Food & Drug Administration’s (FDA) guidance 
for industry to validate analytical procedures (Eqn. 2.1) [138]: 
𝐷𝐿 = 3.3 ∗
𝜎𝑠𝑖𝑔𝑛𝑎𝑙
𝑚𝑐𝑎𝑙𝑖𝑏𝑟𝑎𝑡𝑖𝑜𝑛 𝑐𝑢𝑟𝑣𝑒
 
where σsignal is the standard deviation of the residuals of the calibration curve’s least squares 
regression and mcalibration curve is the slope from the calibration curve at the optimal frequency. 
 
Analysis on blood and plasma EIS data was conducted in a similar fashion, but each biomarker is 
further divided into % of blood and plasma, for which the previously described analysis must be 
reiterated to validate optimal binding frequency and obtain more realistic calibrations curves. To 
determine which of the blood or plasma solutions in which the sensor performed best, two plots 
were compared: slope at the optimal frequency (Ω/pgmL-1) versus % blood or plasma and R2 at the 
optimal frequency versus % blood or plasma. 
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2.2.9.1 EIS Data Analysis on Rat CCI Plasma Samples 
 
EIS measurements to quantify NSE and S-100β concentrations in CCI rat plasma collected 1, 3, 7 
and 14 days after injury (16 samples), in addition to 2 samples collected on 7 from sham surgery 
animals. Differing from the titer spiked rat plasma data, only one EIS measurement was conducted 
in these CCI cases on one unknown rat plasma sample. Thus, a different form of analysis to 
determine NSE and S-100β concentrations was necessary. For each plasma sample, the raw 
complex impedance (Ω) was divided by the last blank that was run on the same GDE and new NSE 
and S-100β calibration curves for the 12.5% spiked plasma data were created by dividing the 
average complex impedance by the average blank. The ratios from the unknown samples were 
plugged into the newly modified calibration curves to predict the concentrations of NSE or S-100β 
(pg/mL) shown in Table 2.16. Standard deviations were calculated on these predicted NSE and S-
100β concentrations based on the N = 2 data (i.e. per severity/per day). The Mann-Whitney U-test 
(α = 0.05) was used to determine if NSE or S-100β concentrations were statistically different in mild 
and moderate CCI rats. 
 
2.2.10 Impedance-Time (Z-t) Measurements 
 
2.2.10.1 Z-t Measurements of NE+SAM 
 
In the first experiments, Z-t measurements were run for 90s at the optimal frequency, 371.1 Hz, on 
the same purified 9-point titer of NE+SAM and in the same manner used for EIS measurements. 
This was repeated with a dead frequency, 46300 Hz. The second Z-t experiments took 
measurements run for 500 continuous seconds at 368 Hz, starting with and initial sample of 50 µL 
of 100 mM ferricyanide, followed by injections of 500 pg/mL NE+SAM in PBS at 30, 40, 85, 145, 
and 325 sec time points. This was repeated at 321, 3676 and 46300 Hz since the Z-t hardware 
was not capable to producing a 371.1 Hz signal, 368 Hz and 321 Hz were the two nearest 
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frequencies available. This was repeated again with injections of pure PBS to characterize the 
injection artifact. No Z-t measurements of NE+SAM were conducted in complex samples. 
 
2.2.10.1 Z-t Measurements of GFAP, NSE, S-100β and TNF-α 
 
Z-t measurements for these biomarkers were conducted on the same purified, blood, and plasma 
solutions and in the same manner as the GDE measurements using EIS. No Z-t measurements of 
GFAP, NSE, S-100β or TNF-α were conducted in complex samples. 
 
2.2.11 Z-t Data Analysis 
 
2.2.11.1 Z-t Analysis of NE+SAM Data 
 
The goal of the first Z-t experiments (where the solutions were run the same way the EIS 
measurements) was to determine the minimum assay time required to reliably detect NE at the 
optimal binding frequency. To this end, data analysis resembled the initial EIS data analysis, only 
complex impedance (Ω) versus the LN concentration of NE (pg/mL) was a function of time instead 
of frequency. Natural logarithmic slope and R2 columns were calculated for each time point and the 
optimal assay time was selected in the same manner as the optimal binding frequency, by 
comparing slopes, R2, calibration curves fits and deviation statistics.  
 
For the second set of Z-t experiments, the goal was to determine if kinetic information could be 
determined from measurement of injections and how quickly the signal returned to baseline. The 
complex impedance data collected on NE+SAM injections were subtracted by the data collected 
on PBS only injections to attempt to remove the injection artifact. The peak heights (peak complex 
Z) at each injection were also compared for the 368 and 321 Hz data. 
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2.2.11.2 Z-t Analysis of GFAP, NSE, S-100β and TNF-α Data 
 
Z-t data analysis for these biomarkers was conducted in the same way as the first Z-t experiments 
to measure NE+SAM. 
 
2.3 Results and Discussion 
2.3.1 EIS Results and Discussion 
 
2.3.1.1 NE+SAM EIS Results and Discussion 
 
The overlaid plots shown in Fig 2.3 are an example of the raw Nyquist data obtained from every 
other solution in a NE+SAM purified gradient on one GDE. Generally, a Randles shape was 
observed along with a positive trend between impedance and NE+SAM concentration. After data 
analysis, calibration curves at 371.1 Hz were found to be the optimal binding frequency for 
NE+SAM. The graph in Fig 2.4 shows one of the best GDEs which measured a purified NE+SAM 
gradient, and yet the slope and R2 peaks did not coincide over the same frequencies, but as 
reproducibility is most desired in regions of acceptable slope, an optimal frequency of 371.1 Hz 
was selected. This frequency was verified in an N = 12 GDE analysis of purified NE+SAM gradients, 
the calibration curve for which is shown in Fig 2.5 (DL = 98 pg/mL). 
 
Verification of this optimal frequency in the blood data was conducted. The 90% blood 
measurement surprisingly behaved the best based on calibration curve fitting at the optimal 
frequency. The 90% blood data displayed an overall larger impedance compared to the averaged 
purified data, but this was expected given the presence of many proteins such as albumin in whole 
blood which would increase impedance. Despite these additional proteins in the blood samples, 
this does not detract from the NE+SAM measurement, given the accuracy of fitting and validation 
of the optimal binding frequency. Calibration curves for purified and 90% blood can be seen in Fig 
2.5, and the calibration curve equations for all percentages of blood measured can be found in 
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Table 2.17. Changes in the calibration curve slopes and R2 at the optimal frequency were also 
analyzed with respect percentage of blood in the sample. The graph in Fig 2.6 plots the R2 (left 
axis, black data) and the slope (right axis, gray data) versus % of blood, but does not yield an 
observable trend in this N = 1 data. For the slope data in particular, a second order polynomial 
provided a better fit (R2 > 0.6), but past data has shown more often than not, that biomarker binding 
events are more often than not logarithmic in nature with respect to concentration of analyte, which 
was difficult to prove given the large jump in blood percentage to 90%. At the time of experimental 
design, it was thought that the 90% blood data would not yield a reliable response given previous 
experience, but testing as near to whole blood (a real-world sample) as possible would be an 
important sensor validation point offering room for progress. 
 
2.3.1.2 GFAP, NSE, S-100β and TNF-α EIS Results and Discussion 
 
Each biomarker was individually measured in purified solutions using EIS. Calibration curves and 
their corresponding equations at the optimal binding and dead frequencies for each of these four 
biomarkers can be found in Figs 2.7-2.10 for GFAP (17.44 Hz, DL = 2.3 pg/mL), NSE (546.9 Hz, 
DL = 2.12 pg/mL), S-100β (2148 Hz, DL = 3.27 pg/mL), and TNF-α (57.44 Hz. DL = 0.55 pg/mL). 
The dead frequencies were also plotted to serve as a basis for comparison for Z-t data discussed 
later. Again, it was observed that the dead frequencies detected little to no response to the same 
purified gradients measured at the optimal frequencies. Eventually, a handheld device could be 
programmed with these equations to quantify these biomarkers. The device would only be able to 
measure impedance, without these equations, the device could not report a concentration. 
However, the end device would measure samples from blood or plasma, not purified samples.  
 
Ideally, a reliable calibration curve from the highest percentage of blood would be used to program 
the end device requiring little to no sample preparation before use. Unfortunately, it is difficult to 
reliably perform electrochemical measurements in whole blood samples due to interference of 
components such as red blood cells [139]. This is why most published electrochemical sensors 
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detect analytes in serum and/or use novel materials or coatings to improve performance [93]–[95], 
[139]. In this work, EIS blood data analysis yielded a calibration curve, and validation analysis of 
the optimal frequency through use of slope versus frequency and R2 versus frequency plots (Figs 
2.11-2.14). A summary of detection limits for each biomarker at each blood and plasma 
concentration can be found in Table 2.17. Generally, natural logarithmic slope for blood data was 
very high (usually greater 1000 Ω/pgmL-1) in the lowest frequencies (< 50 Hz), then falls to nearly 
basal levels. This was not surprising since most biological biomarkers have relatively low optimal 
frequencies [104], [105], [108], [109], [136]. The natural logarithmic R2 versus frequency had similar 
shapes across blood percentage and biomarker: an initial dip in the lower frequencies was followed 
by a relatively sharp increase, then a slow tapper downward. The 5% blood solutions generally 
performed the best with regard to calibration curve fits, but the 15.5% blood solutions also 
performed well (outperformed the 5% GFAP blood data). However, calibration curve variation 
because an issue in the 25% and 90% blood data.\, presumably due to the marked increase in 
blood component interference. However, this is not necessarily a deal breaker if the sample needs 
to be simply diluted with PBS before use with the end device, it still beats isolation of serum before 
sensor use. 
 
Very similar observations were made in the plasma EIS data analysis (Figs 2.15-2.18) regarding 
slope and R2, except that the R2 graphs showed larger initial dips in the lower frequencies than was 
observed in the blood data. The reason for this is unknown, but the differences between blood and 
plasma solution components may be involved. Optimal frequencies selected from the purified data 
were also sufficient for use in blood and plasma analysis to obtain updated and more real-world 
calibration curves for the biomarkers of interest. 
 
Since the envisioned device will simultaneously detect these biomarkers, it is important that these 
optimal frequencies are far enough apart so each analyte can be distinguished in a multi-analyte 
sample. As discussed in the EIS data analysis from section 2, a cluster of approximately 10 
frequencies could be called an optimal frequency for every biomarker-capture protein pair. If these 
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potential optimal frequencies do not overlap with another biomarker-capture protein pair’s range of 
potential optimal frequencies, it should be possible to distinguish one analyte from many using this 
technique [101]. If frequency clusters for multiple biomarkers did overlap, an exchange of capture 
protein would likely change the optimal binding frequency. In the case of these four biomarkers, no 
overlap of frequencies was observed, thus simultaneous detection should be possible. 
 
2.3.1.2 Rat CCI NSE and S-100β EIS Results and Discussion 
 
EIS results from rat CCI plasma collected 1, 3, 7 and 14 days after injury were compared to rat 
sham plasma collected on day 7. A two-tailed Mann-Whitney U test on the mean impedance values 
concluded that there was no statistical difference between mild and moderate CCI injury for either 
NSE (U = 29) or S-100β (U = 16), where α = 0.05 (critical U value = 13). One reason for this could 
be the way in which injury was imparted. While the definitions of TBI severity are somewhat 
ambiguous, the mild injuries in these rats included an open and penetrating wound, which could be 
determined as a moderate or severe TBI in a clinical setting, while the moderate injury would be a 
greater severe TBI. A one-way ANOVA on the raw impedance values of both mild and moderate 
CCI data lumped together for each biomarker resulted in mean NSE concentrations being 
statistically on different days of plasma collection (p = 0.02), while the mean S-100β concentrations 
were almost statistically different (p = 0.06) between days of plasma collection (statistically 
significant at α = 0.1). Each bar shown in Figs 2.19-2.20 represents an average of 2 ratios (EIS 
signal of unknown sample divided by its respective blank) for two rats with the same injury type (i.e. 
same severity, same plasma collection day). This data was only N = 2 (biological replicates without 
technical replicates) due to limited rat CCI plasma available, thus limiting the number of statistical 
tests which could be performed, and therefore limiting the conclusions which can be soundly drawn. 
With this in mind, the remainder of this section attempts to make any observations possible, though 
perhaps not statistically grounded. 
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While it appears that no statistical difference exists between mild and moderate concentrations of 
S-100B, these concentrations do appear to increase over time (probably due to secondary 
damage), then decrease together. This reflects the conclusions by Woertgen et al., in human serum 
[140] and by Hardemark et al., in rat CSF [141] that NSE is a better indicator for extended injury 
assessment, while S-100β may better inform severity assessments within hours after injury. In the 
NSE and S-100β data in Fig 2.19 & 2.20, the rat shams provided lower signal compared to mild 
and moderate data taken on the same day, but the sham data appeared to be relatively high 
compared to mild and moderate data taken on other days (no way to statistically determine 
differences since N = 2). Based on these observations, it is possible that the craniotomy surgery 
performed on all rats caused an increase in NSE and S-100β concentrations. In a study by Cole 
and coworkers, the standard of using craniotomy as a sham animal model was compared (based 
on MRI, CT, behavioral and protein quantification data) using two different drilling techniques 
against naïve rats (no craniotomy) [142]. This study concluded that many rats which underwent the 
sham craniotomy surgery displayed several injuries which could confound a TBI study (e.g. 
subdural and intracerebral bleeding, CO2 level disruption, lesion generation, inflammation, 
metabolism disruption) despite the use of an experience surgeon and third-party confirmation of no 
visible dural damage occurred after the craniotomy of each rat. Furthermore, this study and others 
suggest these injuries were potentially seen after craniotomy due to the surgery disrupting the 
nerve fiber network and blood vessels connecting the skull and brain which could in turn cause a 
cascade of secondary injuries as a result of drilling heat and vibration [142], [143]. 
 
The general trends of NSE and S-100β concentrations over the days monitored after injury found 
some consistency with the Woertgen et al. and Hardemark et al. findings [140], [141] in that an 
increase of NSE was observed between day 1 and day 3. Visually (Fig 2.19), it appears the mild 
and moderate NSE measurements on day 3 were approximately the same since the one standard 
deviation error bars overlap. On day 5, the Woertgen study reported human serum NSE levels 
remained high, which could be evident in the day 7 EIS data. It is probable that secondary injury 
occurred between days 3 and 7 to cause an increase of NSE since this increase was seen in both 
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mild and moderate injuries. Moreover, the NSE data supports the expectation that concentrations 
on day 14 were lower than on day 7, assuming no secondary injury occurred after day 7. 
 
The predicted concentrations in Table 1 were higher and closer in magnitude than was expected. 
The mostly likely cause is that the modified calibration curves were not robust enough or left out 
an unmeasured parameter to make the prediction accurate. However, these data did confirm that 
S-100β concentrations were consistently higher than those of NSE [141]. The predicted NSE 
concentrations were much lower than those reported by the Woertgen study (9,000-30,000 pg/mL), 
however the predicted S-100β concentrations fell within the range reported by Woertgen et al. (400-
2600 pg/mL) [140]. Two reasonable explanations for these concentration differences between the 
measured and reported data is that the reported data were performed in humans instead of rats 
and were measured using a different technique (ELISA). 
 
2.3.2 Z-t Results and Discussion 
 
2.3.2.1 NE+SAM Z-t Results and Discussion 
 
Theoretically, the hardware required to conduct Z-t measurements would be less than the hardware 
required to run the usual EIS measurements if only a few frequencies were to be measured. This 
technique is as sensitive as the EIS technique, but would also help to minimize the size and weight 
of a point-of-care handheld diagnostic. The first set of Z-t data closely matched the EIS 
measurements of the purified NE+SAM solutions. A time-appended plot showing the raw data of 
the separate Z-t measurements on two different GDEs measuring the purified NE+SAM gradient 
(Fig 2.21) at 368 Hz. The overall impedance difference between the two GDEs is not surprising 
since that is seen in the EIS data also, and it is likely due to variation in the immobilization chemistry. 
As expected, a general increase in impedance is also seen as NE+SAM concentrations increase. 
The calibrations curves in Fig 2.22 compare three time points during the Z-t assay (3, 24 and 89 
sec) which corresponded to times where the highest LN slope and R2 occurred. In this case, the 
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most reliable NE+SAM measurement occurred 3 sec into the assay (DL = 8 pg/mL), which rivals 
commercial glucose meters. 
 
The second set of Z-t data explored different frequencies measuring 5 injections of 500 pg/mL 
purified NE+SAM solutions. The raw data of continuous NE+SAM versus PBS spikes at 368 and 
321 Hz can be seen in Fig 2.23. Interestingly, the PBS signal at both frequencies yield greater 
impedance than the NE+SAM signals, this is likely due to the fact that PBS is full of salts, while the 
NE+SAM solutions contain larger, more electrically-neutral molecules. However, the signal at 368 
Hz appears to be more consistent than the 321 Hz data, as shown by Fig 2.24. These bars 
represent the NE+SAM signal subtracted by the PBS signal at the same frequency. Interestingly, 
the second peak yields the highest signal for the 368 Hz data, and the spikes thereafter begin to 
decrease in signal, potentially indicating that one of the reactants was saturated (PNMT enzyme) 
or consumed (SAM co-factor). In data not shown, this experiment was repeated on two other 
frequencies (3676 and 46300 Hz). While no response was observed, this indicates that there is 
little or no harmonic effect, and that high unresponsive frequencies could be used to potentially 
calibrate a handheld device without use of multiple samples. 
 
2.3.2.1 GFAP, NSE, S-100β and TNF-α Z-t Results and Discussion 
 
Purified gradients of these individual four biomarkers were also assed using Z-t to find a minimum 
assay time a handheld device would need to individually quantify these biomarkers. To determine 
the minimum assay time, purified gradients calibration curves were compared (Figs 2.25-2.28): 
GFAP (3 sec), NSE (13 sec), S-100β (15 sec), and TNF-α (2 sec). If one GDE had antibodies for 
all four of these biomarkers, a purified sample containing all of these antigens could be quantified 
one at a time in 33 seconds, which is less than the run time to run one EIS sweep (~90 sec). Z-t 
measurements at the optimal frequencies were also compared to purified measurements at dead 
frequencies (Figs 2.29-2.32). A high frequency which is not responsive to biomarker concentration 
changes could be used to calibrate a handheld sensor in a very short time every time a 
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measurement is made, and would not require the user to perform the calibration in a separate 
solution. One downside to the CHI workstation’s Z-t method was that the exact desired frequencies 
could not be achieved, for the dead frequency used, 37110 Hz was entered as the stimulating 
frequency, but 36670 Hz was actually used. For the purposes of feasibility, this was sufficient, but 
a handheld device would be custom made to provide the frequencies of interest. Z-t is still an idea 
technique to use in a handheld meter which would provide the same sensibility as EIS with less 
hardware (minimum sweep of ~ 15 – 2200 Hz) and in less time than a full EIS sweep. 
 
2.4 Conclusion 
The goals in the first specific aim were successfully addressed. Each of the potential biomarkers 
has been quantified using the electrochemical impedance techniques in purified solutions and 
validated in blood and plasma solutions using capture protein-immobilized gold disk electrodes and 
without the use of coatings or membranes. The resulting calibrations curves will serve as 
mathematical models to program an end device so measured impedance can be converted into 
biomarker concentration. The feasibility of the Z-t method was also explored and found to be 
capable of quantifying the four biomarkers (one biomarker at a time) in less than 35 seconds. 
Moreover, the Z-t method could provide a self-calibrating method for a handheld device without the 
loss of sensitivity. Additionally, these sensors achieved mixed success in measuring two of the 
biomarkers in mild and moderate CCI rat plasma samples. A future study with increased rat TBI 
samples and various levels of sham (naïve and craniotomy only) could lead to better statistical 
significance in quantifying TBI biomarkers in mild and moderate TBI cases. 
 
Next steps include use of novel electrode materials to improve sensor performance in complex 
media and comparing these new data to Nafion-coated GDEs. Future work would include efforts to 
verify Z-t results in complex media and using Z-t to simultaneously detect these TBI biomarkers 
would also be required before a TBI blood diagnostic could be created to positively impact the lives 
of millions each year. 
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2.5 Figures 
 
Fig 2.1: A schematic of the three-electrode system and sample well. 
 
 
Fig 2.2: A schematic summarizing the immobilization process for a PNMT functionalized GDE. 
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Table 2.1: Calculations to create the purified 9-point titer of NE+SAM solutions. 
NE=   MW (g/mol)= 169.18 
STOCK
: 1 0.5 
mg/m
L 
SAM=   MW (g/mol)= 398.44  
1.00E+0
9 
5.00E+0
8 pg/mL 
      0.00591 0.00125 M 
Dilution 
# 
Desired 
[NE] 
(pg/mL) 
Desired 
[NE] (M) 
Dilution [NE] 
(pg/mL) 
Dilution 
[NE] (M) 
Dilution volume to 
make next dilution** 
(µL) 
Volume of PBS to 
Make Next 
Dilution** (µL) 
BLANK 0 0.00E+00 0 0.00E+00 --- --- 
1 1 5.91E-12 2 1.18E-11 --- --- 
2 5 2.96E-11 10 5.91E-11 69.88155 280.11845 
3 10 5.91E-11 20 1.18E-10 175.2966 174.7034 
4 50 2.96E-10 100 5.91E-10 69.88155 280.11845 
5 100 5.91E-10 200 1.18E-09 175.2966 174.7034 
6 500 2.96E-09 1000 5.91E-09 69.88155 280.11845 
7 1000 5.91E-09 2000 1.18E-08 175.2966 174.7034 
8 5000 2.96E-08 10000 5.91E-08 69.88155 280.11845 
9 10000 5.91E-08 20000 1.18E-07 175.2966 174.7034 
For 3 GDEs  from stock: 
0.2995 14998.5025 
Each dilution= 350uL: 150uL for Gradient+ 200uL to make next 
dilution 
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Table 2.2: Calculations to create purified 9-point titer of GFAP solutions. 
MW= 46000 g/mol 
Origin. 
STOCK: 
66.6666 µg/mL  
Int. 
Stock 
460 ng/mL   
   1.4493 µM  10 nM   
Dilution 
# 
Desired 
[GFAP] 
(pg/mL) 
Desired 
[GFAP] 
(g/L) 
Desired 
[GFAP] 
(M) 
Dilution 
[GFAP] 
(pg/mL) 
Dilution 
[GFAP] 
(M) 
Dilution volume to 
make next dilution** 
(µL) 
Volume of 
PBS to Make 
Next Dilution** 
(µL) 
 
BLANK 0.00 0.00E+00 0.00E+00 0.00 0.00E+00 --- ---  
1 0.10 1.00E-10 2.17E-15 0.20 4.35E-15 --- ---  
2 0.75 7.50E-10 1.63E-14 1.50 3.26E-14 66.72 433.28 1 
3 5.00 5.00E-09 1.09E-13 10.00 2.17E-13 75.12 424.88 2 
4 45.00 4.50E-08 9.78E-13 90.00 1.96E-12 55.36 444.64 3 
5 120.00 1.20E-07 2.61E-12 240.00 5.22E-12 187.74 312.26 4 
6 450.00 4.50E-07 9.78E-12 900.00 1.96E-11 133.16 366.84 5 
7 1000.00 1.00E-06 2.17E-11 2000.00 4.35E-11 225.29 274.71 6 
8 1500.00 1.50E-06 3.26E-11 3000.00 6.52E-11 333.59 166.41 7 
9 2800.00 2.80E-06 6.09E-11 5600.00 1.22E-10 267.21 232.79 8 
For 3 GDEs START HERE from INTERMEDIATE stock: 6.10 493.90 9 
Each dilution= 500uL= 150uL for Gradient+ 350uL to make next dilution 
 
    
 
Table 2.3: Calculations to create the purified 9-point titer of NSE solutions.  
Stock: 0.01 mg/mL 0.01 g/L 2.08E-07 M      
   NSE MM: 4.80E+04 0.00E+00 g/mol       
Dilution 
# Desired 
[NSE] 
(pg/mL) 
Desired 
[NSE] 
(g/L) 
Desired 
[NSE] 
(M) 
Dilution 
[NSE] 
(pg/mL) 
Dilution 
[NSE] 
(M) Dilution volume to make 
next dilution (µL) 
Volume of PBS 
to Make Next 
Dilution (µL) 
M
a
k
e
s
 
BLANK 0 0.00E+00 0.00E+00 0 0.00E+00 --- --- 
1 1 1.00E-09 2.08E-14 2 4.17E-14 --- --- 
2 5 5.00E-09 1.04E-13 10 2.08E-13 100.24 399.76 D1 
3 10 1.00E-08 2.08E-13 20 4.17E-13 249.40 250.60 D2 
4 200 2.00E-07 4.17E-12 400 8.33E-12 25.03 474.97 D3 
5 500 5.00E-07 1.04E-11 1000 2.08E-11 200.24 299.76 D4 
6 1200 1.20E-06 2.50E-11 2400 5.00E-11 208.00 292.00 D5 
7 7000 7.00E-06 1.46E-10 14000 2.92E-10 85.62 414.38 D6 
8 12000 1.20E-05 2.50E-10 24000 5.00E-10 292.00 208.00 D7 
9 25000 2.50E-05 5.21E-10 50000 1.04E-09 240.38 259.62 D8 
    
From stock solution 2.50 497.50 D9 
use: 50uL of(PBS+ Dilution Volume) + 50uL of RP= Tested/Actual Solution at desired []  
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Table 2.4: Calculations create the purified 9-point titer of S-100β solutions. 
     MW= 
1071
3 
g/mo
l 
STOCK
: 1 
mg/m
L  
       
93.344
5 µM  
Dilution # 
Desired 
[S-
100B] 
(pg/mL) 
Desired 
[S-100B] 
(g/L) 
Desired 
[S-100B] 
(M) 
Dilution 
[S-100B] 
(pg/mL) 
Dilution [S-
100B] (M) 
Dilution volume to make 
next dilution** (µL) 
Volume of PBS to 
Make Next 
Dilution** (µL) 
M
a
k
e
s
 
BLANK 0 
0.00E+0
0 
0.00E+0
0 0 
0.00E+0
0 --- ---  
1 1 1.00E-09 9.33E-14 2 1.87E-13 --- ---  
2 5 5.00E-09 4.67E-13 10 9.33E-13 100.214 399.786 1 
3 10 1.00E-08 9.33E-13 20 1.87E-12 249.465 250.535 2 
4 50 5.00E-08 4.67E-12 100 9.33E-12 100.214 399.786 3 
5 100 1.00E-07 9.33E-12 200 1.87E-11 249.465 250.535 4 
6 500 5.00E-07 4.67E-11 1000 9.33E-11 100.214 399.786 5 
7 1000 1.00E-06 9.33E-11 2000 1.87E-10 249.465 250.535 6 
8 5000 5.00E-06 4.67E-10 10000 9.33E-10 100.214 399.786 7 
9 10000 1.00E-05 9.33E-10 20000 1.87E-09 249.465 250.535 8 
For 3 GDEs START HERE: from stock: 0.210 10499.790 9 
Each dilution= 500uL= 200uL for Gradient+ 300uL to make next dilution 
 
    
 
Table 2.5: Calculations to create the purified 9-point titer of TNF-α solutions. 
   Original Stock= 20 ug powder + 10 mL PBS= 2 ug/mL    
MW= 17500 g/mol 
Origin. 
STOCK: 
2 µg/mL  
Int. 
Stock 
0.5 ng/mL   
   114.2857 pM  28.5714 pM   
Dilution 
# 
Desired 
[TNF-
A] 
(pg/mL) 
Desired 
[TNF-A] 
(g/L) 
Desired 
[TNF-A] 
(M) 
Dilution 
[TNF-A] 
(pg/mL) 
Dilution 
[TNF-A] 
(M) 
Dilution volume to make 
next dilution** (µL) 
Volume of PBS 
to Make Next 
Dilution** (µL) 
M
a
k
e
s
 
BLANK 0.00 0.00E+00 0.00E+00 0.00 0.00E+00 --- --- 
1 0.10 1.00E-10 5.71E-15 0.20 1.14E-14 --- --- 
2 0.75 7.50E-10 4.29E-14 1.50 8.57E-14 66.51 433.49 1 
3 2.25 2.25E-09 1.29E-13 4.50 2.57E-13 166.73 333.27 2 
4 5.00 5.00E-09 2.86E-13 10.00 5.71E-13 225.04 274.96 3 
5 13.00 1.30E-08 7.43E-13 26.00 1.49E-12 191.61 308.39 4 
6 21.00 2.10E-08 1.20E-12 42.00 2.40E-12 310.42 189.58 5 
7 30.00 3.00E-08 1.71E-12 60.00 3.43E-12 349.85 150.15 6 
8 44.00 4.40E-08 2.51E-12 88.00 5.03E-12 340.95 159.05 7 
9 75.00 7.50E-08 4.29E-12 150.00 8.57E-12 293.47 206.53 8 
For 3 GDEs START HERE from INTERMEDIATE stock: 149.98 350.02 9 
 
  44 
Table 2.6: Calculations to create 5%, 12.5%, 25% blood/plasma 9-point titer of NE+SAM solutions. 
NE= Norepinephrine  MW= 169.18 g/mol STOCK: 1 mg/mL  
      5.9109 mM  
Dilution 
# 
Desired 
[NE] 
(pg/mL) 
Desired 
[NE] 
(g/L) 
Desired 
[NE] (M) 
Dilution 
[NE] 
(pg/mL) 
Dilution [NE] 
(M) 
Dilution volume to 
make next 
dilution (µL) 
Volume of PBS to 
Make Next 
Dilution (µL)  
BLANK 0 0 0 0 0 --- ---  
1 1 
1.00E-
09 5.91E-12 8 4.72869E-11 --- ---  
2 5 
5.00E-
09 2.96E-11 40 2.36E-10 
140.00 
560.00 1 
3 10 
1.00E-
08 5.91E-11 80 4.73E-10 
350.00 
350.00 2 
4 50 
5.00E-
08 2.96E-10 400 2.36E-09 
140.00 
560.00 3 
5 100 
1.00E-
07 5.91E-10 800 4.73E-09 
350.00 
350.00 4 
6 500 
5.00E-
07 2.96E-09 4000 2.36E-08 
140.00 
560.00 5 
7 1000 
1.00E-
06 5.91E-09 8000 4.73E-08 
350.00 
350.00 6 
8 5000 
5.00E-
06 2.96E-08 40000 2.36E-07 
140.00 
560.00 7 
9 10000 
1.00E-
05 5.91E-08 80000 4.73E-07 
350.00 
350.00 8 
For 6 GDEs START HERE: from stock: 0.240 2999.76 9 
Each dilution=  700 uL: 300uL for Gradient+ 400uL to make next dilution   
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Table 2.7: Calculations to create 5%, 12.5%, 25% blood/plasma 9-point titer of GFAP solutions. 
GFAP 
Stock: 0.005 mg/mL 0.005 g/L 1.09E-07 M   
GFAP 
MM: 
4.60E+0
4  
INT Stock: 
1.00E-
09 M  50uL of INT Stock =  
0.46 
uL of 0.81 mg/mL 
stock + 
49.54 
uL PBS  
Dilution # 
Desired 
[GFAP] 
(pg/mL) 
Desired 
[GFAP] 
(g/L) 
Desired 
[GFAP] 
(M) 
Dilution 
[GFAP] 
(pg/mL) 
Dilution 
[GFAP] 
(M) 
Dilution volume to 
make next dilution (µL) 
Volume of PBS to 
Make Next Dilution 
(µL) 
M
a
k
e
s
 BLANK 0 
0.00E+0
0 
0.00E+0
0 0 
0.00E+0
0 --- --- 
1 0.1 
1.00E-
10 
2.17E-
15 0.4 8.70E-15 --- --- 
2 0.75 
7.50E-
10 
1.63E-
14 3 6.52E-14 
86.67 563.33 
1 
3 2.25 
2.25E-
09 
4.89E-
14 9 1.96E-13 
216.67 433.33 
2 
4 5 
5.00E-
09 
1.09E-
13 20 4.35E-13 
292.50 357.50 
3 
5 13 
1.30E-
08 
2.83E-
13 52 1.13E-12 
250.00 400.00 
4 
6 21 
2.10E-
08 
4.57E-
13 84 1.83E-12 
402.38 247.62 
5 
7 30 
3.00E-
08 
6.52E-
13 120 2.61E-12 
455.00 195.00 
6 
8 44 
4.40E-
08 
9.57E-
13 176 3.83E-12 
443.18 206.82 
7 
9 75 
7.50E-
08 
1.63E-
12 300 6.52E-12 
381.33 268.67 
8 
For 3 GDEs 
(N=3) 
From INT Stock 
solution 
4.24 
645.76 9 
use: 50uL of(PBS+ Whole Blood) + 25uL of 200mM Ferri RP + 25uL of dilution= Tested/Actual Solution at desired []  
650 
uL 
total: 75 uL for gradient + 575 uL for making next dilution   
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Table 2.8: Calculations to create the 5%, 12.5%, 25% blood/plasma 9-point titer of NSE solutions. 
NSE 
Stock: 0.81 mg/mL 0.81 g/L 
1.69E-
05 M   
NSE 
MM: 
4.80E+
04  
INT 
Stock: 
1.00E-
06 M  5uL of INT Stock =  
0.30 
uL of 0.81 mg/mL 
stock + 
4.70 
uL 
PBS  
Dilution 
# 
Desire
d 
[NSE] 
(pg/mL
) 
Desire
d 
[NSE] 
(g/L) 
Desired 
[NSE] (M) 
Dilution [NSE] 
(pg/mL) 
Dilutio
n 
[NSE] 
(M) 
Dilution volume to 
make next dilution 
(µL) 
Volume of PBS 
to Make Next 
Dilution (µL) 
M
a
k
e
s
 BLANK 0 
0.00E+
00 0.00E+00 0 
0.00E+
00 --- --- 
1 1 
1.00E-
09 2.08E-14 4 
8.33E-
14 --- --- 
2 5 
5.00E-
09 1.04E-13 20 
4.17E-
13 
80.00 320.00 
1 
3 10 
1.00E-
08 2.08E-13 40 
8.33E-
13 
200.00 200.00 
2 
4 200 
2.00E-
07 4.17E-12 800 
1.67E-
11 
20.00 380.00 
3 
5 500 
5.00E-
07 1.04E-11 2000 
4.17E-
11 
160.00 240.00 
4 
6 1200 
1.20E-
06 2.50E-11 4800 
1.00E-
10 
166.67 233.33 
5 
7 7000 
7.00E-
06 1.46E-10 28000 
5.83E-
10 
68.57 331.43 
6 
8 12000 
1.20E-
05 2.50E-10 48000 
1.00E-
09 
233.33 166.67 
7 
9 25000 
2.50E-
05 5.21E-10 100000 
2.08E-
09 
192.00 208.00 
8 
For 3 GDEs 
(3 GDEs, 
N=3) 
From INT stock 
solution 
0 0.83 
399.17 9 
use: 50uL of(PBS+ Whole Blood) + 25uL of 200mM Ferri RP + 25uL of dilution= Tested/Actual Solution at desired []  
400 
uL 
total: 75 uL for gradient + 325 
uL for making next 
dilution   
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Table 2.9: Calculations to create 5%, 12.5%, 25% blood/plasma 9-point titer of S-100β solutions. 
INT 
Stock: 0.01 1 0.01 g/L 
9.33445E-
07 M  
S-100B MM: 
1.07E+0
4 
 
Dilution # 
Desired 
[S-
100B] 
(pg/mL) 
Desired 
[S-100B] 
(g/L) 
Desired [S-
100B] (M) 
Dilution 
[S-
100B] 
(pg/mL) 
Dilution [S-
100B] (M) 
Dilution volume to 
make next dilution 
(µL) 
Volume of PBS to 
Make Next Dilution 
(µL) 
M
a
k
e
s
 BLANK 0 
0.00E+0
0 0.00E+00 0 0.00E+00 --- --- 
1 1 
1.00E-
09 9.33E-14 4 3.73E-13 --- --- 
2 5 
5.00E-
09 4.67E-13 20 1.87E-12 
35.00 140.00 
1 
3 10 
1.00E-
08 9.33E-13 40 3.73E-12 
87.50 87.50 
2 
4 50 
5.00E-
08 4.67E-12 200 1.87E-11 
35.00 140.00 
3 
5 100 
1.00E-
07 9.33E-12 400 3.73E-11 
87.50 87.50 
4 
6 500 
5.00E-
07 4.67E-11 2000 1.87E-10 
35.00 140.00 
5 
7 1000 
1.00E-
06 9.33E-11 4000 3.73E-10 
87.50 87.50 
6 
8 5000 
5.00E-
06 4.67E-10 20000 1.87E-09 
35.00 140.00 
7 
9 10000 
1.00E-
05 9.33E-10 40000 3.73E-09 
87.50 87.50 
8 
For 3 GDEs 
(3 GDEs, 
N=3) 
From INT Stock 
solution 
0.70 
174.30 9 
use: 50uL of (PBS+ Whole Blood) + 25uL of 200mM Ferri RP + 25uL of dilution= Tested/Actual Solution at desired []  
175 
uL 
total: 75 uL for gradient + 
10
0 
uL for making next 
dilution   
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Table 2.10: Calculations to create 5%, 12.5%, 25% blood/plasma 9-point titer of TNF-α solutions. 
TNF-a 
Stock: 0.05 mg/mL 0.05 g/L 
2.86E-
06 M   
TN
F-a 
MM
: 
1.75E+
04  
INT Stock: 
1.04E-
09 M          
Dilution # 
Desire
d 
[TNF-
A] 
(pg/mL
) 
Desired 
[TNF-A] 
(g/L) 
Desired 
[TNF-A] (M) 
Dilution 
[TNF-A] 
(pg/mL) 
Dilution 
[TNF-A] 
(M) 
Dilution volume to make 
next dilution (µL) 
Volume of PBS 
to Make Next 
Dilution (µL) 
M
a
k
e
s
 BLANK 0 
0.00E+
00 0.00E+00 0 
0.00E+
00 --- --- 
1 0.1 
1.00E-
10 5.71E-15 0.4 
2.29E-
14 --- --- 
2 0.75 
7.50E-
10 4.29E-14 3 
1.71E-
13 
40.00 260.00 
1 
3 2.25 
2.25E-
09 1.29E-13 9 
5.14E-
13 
100.00 200.00 
2 
4 5 
5.00E-
09 2.86E-13 20 
1.14E-
12 
135.00 165.00 
3 
5 13 
1.30E-
08 7.43E-13 52 
2.97E-
12 
115.38 184.62 
4 
6 21 
2.10E-
08 1.20E-12 84 
4.80E-
12 
185.71 114.29 
5 
7 30 
3.00E-
08 1.71E-12 120 
6.86E-
12 
210.00 90.00 
6 
8 44 
4.40E-
08 2.51E-12 176 
1.01E-
11 
204.55 95.45 
7 
9 75 
7.50E-
08 4.29E-12 300 
1.71E-
11 
176.00 124.00 
8 
For 3 GDEs 
(3 GDEs, 
N=3) 
From INT stock 
solution 
4.95 
295.05 9 
use: 50uL of(PBS+ Whole Blood) + 25uL of 200mM Ferri RP + 25uL of dilution= Tested/Actual Solution at desired []  
300 
uL 
total: 75 uL for gradient + 
22
5 
uL for making next 
dilution    
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Table 2.11: Calculations to create the 90% blood/plasma 9-point titer of NE+SAM solutions. 
NE= Norepinephrine  MW= 169.18 g/mol STOCK: 0.5 mg/mL  
      2.9554 mM  
Dilution 
# 
Desired 
[NE] 
(pg/mL) 
Desired 
[NE] 
(g/L) 
Desired 
[NE] (M) 
Dilution 
[NE] 
(pg/mL) 
Dilution 
[NE] (M) 
Dilution volume to 
make next dilution 
(µL) 
Volume of PBS to 
Make Next 
Dilution (µL) 
 
BLANK 0 0 0 0 0 --- ---  
1 1 1.00E-09 5.91E-12 20 1.18E-10 --- ---  
2 5 5.00E-09 2.96E-11 100 5.91E-10 60.00 240.00 1 
3 10 1.00E-08 5.91E-11 200 1.18E-09 150.00 150.00 2 
4 50 5.00E-08 2.96E-10 1000 5.91E-09 60.00 240.00 3 
5 100 1.00E-07 5.91E-10 2000 1.18E-08 150.00 150.00 4 
6 500 5.00E-07 2.96E-09 10000 5.91E-08 60.00 240.00 5 
7 1000 1.00E-06 5.91E-09 20000 1.18E-07 150.00 150.00 6 
8 5000 5.00E-06 2.96E-08 100000 5.91E-07 60.00 240.00 7 
9 10000 1.00E-05 5.91E-08 200000 1.18E-06 150.00 150.00 8 
For 1 GDEs START HERE: from stock: 0.77 1999.23 9 
Each dilution= 300 uL: 100uL for Gradient+ 200uL to make next dilution   
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Table 2.12: Calculations to create the 90% blood/plasma 9-point titer of GFAP solutions. 
GFAP 
Stock: 0.005 mg/mL 0.005 g/L 1.09E-07 M   
GFA
P 
MM: 
4.60E+
04  
INT 
Stock: 
1.00E-
09 M  50uL of INT Stock =  
0.46 
uL of 0.81 mg/mL 
stock +  
49.5
4 uL PBS  
Dilution # 
Desired 
[GFAP] 
(pg/mL) 
Desired 
[GFAP] 
(g/L) 
Desired 
[GFAP] (M) 
Dilutio
n 
[GFAP
] 
(pg/m
L) 
Dilution 
[GFAP] 
(M) 
Dilution volume to 
make next dilution 
(µL) 
Volume of PBS to 
Make Next Dilution 
(µL) 
M
a
k
e
s
 
BLANK 0 
0.00E+
00 0.00E+00 0 0.00E+00 --- --- 
1 0.1 
1.00E-
10 5.71E-15 2 1.14E-13 --- --- 
2 0.75 
7.50E-
10 4.29E-14 15 8.57E-13 
13.33 86.67 
1 
3 2.25 
2.25E-
09 1.29E-13 45 2.57E-12 
33.33 66.67 
2 
4 5 
5.00E-
09 2.86E-13 100 5.71E-12 
45.00 55.00 
3 
5 13 
1.30E-
08 7.43E-13 260 1.49E-11 
38.46 61.54 
4 
6 21 
2.10E-
08 1.20E-12 420 2.40E-11 
61.90 38.10 
5 
7 30 
3.00E-
08 1.71E-12 600 3.43E-11 
70.00 30.00 
6 
8 44 
4.40E-
08 2.51E-12 880 5.03E-11 
68.18 31.82 
7 
9 75 
7.50E-
08 4.29E-12 1500 8.57E-11 
58.67 41.33 
8 
For 3 GDEs 
(1 GDE, 
N=3) 
From INT Stock 
solution 
8.57 
91.43 9 
use: 90uL of Whole Blood + 5uL of 1000mM Ferri RP + 5uL of dilution= Tested/Actual Solution at desired []  
100 
uL 
total: 15 
uL for 
gradient  + 85 
uL for making next 
dilution    
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Table 2.13: Calculations to create the 90% blood/plasma 9-point titer of NSE solutions. 
NSE 
Stock: 0.81 mg/mL 0.81 g/L 1.69E-05 M   
NSE 
MM: 
4.80E+
04  
INT 
Stock: 
1.00E-
06 M  5uL of INT Stock =  
0.30 
uL of 0.81 mg/mL 
stock + 
4.70 
uL PBS  
Dilution # Desired 
[NSE] 
(pg/mL) 
Desired 
[NSE] 
(g/L) 
Desired 
[NSE] (M) 
Dilution 
[NSE] 
(pg/mL) 
Dilution 
[NSE] 
(M) 
Dilution volume to 
make next dilution (µL) 
Volume of PBS to 
Make Next Dilution 
(µL) 
M
a
k
e
s
 BLANK 0 
0.00E+
00 0.00E+00 0 
0.00E+0
0 --- --- 
1 1 
1.00E-
09 2.08E-14 20 4.17E-13 --- --- 
2 5 
5.00E-
09 1.04E-13 100 2.08E-12 
20.00 80.00 
1 
3 10 
1.00E-
08 2.08E-13 200 4.17E-12 
50.00 50.00 
2 
4 200 
2.00E-
07 4.17E-12 4000 8.33E-11 
5.00 95.00 
3 
5 500 
5.00E-
07 1.04E-11 10000 2.08E-10 
40.00 60.00 
4 
6 1200 
1.20E-
06 2.50E-11 24000 5.00E-10 
41.67 58.33 
5 
7 7000 
7.00E-
06 1.46E-10 140000 2.92E-09 
17.14 82.86 
6 
8 12000 
1.20E-
05 2.50E-10 240000 5.00E-09 
58.33 41.67 
7 
9 25000 
2.50E-
05 5.21E-10 500000 1.04E-08 
48.00 52.00 
8 
For 3 GDEs 
(1 GDE, 
N=3) 
From INT Stock 
solution 
1.04 
98.96 9 
use: 90uL of Whole Blood + 5uL of 1000mM Ferri RP + 5uL of dilution= Tested/Actual Solution at desired []  
100 
uL 
total: 15 uL for gradient + 85 
uL for making next 
dilution   
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Table 2.14: Calculations to create the 90% blood/plasma 9-point titer of S-100β solutions. 
INT Stock: 0.01 mg/mL 0.01 g/L 
9.33E-
07 M  
S-100B MM: 
1.07E+
04 
 
Dilution # 
Desired 
[S-
100B] 
(pg/mL) 
Desired 
[S-
100B] 
(g/L) 
Desired 
[S-100B] 
(M) 
Dilution 
[S-
100B] 
(pg/mL) 
Dilution 
[S-
100B] 
(M) 
Dilution volume to 
make next dilution 
(µL) 
Volume of PBS to 
Make Next 
Dilution (µL) 
M
a
k
e
s
 
BLANK 0 
0.00E+0
0 0.00E+00 0 
0.00E+0
0 --- --- 
1 1 
1.00E-
09 9.33E-14 20 
1.87E-
12 --- --- 
2 5 
5.00E-
09 4.67E-13 100 
9.33E-
12 
8.00 32.00 
1 
3 10 
1.00E-
08 9.33E-13 200 
1.87E-
11 
20.00 20.00 
2 
4 50 
5.00E-
08 4.67E-12 1000 
9.33E-
11 
8.00 32.00 
3 
5 100 
1.00E-
07 9.33E-12 2000 
1.87E-
10 
20.00 20.00 
4 
6 500 
5.00E-
07 4.67E-11 10000 
9.33E-
10 
8.00 32.00 
5 
7 1000 
1.00E-
06 9.33E-11 20000 
1.87E-
09 
20.00 20.00 
6 
8 5000 
5.00E-
06 4.67E-10 100000 
9.33E-
09 
8.00 32.00 
7 
9 10000 
1.00E-
05 9.33E-10 200000 
1.87E-
08 
20.00 20.00 
8 
For 3 GDEs 
(1 GDE, 
N=3) 
From INT Stock 
solution 
0.80 
39.20 9 
use: 90uL of Whole Blood + 5uL of 1000mM Ferri RP + 5uL of dilution= Tested/Actual 
Solution at desired []     
40 uL total: 15 uL for gradient + 25 
uL for making next 
dilution   
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Table 2.15: Calculations to create the 90% blood/plasma 9-point titer of TNF-α solutions. 
TNF-a 
Stock: 0.05 mg/mL 0.05 g/L 
2.86E-
06 M   
TN
F-a 
M
M: 
1.75E
+04  
INT Stock: 
1.04E-
09 M          
Dilution # 
Desired 
[TNF-a] 
(pg/mL) 
Desired 
[TNF-a] 
(g/L) 
Desired 
[TNF-a] (M) 
Dilution 
[TNF-a] 
(pg/mL) 
Dilution 
[TNF-a] 
(M) 
Dilution volume to 
make next dilution (µL) 
Volume of 
PBS to Make 
Next Dilution 
(µL) 
M
a
k
e
s
 BLANK 0 
0.00E+0
0 0.00E+00 0 
0.00E+0
0 --- --- 
1 0.1 
1.00E-
10 5.71E-15 2 
1.14E-
13 --- --- 
2 0.75 
7.50E-
10 4.29E-14 15 
8.57E-
13 
10.00 65.00 
1 
3 2.25 
2.25E-
09 1.29E-13 45 
2.57E-
12 
25.00 50.00 
2 
4 5 
5.00E-
09 2.86E-13 100 
5.71E-
12 
33.75 41.25 
3 
5 13 
1.30E-
08 7.43E-13 260 
1.49E-
11 
28.85 46.15 
4 
6 21 
2.10E-
08 1.20E-12 420 
2.40E-
11 
46.43 28.57 
5 
7 30 
3.00E-
08 1.71E-12 600 
3.43E-
11 
52.50 22.50 
6 
8 44 
4.40E-
08 2.51E-12 880 
5.03E-
11 
51.14 23.86 
7 
9 75 
7.50E-
08 4.29E-12 1500 
8.57E-
11 
44.00 31.00 
8 
For 3 GDEs 
(1 GDE, 
N=3) 
From INT Stock 
solution 
6.18 
68.82 9 
use: 90uL of Whole Blood + 5uL of 1000mM Ferri RP + 5uL of dilution= 
Tested/Actual Solution at desired []       
75 uL total: 15 
uL for 
gradient  + 
6
0 
uL for making next 
dilution    
 
 
Fig 2.3: Overlay of EIS Nyquist curves for every other NE+SAM concentration in the purified 9-
point titer gradient, for one GDE. 
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Fig 2.4: A comparison of R2 (left axis, black data) and slope (right axis, gray data) of purified 
NE+SAM measurements from one GDE versus the EIS frequencies measured. This graph was 
used to assist in selection of an optimal binding frequency (371.1 Hz). 
 
 
Fig 2.5: Overlay of EIS calibration curves for NE+SAM concentrations in purified (N = 12, black) 
and 10% blood (N = 1, gray) solutions. 
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Table 2.16: Summary of the predicted NSE and S-100β concentrations based on the rat CCI ratio 
data plugged into modified 12.5% spiked plasma data calibration curves for the same biomarkers. 
Predicted [TBI Biomarker] 
(pg/mL) 
Day 1 Day 3 Day 7 Day 14 
Mild CCI Predicted [NSE] 
513.86 ± 
0.23 
513.96 ± 
7.85 
523.87 ± 
7.62 
518.17 ± 
12.11 
Moderate CCI Predicted [NSE] 
523.94 ± 
8.08 
509.85 ± 
9.36 
517.08 ± 
5.74 
515.96 ± 
0.10 
Sham Predicted [NSE] -- -- 
509.61 ± 
9.23 
-- 
Mild CCI Predicted [S-100β] 
858.75 ± 
3.14 
886.68 ± 
21.66 
871.46 ± 
13.59 
870.44 ± 
0.45 
Moderate CCI Predicted [S-
100β] 
840.22 ± 
16.78 
883.28 ± 
74.94 
869.71 ± 
29.81 
855.47 ± 
3.46 
Sham Predicted [S-100β] -- -- 
853.09 ± 
0.96 
-- 
 
Table 2.17: This table contains the calibration curve equations for the purified (N = 12) versus 5%, 
10%, 25% and 90% blood solutions (N = 1) to measure NE+SAM using EIS.  
% Blood Number of GDEs NE +SAM Calibration Curve Equations 
0 12 
Z = 22.335*ln([NE]) + 2254.7 
R2 = 0.9597 
5 1 
Z = 44.37*ln([NE]) + 1758.7 
R2 = 0.9396* 
10 1 
Z = 19.176*ln([NE]) + 2153.9 
R2 = 0.8053 
25 1 
Z = 16.883*ln([NE]) + 2236.6 
R2 = 0.9737 
90 1 
Z = 30.474*ln([NE]) + 3617.9 
R2 = 0.9739 
*Indicates that the fit excludes the last concentration of NE+SAM, due to experimental error. 
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Fig 2.6: A comparison of R2 (left axis, black data) and slope (right axis, gray data) of NE+SAM 
calibration curves at the optimal frequency (371.1 Hz) versus the various percentages of blood 
samples measured. This data excludes the purified data since a logarithmic fit could not be made 
with 0 (no blood).  
 
 
Fig 2.7: EIS calibration curves (N = 8) for measurements of purified GFAP gradients at the optimal 
frequency (17.44 Hz, black data) and a non-harmonic dead frequency (37110 Hz, gray data). Error 
bars represent standard error. 
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Fig 2.8: EIS calibration curves (N = 7) for measurements of purified NSE gradients at the optimal 
frequency (546.9 Hz, black data) and a non-harmonic dead frequency (81050 Hz, gray data). Error 
bars represent standard error. 
 
 
Fig 2.9: EIS calibration curves (N = 7) for measurements of purified S-100β gradients at the optimal 
frequency (2148Hz, black data) and a non-harmonic dead frequency (66410 Hz, gray data). Error 
bars represent standard error. 
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Fig 2.10: EIS calibration curves (N = 10) for measurements of purified TNF-α gradients at the 
optimal frequency (2148Hz, black data) and a non-harmonic dead frequency (66410 Hz, gray data). 
Error bars represent standard error. 
 
Fig 2.11: Part A shows GFAP EIS calibration curves for 5% (N = 3, light grey), 12.5% (N = 6, grey), 
25% (N = 3, dark grey), and 90% (N = 3, black) blood gradients at the optimal frequency. Parts B 
and C are slope versus frequency and R2 versus frequency comparing the various percentages of 
blood to validate the optimal frequency. 
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Fig 2.12: Part A shows NSE EIS calibration curves for 5% (N = 3, light grey), 12.5% (N = 6, grey), 
25% (N = 3, dark grey), and 90% (N = 3, black) blood gradients at the optimal frequency. Parts B 
and C are slope versus frequency and R2 versus frequency comparing the various percentages of 
blood to validate the optimal frequency. 
 
Fig 2.13: Part A shows S-100β EIS calibration curves for 5% (N = 3, light grey), 12.5% (N = 6, 
grey), 25% (N = 3, dark grey), and 90% (N = 3, black) blood gradients at the optimal frequency. 
Parts B and C are slope versus frequency and R2 versus frequency comparing the various 
percentages of blood to validate the optimal frequency. 
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Fig 2.14: Part A shows TNF-α EIS calibration curves for 5% (N = 3, light grey), 12.5% (N = 6, grey), 
25% (N = 3, dark grey), and 90% (N = 3, black) blood gradients at the optimal frequency. Parts B 
and C are slope versus frequency and R2 versus frequency comparing the various percentages of 
blood to validate the optimal frequency. 
 
Table 2.18: Tabulated summary of EIS detection limits for the GFAP, NSE, S-100β and TNF-α 
biomarkers in purified, blood and plasma solutions. 
DL 
(pg/mL) 
0% 
blood 
5% 
blood 
12.5% 
blood 
25% 
blood 
90% 
blood 
5% 
plasma 
12.5% 
plasma 
25% 
plasma 
GFAP 2.32 7.18 5.74 6.73 14.06 9.08 6.44 14.49 
NSE 2.27 16.44 12.10 3.65 15.31 6.86 6.39 50.67 
S-100β 3.27 7.77 7.55 5.58 31.05 7.68 7.54 11.98 
TNF-α 0.55 6.93 9.55 10.91 67.22 12.64 5.79 16.48 
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Fig 2.15: Part A shows GFAP EIS calibration curves for 5% (N = 3, light grey), 12.5% (N = 6, grey), 
and 25% (N = 3, dark grey), plasma gradients at the optimal frequency. Parts B and C are slope 
versus frequency and R2 versus frequency comparing the various percentages of plasma to 
validate the optimal frequency. 
 
Fig 2.16: Part A shows NSE EIS calibration curves for 5% (N = 3, light grey), 12.5% (N = 6, grey), 
and 25% (N = 3, dark grey), plasma gradients at the optimal frequency. Parts B and C are slope 
versus frequency and R2 versus frequency comparing the various percentages of plasma to 
validate the optimal frequency. 
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Fig 2.17: Part A shows S-100β EIS calibration curves for 5% (N = 3, light grey), 12.5% (N = 6, 
grey), and 25% (N = 3, dark grey), plasma gradients at the optimal frequency. Parts B and C are 
slope versus frequency and R2 versus frequency comparing the various percentages of plasma to 
validate the optimal frequency. 
 
Fig 2.18: Part A shows TNF-α EIS calibration curves for 5% (N = 3, light grey), 12.5% (N = 6, grey), 
and 25% (N = 3, dark grey), plasma gradients at the optimal frequency. Parts B and C are slope 
versus frequency and R2 versus frequency comparing the various percentages of plasma to 
validate the optimal frequency. 
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Fig 2.19: Bar chart showing N = 2 NSE EIS ratio data (converted to concentration) taken 1, 3, 7 
and 14 days after CCI injury where unknown sample impedance value is divided by the impedance 
value of the last blank run on the same GDE, where light gray bars are mild, gray bars are 
moderate, and dark gray bars are sham injuries. The error bars represent one standard deviation. 
 
 
Fig 2.20: Bar chart showing N = 2 S-100β EIS ratio data (converted to concentration) taken 1, 3, 7 
and 14 days after CCI injury where unknown sample impedance value is divided by the impedance 
value of the last blank run on the same GDE, where light gray bars are mild, gray bars are 
moderate, and dark gray bars are sham injuries. The error bars represent one standard deviation. 
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Fig 2.21: A time-appended plot which strings together the individual Z-t measurements made on 
two GDEs (GDE black, GDE 2 gray) on a purified NE+SAM gradient. 
 
 
Fig 2.22: Z-t calibration curves for one GDE measuring a purified NE+SAM gradient, comparing 
three time points (89 sec, black squares; 24 sec, dark gray circles; 3 sec, light gray diamonds) to 
determine optimal assay time for NE detection. 
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Fig 2.23: Raw Z-t data measuring 5 injections over time of 500 pg/mL NE+SAM or PBS at 368 and 
321 Hz (NE at 368 Hz, light blue; PBS at 368 Hz, dark blue; NE at 321 Hz, light green; PBS at 321 
Hz, dark green). Each injection is indicated by a peak (Pk) number. 
 
 
Fig 2.24: Each bar represents a change in complex impedance (N = 2) of Z-t continuous 
measurements of the 5 NE+SAM injections (subtracted by the signal of PBS to help remove 
injection artifacts) at the two frequencies of interest: 368 (black) and 321 (gray) Hz. The error bars 
represent standard error. 
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Fig 2.25: Z-t calibration curves from purified gradients of GFAP comparing different assay time 
points (3 sec, light gray; 9 sec, gray; 75 sec, black). 
 
 
Fig 2.26: Z-t calibration curves from purified gradients of NSE comparing different assay time points 
(6 sec, light gray; 13 sec, gray; 33 sec, black). 
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Fig 2.27: Z-t calibration curves from purified gradients of S-100β comparing different assay time 
points (15 sec, light gray; 42 sec, gray; 72 sec, black). 
 
 
Fig 2.28: Z-t calibration curves from purified gradients of TNF-α comparing different assay time 
points (2 sec, light gray; 3 sec, gray; 7 sec, black). 
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Fig 2.29: Z-t measurements of purified gradients of GFAP at the optimal frequency (17.44 Hz, N = 
3) and a dead frequency (36760 Hz, N = 1) at the minimum assay time (3 sec). Standard error bars. 
 
 
Fig 2.30: Z-t measurements of purified gradients of NSE at the optimal frequency (546.9 Hz, N = 
3) and a dead frequency (36760 Hz, N = 1) at the minimum assay time (13 sec). Standard error 
bars. 
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Fig 2.31: Z-t measurements of purified gradients of S-100β at the optimal frequency (2148 Hz, N = 
3) and a dead frequency (36760 Hz, N = 1) at the minimum assay time (15 sec). Standard error 
bars. 
 
 
Fig 2.32: Z-t measurements of purified gradients of TNF-α at the optimal frequency (17.44 Hz, N = 
3) and a dead frequency (36760 Hz, N = 1) at the minimum assay time (2 sec). Standard error bars. 
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CHAPTER 3 
ANTIBODY ENCAPSULATION IN MESOPOROUS CARBON TO DETECT TBI BIOMARKERS 
3.1 Introduction 
In this work, the first attempts to encapsulate a protein into mesoporous carbon (MPC) used the 
PNMT (phenylethanolamine N-methyltransferase) enzyme to detect norepinephrine in the 
presence of the co-factor (S-adenosylmethionine). Later, this technique was refined and used to 
detect the four selected TBI biomarkers on an individual basis in purified and complex solutions. 
The goals of these experiments were to address specific aim 2: to determine if MPC could quantify 
each of the TBI biomarkers individually, if the characteristics determined in Chapter 1 (optimal 
binding frequency, minimum assay time, calibration curves) would change due to the use of MPC, 
and to compare the performance of MPC sensors to Nafion-coated gold disk electrodes (GDEs). 
 
Each TBI biomarker was encapsulated within the MPC structure and studied again with both 
electrochemical impedance spectroscopy (EIS) and impedance-time (Z-t) techniques since this 
MPC material behaves differently from the gold disk electrode and required a different antibody 
functionalization process. After encapsulation, the MPC+antibody was mixed with a polymer glue, 
then deposited onto the working electrode of a commercial screen-printed electrode (SPE). 
However, the polymer glue which was previously used in published experiments [3], [97] was 
discontinued, including the polymer’s monomer. Efforts were made to synthesize the polymer glue, 
but eventually a slightly different polymer was selected to replace the previous glue. 
 
Nafion (a perfluorinated ion-exchange polymer) was used to compare to the filtering and 
performance capabilities of MPC in complex solutions [144], [145]. Several publications have used 
Nafion and modified versions of Nafion to improve sensor performance and sensitivity, and as a 
filter [146]–[148]. At present, the standard gold disk electrode has difficulty with sensitivity in 
complex solutions because there is no filter to keep large proteins such as albumin away from the 
immobilized antibodies (causing non-specific increased impedance) [105]. The glucose test strip 
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industry has been using the Nafion coating for decades to solve this problem, but it is far more 
expensive than MPC [97], [149]. 
 
3.2 Experimental Methods 
3.2.1 Chemical Reagents 
 
Chemical reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA) unless otherwise 
indicated. Ferricyanide, potassium hexacyanoferrate (III), was dissolved to 100 mM in 10 mM 
phosphate buffer saline (PBS; EMD Chemicals, Billerica, MA, USA). The same TBI biomarker 
antibodies and antigens were purchased from the same sources discussed in Chapter 2. Rat whole 
blood (Sprague Dawley) stabilized with K2-EDTA was bought from BioreclamationIVT (Westbury, 
NY, USA). Reagents for the Nafion (5% wt diluted to 2.5% wt in ethanol) coated antibody-
immobilized GDEs were decribed in Chapter 2, section 2.2.2. Requirements for mesoporous 
carbon synthesis included 99% Phenol, pellets of sodium hydroxide (NaOH), 37%wt formaldehyde 
(in DI water), 2M hydrochloric acid (HCl), pluronic F-127, high purity ethanol (EtOH), and tetraethyl 
orthosilicate (TEOS). The ensure protein encapsulation, a Pierce BCA Protein Assay kit was 
purchased from ThermoFisher Scientific (Waltham, MA, USA). Polymer poly(hydroxypropyl 
methacrylate) (PHPMA) was obtained from Scientific Polymer Products (Ontario, NY, USA) and 
dissolved to 5% wt in dimethylformamide (DMF). To synthesize poly(hydroxybutyl acrylate) (PHBA) 
glue, the following were required: 4-hydroxybutyl acrylate (4HBA) monomer, dry ice (from local 
grocery store), isopropyl alcohol (IPA), benzene, azobisisobutyronitrile (AIBN), and diethyl ether 
(sometimes referred to as ether). 
 
3.2.2 Equipment Requirements 
 
Electrochemical measurements were conducted using a CH Instruments 660c Electrochemical 
Analyzer (Austin, TX, USA). To thoroughly mix solutions, a VWR Digital Vortex Mixer (VWR, 
Randor, PA, USA), referred to as vortexer, was used. A Vulcon Technologies (Grandview, MO, 
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USA) Clinaseal centrifuge was used in several parts of this protocol in addition to an ultracentrifuge 
(Beckman Coulter, Brea, CA, USA). Equipment for mesoporous carbon synthesis includes a water 
bath (Lauda-Brinkman, Delran, NJ, USA), stir plate (Sigma-Aldrich, St. Louis, MO, USA), fume 
hood, rotary evaporator with water chiller (IKA, purchased from Sigma-Aldrich), tube furnace 
(Sentro Tech, Strongsville, OH, USA), nitrogen compressed gas (Praxair, Danbury, CT, USA), a 
nitrogen volumetric flow controller (Cole-Parmer, Vernon Hills, IL, USA), and a conventional oven 
(Salvislab, Rotkreuz, Switzerland). Additional equipment required includes an orbital shaker (VWR, 
Radnor, PA, USA), and an absorbance spectrometer (Molecular Devices, Sunnyvale, CA, USA). 
Moreover, specialized glassware was required for these synthesis protocols includes a Schlenk set 
up (manifold, bubbler, Schlenk flask) purchased from Laboy Chemical Laboratory Glassware. 
 
3.2.3 Preparation of Purified TBI Biomarker Solutions 
 
A purified (no blood or plasma) 9-point titer was used to characterize each of the 4 TBI markers on 
an individual basis over a physiologically relevant range: 0.1 – 2,800 pg/mL GFAP, 1 – 25,000 
pg/mL NSE, 1 – 10,000 pg/mL S-100β, 0.1 – 75 pg/mL TNF-α. The purified titer details can be 
found in Tables 2.2-2.5. Each sensor measured 3 blank solutions (50 µL PBS + 50 µL 100 mM 
ferricyanide), followed by the 9-point TBI biomarker titers. These solutions were measured lowest 
to highest concentration with a rinse of PBS between each measurement. 
 
3.2.4 Preparation of TBI Biomarker-Spiked Whole Blood and Plasma Samples 
 
For the spiked whole blood and plasma experiments, Sprague Dawley rat whole blood was used. 
Centrifugation to separate the plasma from the whole blood can be found in Chapter 2, section 
2.2.6. The protocols for creating these TBI biomarker-spiked blood and plasma solutions were also 
described in Chapter 2, section 2.2.6. Each sensor measured 12 solutions: 1 purified blank (50 µL 
of PBS + 50 µL of 200 mM ferricyanide), 2 blood/plasma blanks (50 µL of blood/plasma + 50 µL of 
200 mM ferricyanide), followed by the TBI biomarker 9-point titer solutions (run lowest to highest 
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concentration with PBS rinses between measurements). Solutions were mixed directly before 
pipetting onto the sensor for measurement. 
 
3.2.5 Electrochemical Apparatus & Measurement Parameters 
 
These experiments used the three-electrode system described in Chapter 2, section 2.2.3 and 
modified screen-printed electrodes (SPEs) called zensors in conjunction with a CHI 660c 
Electrochemical Workstation (CH Instruments, Austin, TX, USA). All samples were 100 µL in total 
volume. Alligator clip connections from the CHI to the SPEs were red, green, white from left to right 
(if the sample well is in the front and leads are at the back when looking at the SPE). Samples were 
mixed immediately before placement in to sample wells and electrochemical measurements took 
place within seconds thereafter. The descriptions and parameters of the three electrochemical 
techniques used in the work (cyclic voltammetry, CV; electrochemical impedance spectroscopy, 
EIS; and impedance-time, Z-t) appear in Chapter 2, section 2.2.3. 
 
3.2.6 GDE Functionalization and Nafion Coating 
 
The general GDE cleaning and TBI antibody immobilization processes were the same as those 
described in Chapter 2, section 2.2.4. However, after the ethanolamine incubation, each GDE was 
three times quickly dipped into 2.5% wt Nafion before drying (covered but not capped) at 4°C for 
at least one hour before use. Nafion coatings were only used in conjunction with anti-NSE 
immobilized GDEs in purified, 12.5% and 90% blood solutions. Nafion was not studied for the other 
three biomarkers. 
 
3.2.7 Synthesis of Mesoporous Carbon (MPC) 
 
Synthesis of mesoporous carbon was achieved as previously published, by the assembly of three 
constituents (phenol, surfactant, and silica template) followed by carbonization and etching of the 
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template to leave nanopores in the carbon structure (Fig 3.1) [3], [97], [117]. The details of this 
protocol can be found in Appendix A, but are generally described here. First, 8g of phenol in a 
round bottom flask were melted while stirring in a 45°C bath. Next, NaOH solution (0.34g of NaOH 
pellets in 1.36g of DI water) was added dropwise to the round bottom flask stirring at 400 rpm, 
which mixed for 10 mins in the bath before 14.16g of 37%wt formaldehyde were added to the round 
bottom flask stirring at 700 rpm. After addition of the formaldehyde, the water bath temperature was 
raised to 75°C and a cooling reflux condenser was added to the top of the round bottom flask, at 
which point a 1 hr waiting period commenced. At the end of the hour, the round bottom flask was 
capped and placed into a cool water bath while stirring at 200 rpm. Once reaching room 
temperature, the mixture was brought to a pH between 6 and 7 by adding 2M HCl dropwise. The 
round bottom flask then spent 30 mins on the rotary evaporator in a 50°C oil bath (rotation set to 
50 rpm and use of dry ice and IPA cold finger). The resulting thick polymer was dissolved to 20% 
wt in ethanol, then thoroughly mixed and centrifuged for 15 mins. The abundant supernatant, known 
as resol, was stored and saved for later use. 
 
Next, 1.6g of pluronic F-127 surfactant, 8g of EtOH, 0.1g of 2M HCl, and 0.9g of DI water were 
heated in a round bottom flask stirred at 400 rpm in a 40°C water bath for 1 hr. At the end of the 
hour, 2.08g of TEOS silica template and 5g of resol polymer were added dropwise to the round 
bottom flask which continued to stir at 400 rpm in the 40°C water bath for 2 hrs. Following cooling 
to room temperature, the contents of the round bottom flask were syringe filtered (0.22 µm) and 
spread over 6” watch glasses before being allowed to dry overnight partially covered. On the next 
day, the watch glasses were baked at 100°C for 24 hrs. Following the 24 hour baking period, the 
dried polymer was scratched and collected from the watch glasses into a combustion boat, which 
was placed into the tube furnace. After a 30 min N2 purging period (at 1 slpm), the N2 flow rate was 
reduced to 0.2 slpm and the carbonization program began (up to 900°C, for about 8 hrs). After 
carbonizing, the combustion boat’s contents were ground using a mortar and pestle until the 
powder was very fine and visually uniform. Then, the powder was divided into several centrifuge 
tubes, into which ~15 mL of etchant solution was placed (8g NaOH in 100 mL DI water and 100 mL 
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EtOH). After vortexing each centrifuge tube, the tubes were allowed to settle for 24 hrs, followed 
by centrifugation for 20 mins. The supernatant was discarded and replaced with more etchant 
solution, repeating the process. The powder was in etchant solution for 72 hours total (with a 
solution exchange every 24 hours). After removing the last etchant solution, it was replaced by ~15 
mL of DI water followed by centrifugation for 10 mins to rinse the power. This was repeated two 
more times before the powder was collected onto a 3” watch glass and baked at 100°C for 24 hrs. 
The dried powder was collected and stored for future use. 
 
Characterization of the created mesoporous carbons was achieved through transmission electron 
microscopy (TEM, JEOL 2010F microscope using 200 kV) to visualize morphology and using the 
Brunauer-Emmett-Teller (BET) method of Nitrogen adsorption-desorption isotherm (Tristar II 3020 
Micrometrics 77K) application and the Barrett-Joyner-Halenda (BJH) analysis to estimate MPC 
pore size and surface area. These procedures are better described in a previous works [3], [97]. 
TEM work was supported by the Center for Solid State Science at Arizona State University. 
  
3.2.8 Synthesis of poly(hydroxybutyl acrylate) (PHBA) 
 
Due to the fact that the PHBMA polymer binder/glue used in previous publications [3], [97] was 
discontinued due to the complete commercial disappearance of the monomer, a new but similar 
polymer binder (PHBA) was synthesized to replace the discontinued one. PHBMA, 
poly(hydroxybutyl methacrylate), and PHBA, poly(hydroxybutyl acrylate), are very similar, except 
the methacrylate group in the PHBMA monomer is an acrylate group in the PHBA monomer. Since 
there was a small difference between the two polymers, it was hoped that the new binder would 
work in the same way as the discontinued binder. Owing to the fact that free radical polymerization 
had not been done in our lab before, it took about a year to build the infrastructure, speak with 
experts (Drs. Bryan Vogt, Derek Overstreet, and Amrita Pal), and a few failures to refine the 
protocol described below and in Appendix B. 
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First, the Schlenk line was purged with N2 while the rubber-septum closed glassware to be used 
was flame dried using a propane torch and N2 purged. Next, 10 mL of benzene was cannulated 
into the reaction vessel (Schlenk flask). 2.5g of the 4HBA monomer was added to the Schlenk flask 
via N2 purged syringe. The Schlenk flask was heated for 10 mins in a 40°C water bath with N2 
bubbling through the mixture as it was stirred. Since there was no easy way to add the AIBN initiator 
to the N2 purged Schlenk flask, the flow rate of the N2 already flowing into the Schlenk flask in the 
water bath was increased, the rubber septum was quickly removed and the 1g of AIBN was added 
followed by quick re-closing of the Schlenk flask. After reducing the N2 flow rate and allowing N2 to 
refill the flask, all N2 flow was stopped, and the closed Schlenk flask remained in the water bath 
(now set to 60°C) stirring for 6 hrs. At the end of the 6 hours, the Schlenk flask was opened to 
atmosphere and allowed to chill in an ice bath for 20 mins before being placed on a 400 rpm stir 
plate followed by the dropwise addition of 100 mL of cold ether. The remaining liquid was discarded 
and the resulting polymer was vacuum dried overnight before being dissolved to 5% wt in DMF. To 
encourage full dissolution, the mixture was heated on a 60°C hotplate for 5 hours while stirring. 
 
Unfortunately, these efforts yielded little success, and a different commercially available polymer 
was used to make sensors in this study, poly(hydroxypropyl methacrylate), or PHPMA at 5% wt in 
DMF. This polymer binder was studied before and found to be less electrochemically active than 
PHBMA [97], but it function as desired. 
 
3.2.9 Functionalization of Commercial Screen-Printed Electrodes (SPEs) with Single Antibody-
Encapsulated MPC 
 
Before modification, each zensor was characterized via CV and EIS using 100 µL of 100 mM 
ferricyanide, as was described in the Chapter 2, section 2.2.4 for GDEs. 
 
For MPC experiments without encapsulated antibody, MPC was mixed with 5% wt PHPMA glue (in 
DMF) in a 1 mg MPC:10 mg PHBMA ratio. Then, 1.5 µL of the MPC-PHPMA mixture was pipetted 
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onto the working electrode of the zensor (~0.25 mg of MPC required for each zensor). Following 
modification, the sensors were baked at 40°C oven for 2 hrs, then cooled to room temperature 
before use. 
 
The fully detailed protocol to encapsulate antibodies into MPC was adapted from Shimomura et al., 
and can be found in Appendix C (Fig 3.2) [127], [128]. Into eppendorf tubes, MPC and one antibody 
solution in PBS (same concentration used in GDE immobilizations) were added in a ratio of 10 mg 
MPC to 100 µL antibody solution. After being well mixed, the tube was incubated on an orbital 
shaker set to 300 rpm for 24 hrs at 4°C. Next, the powder was collected into ultracentrifuge tubes 
and rinsed with DI water following ultracentrifugation at 30,000 rom for 10 mins at 4°C. This was 
repeated two more times. Each of the rinse solutions was saved (50 -150 µL) in a microplate for 
future absorbance verification. After rinsing and ultracentrifugation, the MPC-antibody powder dried 
overnight in a 3” watch glass, partially covered at 4°C. 
 
Two methods could be used to verify that the antibody had been encapsulated into the MPC: 
running regular absorbance spectra (235 to 180 nm in 5 nm steps) if protein concentrations 
exceeded ~200 µg/mL, or BCA colorimetric protein assays for concentrations ranging 0.5 – 40 
µg/mL [150]. For this study, the BCA method was employed and compared to BSA standards and 
N = 3 standards for the four antibodies used in this study (GFAP, NSE, S-100β, and TNF-α), specific 
protocol details can be found in Appendix D. 
 
To make MPC-antibody modified zensors on the following day, the dried MPC-antibody was mixed 
with 5% wt PHPMA in DMF at a 1 MPC:10 PHPMA mass ratio. Then 1.5 µL of the resulting mixture 
was pipetted onto the working electrode of a zensor before being baked at 40°C for 2 hours. These 
modified sensors were stored at 4°C until use later that day. 
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3.2.10 EIS Data Analysis on TBI Biomarker Measurements 
 
EIS data analysis of the MPC sensor data was conducted in the same as the GDE sensor data 
described in Chapter 2, section 2.2.9. 
 
3.2.11 Z-t Data Analysis on TBI Biomarker Measurements 
 
Z-t data analysis for MPC data was conducted in the same way as the GDE data described in 
Chapter 2, section 2.2.11. 
 
3.3 Results and Discussion 
3.3.1 Characterization of MPC 
 
TEM images show that the MPC structure is highly ordered in the form of channels or holes, 
depending on which angle the MPC is viewed from (Fig 3.3). Thus, verification of MPC was 
important to know that protein encapsulation was possible. The reports from the BET-BJH analysis 
showed that the best attempts to synthesize MPC somewhat matches results from previous 
publications (which was extremely important since the MPC reported here was made using entirely 
different equipment and set ups). Surface area for MPC batches 6 and 9 were 1486.88 and 1730.69 
m2/g, while the average pore sizes were 3.16-3.56 and 3.96-4.52 nm. 
 
3.3.2 Characterization of Failed PHBA Glues 
 
More often than not, the product which was obtained at the end of synthesis was very white and 
gummy, even after vacuum drying. It was also a great effort to find a solvent in which the glue would 
dissolve besides the solvent in which it was synthesized (benzene). The previous glue, PHBMA 
would dissolve in ethanol (though it took several minutes of vortexing), but the newly synthesized 
glue never dissolved in ethanol with vortexing or pressurized heating. Several batches of this glue 
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were characterized using FTIR analysis and compared to a small amount of the old glue which was 
still left over from old experiments (Fig 3.4). These spectra show that the two glues were too were 
similar with slightly different bonds (which likely accounted for the difficulty in dissolution of the new 
glue), but physically behaved in completely different ways. Efforts to create a glue which would 
most closely resemble the original glue’s physical properties included changes in synthesis solvent 
(specifically polarity, which most greatly affected polymer chain length and in part dissolution 
abilities), changes in temperature (to increase or decrease the activation energy for alternative 
products), changes to synthesis time (if less time was allotted, the polymer chains might be shorter 
and dissolve more easily), and efforts to reduce contaminants and the introduction of air (which 
would cause the formation of undesired products.  
 
Eventually, after more than 12 batches of PHBA attempts, an alternative commercial product was 
selected. PHPMA is a propyl-methacrylate instead of the original butyl-methacrylate. The behavior 
of this polymer was controllable and was abundantly commercially available. 
 
3.3.3 Verification of Protein Encapsulation- BCA Protein Assay 
 
The BCA colorimetric assay was used to test if the MPC rinsing (after 24 hr period of incubation in 
MPC on orbital shaker) contained the antibody, or if all the antibody had gone into the MPC. 
Standards of the antibodies were also run in addition to the kit’s BSA standard. Four solutions were 
tested: solution 1- solution was removed from the tube in which incubation had occurred, before 
centrifugation or any rinsing; solution 2- solution removed after the first MPC rinse in DI water and 
after centrifugation; solution 3- removed after second MPC rinse in DI water and after 
centrifugation; solution 4- removed after third and last MPC rinse with DI water and centrifugation. 
Using the calibration curves fitted to the (N = 3) antibody standards (one small gradient for each of 
the antibodies), antibody concentrations of the 4 unknown solutions were predicted. The results 
from this BCA assay are summarized in Table 3.1. Generally, solution 1 was found to contain some 
amount of antibody, ranging from ~ 65-105% of the original antibody placed into the incubation 
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tube. These errors are likely attributed to the ABS measurement and the error associated with the 
antibody standard curves. However, MPC data will show that there is a difference between MPC 
with and without antibody encapsulated in this manner. Nearly all of the remaining solutions had 
very small predicted amounts of antibody in the rinse solutions. 
 
3.3.4 Quantification of Individual Biomarkers in Purified Solutions using Single Antibody-
Encapsulated MPC 
 
Optimal binding frequencies for GFAP, NSE, S-100β, and TNF-α found in the GDE data were found 
to be the same in the MPC data, by comparing slopes and R2 of least squares natural logarithmic 
fits across several potential optimal frequencies. One very large difference between the GDE and 
MPC data is the MPC data exclusively exhibits negative logarithmic slopes, meaning the 
impedance decreases as biomarker concentration increases. This is due to the diffusion-dominated 
characteristics MPC displays (discussed later). The MPC data which did not contain antibodies to 
the TBI biomarkers were analyzed at the same frequencies. The graphs in Figs 3.5-3.8 compare 
the calibrations curves of MPC without antibodies at the optimal binding frequency compared to 
the dead frequency using both EIS and Z-t techniques. The graphs in Figs 3.9-3.12 compare the 
calibrations curves of MPC without antibodies at the optimal binding frequency compared to the 
dead frequency using both EIS and Z-t techniques. Generally, higher impedance values and slopes 
were observed in the MPC with antibody data. This was expected since the response to TBI 
biomarker concentrations was expected to increase when antibody-biomarker binding occurred.  
This observation, however, was not made in the GFAP case. While the overall impedance was 
higher in the presence of antibody, the smaller slopes (response) was likely due to the fact that 
only 2.5 µg/mL of anti-GFAP was used (compared to 20 and 5 µg/mL antibody concentrations of 
the other three antibodies). These antibody concentrations were tested to match the GDE data, but 
perhaps need to be increased for the MPC platform, at least in the GFAP case. The detection limits 
for MPC with and without antibodies for all four biomarkers detected in purified conditions can be 
found in Table 3.2. All of these values are negative because the slopes in all of the calibration 
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curves are negative. However, it is clear that reliable detection of these biomarkers in purified 
solutions is possible using MPC sensors. 
 
3.3.4 Detection of NSE: Comparing Nafion-coated GDEs and Single Antibody-Encapsulated MPC 
 
The differences between Nafion-coated GDEs and antibody-encapsulated MPCs are very obvious 
when looking at the EIS calibrations curves for purified solutions of each of the four biomarkers 
(Figs 3.13-3.16). Firstly, the Nafion-coated GDEs show very high impedances as expected due to 
the nature of coating an electrode with a conductive polymer. Fortunately, this increase in 
impedance has also corresponded to a very high slope value in the calibration fit. If the Nafion did 
not allow the biomarkers to pass through to get to the GDE surface where the antibodies were 
immobilized, high impedance would have been accompanied by little to no slope. While the MPC 
data showed more reliable calibration curves, the slopes were much smaller than those shown in 
the Nafion data. This may also be due to the additional diffusion aspect in the MPC system, and/or 
due to the fact that glue was used to fix the MPC to the zensor surface, partially blocking MPC 
pores. The purified Z-t calibrations curves can be found in Figs 3.17-3.20. This data confirms the 
EIS observations that MPC provided better reliable data compared to the Nafion purified data, 
though the Nafion data still had more response (slopes), but generally far worse curve fits (R2).  
The EIS and Z-t detection limits of the purified MPC data can be found in Table 3.3. 
 
Regarding blood data, only the NSE biomarker was studied at 12.5% blood and 90% blood in both 
the Nafion-coated GDE and single antibody-encapsulated MPC systems using both EIS and Z-t at 
optimal and dead frequencies. The EIS data is summarized in Fig 3.21 displaying calibration curves 
for Nafion and MPC data at 12.5 and 90% blood at the optimal binding frequency for NSE (546.9 
Hz). As far as calibration curve fits, the MPC data for 12.5% blood performed the best and most 
closely matched the purified NSE MPC data previously discussed: -7.87 versus -8.19 Ω/pgmL-1 for 
slopes and 0.96 versus 0.99 for R2 from 12.5% blood and purified solutions of NSE, respectively. 
Neither Nafion nor MPC data displayed good fits for the 90% blood data (N = 4, R2 ~ 0.50), likely 
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due to blood component interference previously discussed. However, further replicates may help 
with obtaining a better calibration curve fitting, especially since much of the MPC protocol can vary 
when screen printing and mixing is done by hand. It is somewhat encouraging that the Nafion did 
not greatly outperform the MPC protocol. In fact, the Z-t measurements in 90% blood using Nafion-
coated GDEs, especially at the dead frequency, showed great variance compared the MPC 90% 
blood data (range of σ2Nafion= 0.05 – 12,034.2 Ω versus σ2MPC= 99.4 – 1,255.0 Ω over all 
concentrations in the gradient). Since the variance in the 12.5% blood Nafion data was less (range 
of σ2Nafion= 0.38 – 883.3 Ω over all concentrations in the gradient), the cause was likely the whole 
blood components interfering with the Z-t measurements, or more likely that this was an N = 2 
measurement. Possibilities for a bad Nafion electrode might be that the coating was perforated or 
scratched or was not fixed properly to the GDE allowing movement of the coating. Z-t calibration 
curves for MPC in blood NSE solutions are in Fig 3.22, and the Nafion data are in Fig 3.23. 
Detection limits for 12.5% and 90% blood data for MPC and Nafion sensors can be found in Tables 
3.4 and 3.5, respectively. 
 
3.3.5 Diffusion in the GDE versus MPC cases 
 
The main difference between mass transfer in the GDE and MPC cases is that the MPC structure 
presents a diffusion-dominated system since biomarkers have to travel into the MPC structure to 
bind to their capture antibodies, rather than binding to antibodies immobilized to a flat surface as 
in the GDE set up. This is evident in the Nyquist plots (imaginary versus real impedance): the GDE 
(Fig 3.24A) and even Nafion-coated GDE (Fig 3.24B) yield Randles-like Nyquist plots, suggesting 
that convection is the dominating influence, while the Nyquist for the MPC has a distinctly different 
Warburg-like shape (Fig 3.24C) suggesting diffusion is the dominating influence [96], [102], [103]. 
 
The three forms of mass transfer are migration (charged molecules moving and an electric field), 
diffusion (molecules moving with a concentration gradient), and convection (molecules moving due 
to hydrodynamic transport like Brownian motion) [96]. With regard to the mass transfer coefficient 
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in the diffusion through strictly liquid cases, it is assumed that the concentration of the mediators 
(redox probe) is in excess (eliminates migration problems) so the mass transfer is directly related 
to the concentration gradient of charged species at the electrode surface, the relationship between 
mass transfer and diffusion is shown in (Eqn. 6): 
𝑚𝑂 =  
𝐷𝑂
𝛿𝑂
 
where mo is the mass transfer coefficient, Do is the diffusion coefficient, and δo is the distance from 
the electrode [96]. 
 
In the GDE case, mass transfer can be simplified into the one-dimension infinite diffusion occurs 
through the bulk solution (100 µL total volume for all solutions) since EIS and Z-t are near-field 
measurements [96], [102], [103]. Some migration is possible depending on the potentials applied, 
but since no more than 0.2 V is ever applied, it is assumed that the resulting electromotive force is 
not very strong. This infinite linear diffusion can be modeled by the Nernst-Planck equation (Eqn. 
3.1): 
𝐽𝑖(𝑥) = −𝐷𝑖
𝜕𝐶𝑖(𝑥)
𝜕𝑥
− 
𝑧𝑖𝐹
𝑅𝑇
𝐷𝑖𝐶𝑖
𝜕𝜑(𝑥)
𝜕𝑥
+ 𝐶𝑖𝑣(𝑥) 
where Ji(x) is the flux of species i at distance x from the surface, Di is the diffusion coefficient, ∂Ci(x)/ 
∂x is the concentration gradient at distance x, ∂ф(х)/ ∂х is the potential gradient, zi and Ci are the 
charge (dimensionless) and concentration of species i, respectively, and v(x) is the velocity with 
which a volume element in solution moves along the x axis [96]. The first term on the right side is 
diffusion, the next migration, the last, convection [96]. 
 
Diffusion in the MPC case is more complex as it involves simple linear diffusion through the bulk 
solution as in the GDE case, but also through the solid porous electrode into which the capture 
antibodies are encapsulated. Diffusion through the solid MPC is most likely migration-dominated 
which would draw the analyte into the MPC first due to electromotive (and realistically, gravitational) 
forces, then due to affinity to the capture antibody once the analyte is within proximity. If the pores 
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are uniform and cylindrical in shape and assuming a quasi-reversible reaction, the axial internal 
diffusion that drives mass transfer inside the MPC can be modeled by the current-overpotential 
form of the Butler-Volmer model (Eqn. 3.2): 
𝑗 =  𝑗0[𝑎(𝑒
𝑏𝜂 + 𝑚𝑒−𝑏𝜂) − (𝑚 + 1)𝑒−𝑏𝜂] 
where j is the current density, η is the overpotential, and b is a constant depending on the number 
or electrons in the reaction and temperature; a is CO/CO* and m is CO*/CR* [Ci and Ci* are the 
surface and bulk concentrations of the oxidized species and the reduced species, respectively 
[102]. *Assumes the diffusion of oxidized and reduced species is the same. The overpotential is 
defined as the following if current flow is dependent on concentration of species in the pores, as a 
function of diffusion (Eqn. 3.3): 
𝜂 −  𝜂0 = 𝑛𝐹𝐷𝐶𝑂
∗ 𝜌(𝑎 − 1) 
which describes the potential drop in a pore due to diffusion assuming steady-state conditions: n is 
the number of electrons in the reaction, F is Faraday’s constant, D is the diffusion coefficient, CO* 
is the concentration of the oxidized species in bulk solution, ρ is resistivity, a is Co/Co* [102]. If v = 
nFDCo*ρ, and v>1, diffusion is dominated by the concentration gradient (simple diffusion) 
throughout the mesoporous structure, if v<1 diffusion is dominated by the potential drop throughout 
the mesoporous structure due to applied potentials in the electrochemical technique [102]. 
 
3.4 Conclusion 
Overall, this study addressed the main concerns in the second aim. The MPC protocol was 
optimized and shown to be capable of detection biomarkers individually in purified and blood 
solutions (with very low detection limits). These data were compared to Nafion (the commercial 
standard) data in purified and blood solutions. It was found that overall, MPC sensors performed 
as well or better than the Nafion sensors in purified and blood solutions. Future work would include 
running the blood and Nafion data in all of the biomarkers, and further replicating the NSE data 
obtained. Moreover, it would be beneficial for a handheld diagnostic to use mass-manufacturable 
test strips, thus the ability for these protocols to be mass produced should be studied. 
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3.5 Figures 
Fig 3.1: A schematic illustrating the synthesis of mesoporous carbon (MPC) using three 
constituents: the resol polymer precursor, a surfactant (F-127), and the tetraethyl orthosilicate 
template. 
Fig 3.2: A schematic illustrating antibody encapsulation into MPC followed by gluing onto a 
commercial screen-printed sensor. 
 
  
Surfactant 
Resol 
Polymer 
Silica 
Template 
Carbonization Etching of Si 
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Table 3.1: Summary of BCA colorimetric assay results that predict the concentration of antibody in 
solution (µg/mL). * indicates data which was contaminated with MPC powder. Y represents 
absorbance values (A.U.) and X represents antibody concentration (µg/mL). Original antibody 
concentrations for GFAP, NSE, S-100β and TNF-α were 5, 20, 2.5, and 5 µg/mL, respectively. 
BCA 
Colorimetric 
Predictions 
of 
[Antibody] 
N = 3 Calibration 
Curve Eqn from 
Standards 
Solution 1 
[Antibody] 
Solution 2 
[Antibody] 
Solution 3 
[Antibody] 
Solution 4 
[Antibody] 
Anti-GFAP 
y = 0.0001x2 + 0.0578x 
+ 0.1248 (R2 = 0.9977) 
3.39 0.18 0.18 -0.19 
Anti-NSE 
y = -0.0001x2 + 0.0153x 
+ 0.1351 (R2 = 0.9982) 
21.06 1.59 0.26 -0.25 
Anti-S-100β 
y = 0.0326x2 – 0.0535x 
+ 0.1654 (R2 = 0.9274) 
2.26 1.15 1.29 1.28 
Anti-TNF-α 
y = 0.0043x2 - 0.0062x 
+ 0.1313 (R2 = 0.9690) 
3.53 1.95 2.10 1.79 
 
 
 
 
Fig 3.3: TEM images of two MPC batches showing ordered structures. 
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Fig 3.4: FTIR overlay of PHBA batch 6 (pink) and the old PHBMA glue (red). 
 
 
Fig 3.5: This graph is an overlay of several calibration curves of MPC without antibody detecting 
GFAP: EIS at the optimal binding frequency (black), Z-t at the optimal binding frequency at 10 sec 
(dark gray), EIS at the dead frequency (lightest gray with dark outline), and Z-t at the dead 
frequency at 10 sec (medium gray). 
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Fig 3.6: This graph is an overlay of several calibration curves of MPC without antibody detecting 
NSE: EIS at the optimal binding frequency (black), Z-t at the optimal binding frequency at 10 sec 
(dark gray), EIS at the dead frequency (lightest gray with dark outline), and Z-t at the dead 
frequency at 10 sec (medium gray). 
 
 
Fig 3.7: This graph is an overlay of several calibration curves of MPC without antibody detecting S-
100β: EIS at the optimal binding frequency (black), Z-t at the optimal binding frequency at 10 sec 
(dark gray), EIS at the dead frequency (lightest gray with dark outline), and Z-t at the dead 
frequency at 10 sec (medium gray). 
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Fig 3.8: This graph is an overlay of several calibration curves of MPC without antibody detecting 
TNF-α: EIS at the optimal binding frequency (black), Z-t at the optimal binding frequency at 10 sec 
(dark gray), EIS at the dead frequency (lightest gray with dark outline), and Z-t at the dead 
frequency at 10 sec (medium gray). 
 
 
Fig 3.9: This graph is an overlay of several calibration curves of MPC with antibody detecting GFAP: 
EIS at the optimal binding frequency (black), Z-t at the optimal binding frequency at 10 sec (dark 
gray), EIS at the dead frequency (lightest gray with dark outline), and Z-t at the dead frequency at 
10 sec (medium gray). 
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Fig 3.10: This graph is an overlay of several calibration curves of MPC with antibody detecting 
NSE: EIS at the optimal binding frequency (black), Z-t at the optimal binding frequency at 10 sec 
(dark gray), EIS at the dead frequency (lightest gray with dark outline), and Z-t at the dead 
frequency at 10 sec (medium gray). 
 
 
Fig 3.11: An overlay of several calibration MPC curves with antibody detecting S-100β: EIS at the 
optimal frequency (black), Z-t at the optimal frequency at 10 sec (dark gray), EIS at the dead 
frequency (lightest gray with dark outline), and Z-t at the dead frequency at 10 sec (medium gray). 
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Fig 3.12: This graph is an overlay of several calibration curves of MPC with antibody detecting TNF-
α: EIS at the optimal binding frequency (black), Z-t at the optimal binding frequency at 10 sec (dark 
gray), EIS at the dead frequency (lightest gray with dark outline), and Z-t at the dead frequency at 
10 sec (medium gray). 
 
Table 3.2: Summary of detection limits for GFAP, NSE, S-100β, and TNF-α in MPC with and without 
antibody. The EIS data was N = 3, Z-t at optimal frequency was N = 3, and the Z-t at the dead 
frequency was N = 1 for all biomarkers. The Z-t data was taken at 10 sec for all biomarkers. 
Detection 
Limits 
(pg/mL) 
EIS @ Opt f 
MPC 
without 
Antibody 
EIS @ Opt f 
MPC with 
Antibody 
Z-t @ Opt 
f MPC 
without 
Antibody 
Z-t @ Opt 
f MPC 
with 
Antibody 
Z-t @ 
Dead f 
MPC 
without 
Antibody 
Z-t @ 
Dead f 
MPC 
with 
Antibody 
GFAP -1.04 -3.45 -3.16 -6.31 -8.14 -1.70 
NSE -1.41 -1.50 -3.82 -8.33 -6.61 -26.54 
S-100β -2.34 -2.99 -3.27 -1.77 -4.04 -2.27 
TNF-α -2.55 -1.40 -2.77 -2.25 -1.67 -1.70 
 
 
y = -10.64ln(x) + 388.38
R² = 0.9672
y = -8.944ln(x) + 356.25
R² = 0.9192
y = -1.682ln(x) + 187.33
R² = 0.912
y = -1.828ln(x) + 180.78
R² = 0.9524
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Fig 3.13: This graph is an overlay of an EIS MPC with antibody calibration curve (N = 3, black data) 
and an EIS Nafion-coated GDE calibration curve (N = 3, gray data) at the optimal binding frequency 
detecting purified GFAP. 
 
 
Fig 3.14: This graph is an overlay of an EIS MPC with antibody calibration curve (N = 3, black data) 
and an EIS Nafion-coated GDE calibration curve (N = 3, gray data) at the optimal binding frequency 
detecting purified NSE. 
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Fig 3.15: This graph is an overlay of an EIS MPC with antibody calibration curve (N = 3, black data) 
and an EIS Nafion-coated GDE calibration curve (N = 3, gray data) at the optimal binding frequency 
detecting purified S-100β. 
 
 
Fig 3.16: This graph is an overlay of an EIS MPC with antibody calibration curve (N = 3, black data) 
and an EIS Nafion-coated GDE calibration curve (N = 3, gray data) at the optimal binding frequency 
detecting purified TNF-α. 
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Table 3.3: Summary of detection limits for GFAP, NSE, S-100β, and TNF-α using Nafion-coated 
immobilized GDEs. The EIS data was N = 3, Z-t at optimal frequency was N = 3, and the Z-t at the 
dead frequency was N = 1 for all biomarkers. 
Detection 
Limits 
(pg/mL) 
EIS @ Opt 
freq 
Z-t @ Opt 
freq @ 10 
sec 
Z-t @ 
Dead freq 
@ 10 sec 
GFAP 4.53 5.63 123.80 
NSE 1.77 21.45* 23.18 
S-100β 1.93 1.89 29.19 
TNF-α 3.40 7.33 7.55 
*Indicates that the last biomarker solution was not included in this calculation since it was ruled out 
due to experimental error. 
 
 
Fig 3.17: Comparison of Z-t calibration curves detecting purified GFAP using: MPC+antibody at the 
optimal frequency (N = 5, black data) and at a dead frequency (N = 3, dark gray data), Nafion-
coated GDEs at optimal frequency (N = 3, medium gray data) and and at a dead frequency (N = 1, 
lightest gray data). 
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Fig 3.18: Comparison of Z-t calibration curves detecting purified NSE using: MPC+antibody at the 
optimal frequency (N = 5, black data) and at a dead frequency (N = 3, dark gray data), Nafion-
coated GDEs at optimal frequency (N = 3, medium gray data) and at a dead frequency (N = 1, 
lightest gray data). 
 
 
Fig 3.19: Comparison of Z-t calibration curves detecting purified S-100β using: MPC+antibody at 
the optimal frequency (N = 5, black data), MPC+antibody at a dead frequency (N = 3, dark gray 
data), Nafion-coated GDEs at optimal frequency (N = 3, medium gray data), and Nafion-coated 
GDEs at a dead frequency (N = 1, lightest gray data). 
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Fig 3.20: Comparison of Z-t calibration curves detecting purified TNF- α using: MPC+antibody at 
the optimal frequency (N = 5, black data), MPC+antibody at a dead frequency (N = 3, dark gray 
data), Nafion-coated GDEs at optimal frequency (N = 3, medium gray data), and Nafion-coated 
GDEs at a dead frequency (N = 1, lightest gray data).  
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Fig 3.21: Overlay of EIS calibration curves detecting NSE in 12.5% and 90% blood data using 
Nafion-coated GDEs and MPC+Anti-NSE at the optimal NSE frequency. 
 
Table 3.4: Summary of detection limits for 12.5% and 90% blood NSE solutions using MPC with 
antibody. The EIS data was N = 4, Z-t at optimal frequency was N = 5, and the Z-t at the dead 
frequency was N = 2 for all biomarkers. The Z-t data was taken at 10 sec for all biomarkers. 
Detection 
Limits (pg/mL) 
EIS @ 546.9 
Hz 
EIS @ 81050 
Hz 
Z-t @ 
546.9 Hz 
Z-t @ 
81050 Hz 
12.5% Blood -2.45 -4.27 -4.92 -3.46 
90% Blood -12.90 19.16 -9.30 23.31 
 
 
Table 3.5: Summary of detection limits for 12.5% and 90% blood NSE solutions Nafion-coated 
GDEs. The EIS data was N = 4, Z-t at optimal frequency was N = 5, and the Z-t at the dead 
frequency was N = 2 for all biomarkers. The Z-t data was taken at 10 sec for all biomarkers. 
Detection 
Limits (pg/mL) 
EIS @ 546.9 
Hz 
EIS @ 81050 
Hz 
Z-t @ 
546.9 Hz 
Z-t @ 
81050 Hz 
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Fig 3.22: Z-t Calibrations curves of Nafion sensors detecting NSE gradients in 12.5% blood at 
81050 Hz (black data), 90% blood at 81050 Hz (dark gray data), 12.5% blood at 546.9 Hz (medium 
gray data), and 90% blood at 546.9 Hz (lightest gray data). 
 
 
Fig 3.23: Z-t Calibrations curves of MPC+anti-NSE sensors detecting NSE gradients in 12.5% 
blood at 81050 Hz (black data), 90% blood at 81050 Hz (dark gray data), 12.5% blood at 546.9 Hz 
(medium gray data), and 90% blood at 546.9 Hz (lightest gray data). 
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Fig 3.24: Part A displays a GDE immobilized with anti-NSE, part B a Nafion-coated GDE 
immobilized with anti-NSE, and part C, an anti-NSE encapsulated MPC sensor measuring one 
purified blank (black data) and 500 pg/mL NSE (gray data) solutions. 
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CHAPTER 4 
FEASABILITY OF MULTIPLEXED AND SIMULTANEOUS DETECTION OF TBI BIOMRAKERS 
4.1 Introduction 
The last development step in this work was to explore the feasibility of simultaneously quantifying 
multiple biomarkers with multiple capture antibodies encapsulated within a mesoporous structure 
(goals of aim 3). To achieve this, the encapsulation protocol discussed in Chapter 3 was slightly 
adapted to encapsulate multiple antibodies within the same mesoporous carbon structure. First, 
two antibodies were co-encapsulated into the same MPC structure, followed by quantification of 
individual biomarkers (multiplexed) or combinations of both biomarkers (simultaneous) in purified 
and complex solutions. Finally, three antibodies were co-encapsulated into the same MPC structure 
to individually or to simultaneously detect biomarkers in purified solutions. The importance of 
measuring multiple biomarkers in the same sample, extensively discussed in Chapter 1, makes a 
blood-based TBI diagnostic feasible by enabling quantification of several TBI biomarkers in addition 
to biomarkers for non-TBI injuries (to rule out conditions which could cause false-positives). The 
ability to quickly quantify several biomarkers in the same sample has great commercial and clinical 
value. While other research efforts to simultaneously detect biomarkers for various diseases 
(discussed in Chapter 1), none have had published success in blood samples, and many do not 
use FDA-favored electrochemical techniques over optical techniques. The experiments described 
here investigated the feasibility of simultaneously detecting biomarkers using the electrochemical 
impedance spectroscopy technique. 
 
4.2 Experimental Methods 
4.2.1 Chemical Reagents & Equipment Requirements 
 
The same reagents and equipment described in Chapter 3, sections 3.2.1 and 3.2.2 were used in 
this study. 
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4.2.2 Electrochemical Apparatus and Measurements Parameters 
 
The electrochemical apparatus and techniques described in Chapter 3, section 3.2.3 were also 
applied in this study. 
 
4.2.3 Synthesis of Mesoporous Carbon (MPC) 
 
The MPC synthesis protocol described in Chapter 3, section 3.2.7 and in Appendix A were also 
employed in this study. 
 
4.2.4 Functionalization of Commercial Screen-Printed Electrodes (SPEs) with Multiple Antibodies-
Encapsulated MPC 
 
Encapsulation of two or more antibodies into one MPC structure was similar to the single antibody 
encapsulation protocol described in Chapter 3, section 3.2.9 (Fig 4.1). In this study, 2-antibody co-
encapsulated MPC was achieved using 500 µL of 40 µg/mL anti-NSE and 500 µL of 5 µg/mL anti-
S-100β for each mg of MPC. The 3-antibody co-encapsulated MPC was achieved using 333.33 µL 
of 60 µg/mL anti-NSE, 333.33 µL of 7.5 µg/mL anti-S-100β, and 333.33 µL of 15 µg/mL anti-TNF-
α for each mg of MPC. A 4-atnibody co-encapsulation MPC was not studied. All other sensor 
creation and handling processes were the same as those described in Chapter 3, section 3.2.9. 
 
4.2.5 Preparation of Purified TBI Biomarker Solutions 
 
Biomarker solutions for the 2-antibody co-encapsulation in MPC were created by evenly mixing 
combinations of high (100,000 pg/mL; 40,000 pg/mL) and low (4 pg/mL; 4 pg/mL) biomarker 
concentrations of NSE and S-100β, respectively. Each co-encapsulated MPC sensor measured 
purified 3 blanks, then one purified solution of NSE+S-100β. Titer information for these solutions 
can be found in Table 4.1. Also, half titers of individual biomarkers NSE or S-100β were run on the 
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co-encapsulated MPC: every other solution from the gradients described in Chapter 2, section 2.2.5 
created the half gradients (3 blank solutions still proceeded the half gradients). The 2-antibody 
MPC was also tested using these same solutions in 12.5% blood, details of these solutions can be 
found in Table 4.2. Each co-encapsulated MPC sensor measured 1 purified blank, 2 blood blanks, 
then one solution of NSE+S-100β in 12.5% blood. 
 
Biomarker solutions for the 3-antibody co-encapsulation in MPC were created by combinations of 
high (150,000 pg/mL; 60,000 pg/mL; 450 pg/mL) and low (6 pg/mL; 6 pg/mL; 0.6 pg/mL) biomarker 
concentrations of NSE, S-100β, and TNF-α, respectively. Each 3-antibody co-encapsulated sensor 
measured purified 3 blanks, then one purified solution of NSE+S-100β+TNF-α. Titer information for 
these solutions can be found in Table 4.3. Half titers of individual biomarkers NSE, S-100β, or TNF-
α were also run on the co-encapsulated MPC sensors. Every other solution from the gradients 
described in Chapter 2, section 2.2.5 created the half gradients (3 blank solutions proceeded the 
half gradients). 
 
4.3 Results and Discussion 
4.3.1 Interferents Testing of Single Antibody-Encapsulated MPC in Purified Solutions 
 
In these experiments, one antibody was encapsulated into MPC (as described in the Chapter 3 
experiments), then EIS was used to measure purified half titers of the correct antigen (N = 1), and 
half titers of the other three antigens individually (N = 2). An SNR was calculated based on the 
variance of the signal (the average of the three purified blanks subtracted from the signal of the 
third concentration run in the half titer) divided by the variance of the noise (average of the three 
purified blanks). These calculated SNR are shown in Table 4.4. While the SNR signals for GFAP 
were not very high (likely due to the fact that only 2.5 µg/mL of anti-GFAP was used), the best anti-
GFAP SNR occurred where only GFAP was in solution, as expected. Anti-S-100β and Anti-NSE 
performed very well against the other biomarkers (high SNR only when correct antigen was 
present). Anti-TNF-α on the other hand had a slightly higher SNR when S-100β was in solution, 
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and the SNR for TNF-α was not greater than 3 (the general cutoff value). It is possible that this 
antibody’s affinity is weak and also binds to a part of the S-100β antigen. However, more replicates 
might improve SNR signals since in EIS data, blanks are notoriously variable. These SNR 
calculations are based on N = 2 data (for incorrect antibody-antigen pairs) and N = 1 (for correct 
antibody-antigen pairs). With the exception of a potential  anti-TNF-α and S-100β interaction, the 
antibodies used in all these experiments can confidently detect their antigen specifically. 
 
4.3.2 Quantification of Two Biomarkers using Two-Antibody-Encapsulated MPC 
 
Modified SPEs containing MPC+anti-NSE+anti-S-100β measured half titers of NSE (N = 5) and 
half titers of S-100β (N = 5) using EIS. Calibrations curves to these data can be found in Figs 4.2-
4.3. When compared to the purified full gradients run on 1-antibody MPC sensors from Chapter 3, 
the average calibrations curves were similar: -6.5 versus -8.2 Ω/pgmL-1 and 0.91 versus 0.99 for 
R2 values for the 2-antibody MPC and 1-antibody MPC, respectively. This was a good sign and an 
important first step to determine (based on these similar calibrations curves) that detecting one 
biomarker at a time in a 2-antibody sensor is possible. An independent t test was performed on the 
N = 5 means to compare the 1-antibody to 2-antibody MPC measurements of the half gradients. 
For the purified data, the means of the half gradients measured using the 2-antibody MPC sensors 
were statistically similar to the means of the purified gradients measured by the 1-antibody MPC 
sensors (p = 0.024 and 0.020 for NSE and S-100β, respectively). However, 12.5% blood data was 
only obtained for NSE in the 1-antibody case (not also for S-100β). The 12.5% blood NSE 1-
antibody case was compared to the 12.5% blood NSE 2-antibody case which was found to be 
statistically different in means (p = 0.16). This statistical difference may be the fact that only N = 5 
was compared and detection variance in blood solutions is known to be greater than in purified 
solutions, a greater sample size may help to decrease the difference between the means in the 1-
antibody and 2-antibody cases as seen in the purified cases. The presence of anti-S-100β in the 
2-antibody 12.5% blood NSE measurement case  was not likely to cause a statistically different 
mean, as indicated by the SNR interference data previously discussed. 
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In addition to half titers of individual biomarkers, MPC+anti-NSE+anti-S100β sensors also 
measured solutions containing combinations of high and low concentrations of both NSE and S-
100β using EIS (N = 3). The averaged complex impedance values measured were corrected 
(subtracted) by the average of the last blank run on the sensor. These corrected complex 
impedances were compared to the summation of corrected impedance values from the purified one 
antibody MPC data. For example, the NH+SH (high NSE and high S-100β) solution (minus the 
average of the 3rd blanks) was compared to the summation of the NH impedance value from the 
anti-NSE+MPC (minus the impedance value from the solution measured before NH in the full anti-
NSE+MPC gradient from Chapter 3 data) and the SH impedance value from the anti-S-100β+MPC 
(minus the impedance value from the SH-1 solution). These data can be found in Fig 4.4. 
Interestingly, the highest NSE impedance value occurred at its optimal frequency when it was 
accompanied by low S-100β, not when it was accompanied by high S-100β, suggesting a potential 
interactive effect. However, S-100β signal (at its optimal frequency) was highest in the same 
solution, but was also statistically different from the solution in which both NSE and S-100β were 
high (p = 0.3). A two-way ANOVA where [NSE] and [S-100β] were treated as categorical factors 
with 3 levels (no NSE/S-100β from half titer data, low NSE/S-100β and high NSE/S-100β from 
high/low combination data), with the corrected impedance data as the dependent variable were run 
in Design Expert software for each of the two optimal frequencies to determine which factors were 
the most significant. The 546.9 Hz model for complex impedance was (Eqn. 4.1): 
Change in Complex Z (546.9 Hz) = -47.29 Ω – 47.15*NSEnone +  25.03*NSElow + 22.12*NSEhigh – 73.90*S-
100βnone + 40.63*S-100βlow + 33.27*S-100βhigh – 110.50*NSEnone*S-100βnone + 46.73*NSElow*S-100βnone + 
63.81*NSEhigh*S-100βnone + 48.11*NSEnone*S-100βlow – 19.35*NSElow*S-100βlow – 28.76*NSEhigh*S-100βlow. 
 
The 2148 Hz ANOVA model for complex impedance was (Eqn. 4.2): 
Change in Complex Z (2148 Hz) = -49.64 Ω – 42.16*NSEnone +  22.44*NSElow + 19.72*NSEhigh – 61.63*S-
100βnone + 33.13*S-100βlow + 28.5*S-100βhigh – 98.71*NSEnone*S-100βnone + 41.92*NSElow*S-100βnone + 
56.79*NSEhigh*S-100βnone + 43.47*NSEnone*S-100βlow – 16.42*NSElow*S-100βlow – 27.05*NSEhigh*S-100βlow. 
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Based on these two-way ANOVA analyses, the two main and one interaction effects ([NSE], [S-
100β], and [NSE]*[S-100β]) were found to be very significant (p = 0.008 – 0.0189). This is evidence 
that changes in either or both concentrations of the two biomarkers would yield a difference in 
complex Z. Therefore, simultaneous detection of two biomarkers in the same purified sample is 
possible. Moreover, post-hoc testing using the Gabriel and Hochberg methods in the SPSS 
software package concluded that for measuring either biomarker at either frequency, the statistical 
significance arises from the differences between the none and low or none and high biomarker 
concentration comparisons; no statistical significance was found between low and high 
measurements of the biomarkers. Ideally, the sensor could also differentiate between high and low 
concentrations of biomarker, but this lack of significance may be due to the fact that only 3 
measurements were compared in the ANOVA. 
 
These experiments and analysis methods were repeated in 12.5% whole blood solutions. The 
calibrations curves from the NSE and S-100β half titers in blood can be found in Figs 4.5-4.6. When 
compared to the purified half titers, the slopes and R2 decrease in the blood calibration curves (from 
~6 to ~2 Ω/pgml-1). However, this was also seen in the single-antibody MPC purified and 12.5% 
blood data in Chapter 3. The calibration curves look very similar between the individual biomarker 
half titers at both of the optimal frequencies. The two-way ANOVA on 12.5% blood samples were 
conducted on 54.69 Hz and 2148 Hz data (Eqns. 4.3 and 4.4, respectively): 
Change in Complex Z (546.9 Hz) = -15.69  Ω – 4.19*NSEnone – 3.65*NSElow + 7.84*NSEhigh – 2.98*S-
100βnone – 9.41*S-100βlow + 12.39*S-100βhigh – 21.18*NSEnone*S-100βnone + 9.38*NSElow*S-100βnone + 
11.8*NSEhigh*S-100βnone + 15.43*NSEnone*S-100βlow – 10.09*NSElow*S-100βlow – 5.34*NSEhigh*S-100βlow. 
 
Change in Complex Z (2148 Hz) = -15.29  Ω – 4.32*NSEnone – 5.53*NSElow + 9.85*NSEhigh – 3.46*S-
100βnone – 8.66*S-100βlow + 12.12*S-100βhigh – 20.69*NSEnone*S-100βnone + 5.65*NSElow*S-100βnone + 
15.04*NSEhigh*S-100βnone + 15.32*NSEnone*S-100βlow – 7.86*NSElow*S-100βlow – 7.46*NSEhigh*S-100βlow. 
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Interestingly, the [NSE] main effect was found to be close, but not actually significant at the 546.9 
Hz data (the NSE optimal frequency), but was found to be significant at the 2148 Hz data (optimal 
frequency for S-100β). The reason for this is not clear, but this suggests that variance may also 
depend on frequency. Also, the fact that variance is higher in blood versus purified samples may 
account for this change in significance. The main effect of [S-100β] and the interactive effect 
[NSE]*[S-100β] were found to be very significant at bot frequencies of interest. Gabriel and 
Hochberg post-hoc techniques found near significance for the NSE main effect in the comparison 
between high and no NSE concentration impedance data at 546.9 Hz, which suggests the sensor 
may have difficulty in distinguishing between low and no concentrations of NSE or low and high 
concentration of NSE in blood solutions at this frequency. However, at the 2148 Hz frequency, 
comparisons between high and low, and high and no concentrations of NSE were significant, but 
the difference between low and no concentration of NSE was not statistically significant at 2148 
Hz. Regarding the S-100β main effect at both frequencies, the post-hoc tests agreed that all 
comparisons were statistically significant except the low to no S-100β concentration comparison. If 
the additional variance found in blood was to affect any comparison, the low to no concentration 
comparison seems the most logical, since the expectation is that the differences between low and 
no concentration would be smaller than the other comparison differences. With greater replicates, 
these equations may be helpful in the future for developing more accurate calibration curves for a 
future handheld device to simultaneously detect these two biomarkers. A summary of purified and 
12.5% blood detection limits based on the half-titer data can be found in Table 4.5. 
 
4.3.3 Quantification of Three Biomarkers using Three-Antibody-Encapsulated MPC 
 
Using MPC encapsulated with three antibodies, the first experiments were half gradients of single 
biomarkers shown in Figs 4.7-4.9. Only purified solutions of the three-biomarker system were 
studied. When comparing the NSE and S-100β half titers between the 2-antibody and 3-antibody 
MPC systems, the overall impedance values have increased by about 3x, corresponding to ~3x 
increase in slope, while all the R2 are about the same (0.96-0.99). The calibration curves for the 
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TNF-α half titers have the highest slopes and lowest R2 of all three calibration curve sets (~0.95). 
From this data, it was clear that detection of the biomarkers was possible, but not clear if the 
biomarkers were distinguishable from each other. 
 
Next, solutions containing high and low combinations of all three biomarkers were measured using 
EIS (Fig 4.10) in purified solutions only. The concentration of antibody matched those which were 
used to obtain GDE and single-antibody MPC data: anti-NSE (20 µg/mL), anti-TNF-α (5 µg/mL), 
anti-S-100β (2.5 µg/mL). The highest impedance magnitude signals for all three biomarkers was 
observed in the NL+SL+TL solution, which was expected in light of the negative relationship 
between concentration and complex impedance, as shown in all the MPC calibration curves. The 
fact that the lowest impedance signals occur in the NH+SH+TH solution confirms this theory. From 
these data, it was difficult to discern trends for individual biomarkers. Thus, a three-way (3 factors: 
[NSE], [S-100β], and [TNF-α]), 3-level (none, low, high) ANOVA was conducted on corrected 
impedance data (corrected in the way described in the previous section). A full three-way ANOVA 
could not be modeled (not enough data to allow degrees of freedom to estimate all interactions) 
resulted in partially aliased effects (NSEnone*TNF-αnone, NSElow*TNF-αnone, NSEnone*TNF-αlow, and 
NSElow*TNF-αlow) and aliased effects (all three-factor interactions). The three-factor interactions 
were not included in the model as those effects were less likely to contribute to significance 
compared to the two-factor interactions. Table 4.6 provides details regarding significance of the 
concentration effects used in the models. Equations 4.5-4.7 include details for the 57.44, 546.9 and 
2148 Hz three-way ANOVA models, respectively: 
Change in Complex Z (57.44 Hz) = 35.05 Ω + 131.71*NSEnone – 72.34*NSElow – 59.37*NSEhigh + 156.43*S-
100βnone – 75.07*S-100βlow – 81.36*S-100βhigh – 421.97*TNF-αnone + 210.17*TNF-αlow – 211.8*TNF-αhigh  
– 566.98* NSEnone*S-100βnone + 254.65*NSElow*S-100βnone + 312.33*NSEhigh*S-100βnone + 267.6*NSEnone*S-
100βlow – 129.44*NSElow*S-100βlow – 138.16*NSEhigh*S-100βlow. 
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Change in Complex Z (546.9 Hz) = -25.32 Ω + 71.36*NSEnone – 18.09*NSElow – 53.27*NSEhigh + 219.6*S-
100βnone – 64.91*S-100βlow – 154.69*S-100βhigh – 452.87*TNF-αnone + 224.66*TNF-αlow – 228.21*TNF-αhigh  
– 532.03* NSEnone*S-100βnone + 222.56*NSElow*S-100βnone + 309.47*NSEhigh*S-100βnone + 
272.23*NSEnone*S-100βlow – 158.13*NSElow*S-100βlow – 114.1*NSEhigh*S-100βlow. 
 
Change in Complex Z (2148 Hz) = -19.74 Ω + 65.73*NSEnone – 17.58*NSElow – 48.15*NSEhigh + 214.93*S-
100βnone – 66.96*S-100βlow – 147.97*S-100βhigh – 432.85*TNF-αnone + 216.13*TNF-αlow – 216.72*TNF-αhigh  
– 514.21* NSEnone*S-100βnone + 208.9*NSElow*S-100βnone + 305.31*NSEhigh*S-100βnone + 260.56*NSEnone*S-
100βlow – 147.79*NSElow*S-100βlow – 112.77*NSEhigh*S-100βlow. 
 
These ANOVA models and analysis concluded that all main effects and interactive effects tested 
were extremely significant for all impedance ratio data collected at all three frequencies. The same 
post-hoc techniques previously discussed were also used to determine which comparisons 
contributed most to significance. For the NSE main effect, all concentration combinations were 
statistically significant at all three frequencies of interest except the comparison between high and 
low concentrations of NSE. While the reason for this is unclear, the same result was obtained in 
the 2- antibody purified two-way ANOVA models. Interestingly, this high and low concentration of 
NSE comparison became increasingly significant as frequency increased, again supporting that 
impedance variance may be a function of frequency. Regarding the main effect of S-100β, the 
same pattern seen in the NSE main effect was also seen here: only the high-low comparison was 
not statistically significant. This is particularly puzzling since the comparison which would be 
expected to have the greatest difficulty in establishing significance should be between none and 
low concentrations. However, in the case of S-100β, the least amount of antibody was used and 
this comparison between low and high comparisons would be the most difficult to determine 
significance if antibody saturation is occurring at the low concentration. The TNF-α main effect 
comparisons were found to be all statistically significant at the 546.9 and 2148 Hz frequencies, but 
at the optimal TNF-α frequency, the comparison between high and low concentrations was very 
non-significant. One possibility for this might be the potential interaction between anti-TNF-α and 
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the S-100β antigen discovered in the interferents tests discussed previously in this chapter. Another 
possibility for seeing consistent non-significance between the high and low concentrations between 
any of the three biomarkers may be diffusion related. However, the more likely cause is increased 
variation (greater signal and greater noise) in combination with a small sample size.  
 
While the models for the 3-antibody MPC sensors are not fully realized, they have shown promise 
for creating robust characterizing equations which might allow for simultaneous detection of three 
biomarkers in one sample. More replicates and an expanded factorial design would likely obtain 
models such as those from the 2-antibody MPC sensor systems. A summary of the detection limits 
based on the half titer data can be found in Table 4.7. 
 
4.4 Conclusion 
The feasibility of simultaneous detection of two and three biomarkers was studied. Two-way and 
three-way ANOVA in combination with post-hoc testing showed that the greatest source of non-
significance is between high and low concentration impedance measurements. This is likely due to 
the small sample size (N = 3), and the increased variation between these two particular data sets 
(with increased signal, comes increased noise in general). However, based on the promising data 
and foundation for multiplexed models presented here, the goal of simultaneously detecting 
multiple biomarkers is feasible. Future work would include running more replicates and full factorial 
designs for the multiplexed experiments, especially for the three-antibody encapsulated MPC tests. 
Moreover, running fewer gradients (one solution after another on the same sensor) and running 
the sensors as they would be used in the final device (read only one solution) would help determine 
where reproducibility could be improved in the sensor manufacturing process. While the cross-
reactivity of each biomarker against the individual antibodies was conducted, a future study is 
needed to ensure that several antibodies in the same solution do not interact with each other. If for 
example, multiple antibodies coalesce when in the same solution, this might affect biomarker 
binding and impedance readings in the simultaneous detection cases. Multiplexed data in blood, 
not plasma or serum samples has not been previously published, for this reason alone, the work 
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presented here bears significance in the biosensors field. If future studies could further elucidate 
these models to simultaneously detect biomarkers, this could not only help diagnose TBI in a matter 
of seconds in a small blood sample with little or no sample preparation, but could also be expanded 
to diagnose or monitor any disease with known biomarkers. 
 
4.5 Figures  
Fig 4.1: A schematic illustrating the process of creating multi-antibody encapsulated MPC sensors. 
 
Table 4.1: Titer information for 2-antibody tests (NSE and S-100β). NH stands for NSE-high, NL 
stands for NSE-low, and the same is true for S-100β. Concentrations are in pg/mL. 
2-Antibody 
Solutions 
Dilution 
[NSE] in PBS 
Dilution [S-
100β] in PBS 
Effective 
[NSE] 
Effective 
[S-100β] 
NL + SL 8 8 1 1 
NH + SL 200,000 8 25,000 1 
NL + SH 8 80,000 1 10,000 
NH + SH 200,000 80,000 25,000 10,000 
 
Table 4.2: Titer information for 2-antibody tests (NSE and S-100β) in 12.5% blood. NH stands for 
NSE-high, NL stands for NSE-low, and the same is true for S-100β. Concentrations are in pg/mL. 
2-Antibody 
Solutions 
Dilution 
[NSE] in PBS 
Dilution [S-
100β] in PBS 
Effective 
[NSE] 
Effective 
[S-100β] 
NL + SL 4 4 1 1 
NH + SL 100,000 4 25,000 1 
NL + SH 4 40,000 1 10,000 
NH + SH 100,000 40,000 25,000 10,000 
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Table 4.3: Titer information for 3-antibody tests (NSE, S-100β and TNF-α). NH stands for NSE-
high, NL stands for NSE-low, and the same is true for S-100β and TNF-α. Concentrations are in 
pg/mL. 
3-Antibody 
Solutions 
Dilution 
[NSE] in 
PBS 
Dilution [S-
100β] in 
PBS 
Dilution 
[TNF-α] 
in PBS 
Effective 
[NSE] 
Effective 
[S-100β] 
Effective 
[TNF-α] 
NL + SL + TL 6 6 0.6 1 1 0.1 
NH + SL + TL 150,000 6 0.6 25,000 1 0.1 
NL + SH + TL 6 60,000 0.6 1 10,000 0.1 
NL +SL + TH 6 6 450 6 6 75 
NH + SH + TH 150,000 60,000 450 25,000 10,000 75 
 
Table 4.4: This table includes SNR values (variance of signal divided by variance of noise) for each 
of the TBI antibodies against each of the TBI biomarkers to check for cross-reactivity at the optimal 
frequency for the antibody on GDEs. All SNR calculations are based on N = 2, except for the 
matching antibody-antigen pairs are based on N = 1 (denoted by *). 
Biomarker/Antibody 
Anti-GFAP @ 
17.44 Hz 
Anti-NSE @ 
546.9 Hz 
Anti-S-
100β @ 
2148 Hz 
Anti-TNF-
α @ 57.44 
Hz 
GFAP 0.35* 0.26 0.01 0.002 
NSE 0.42 4.21* 0.06 0.15 
S-100β 1.12 0.01 6.06* 2.02 
TNF-α 0.000 0.06 1.34 1.23* 
 
 
Fig 4.2: Calibration curve (N = 5) of a half titer of NSE measured by a 2-antibody co-encapsulated 
MPC sensor, where the optimal frequency of both antibodies (546.9 Hz for NSE and 2148 Hz for 
S-100β) are displayed. Standard error bars. 
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Fig 4.3: Calibration curve (N = 5) of a half titer of S-100β measured by a 2-antibody co-encapsulated 
MPC sensor, where the optimal frequency of both antibodies (546.9 Hz for NSE and 2148 Hz for 
S-100β) are displayed. Standard error bars. 
 
 
Fig 4.4: Bar chart showing the raw impedance values measured on high and low combinations of 
NSE and S-100β solutions using a 2-antibody encapsulated MPC at the optimal frequencies for 
NSE (546.9 Hz) and S-100β (2148 Hz). Standard error bars. 
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Fig 4.5: Calibration curve (N = 5) of a half titer of NSE in 12.5% blood solutions measured by a 2-
antibody co-encapsulated MPC sensor, where the optimal frequency of both antibodies (546.9 Hz 
for NSE and 2148 Hz for S-100β) are displayed. Standard error bars. 
 
 
Fig 4.6: Calibration curve (N = 5) of a half titer of S-100β in 12.5% blood solutions measured by a 
2-antibody co-encapsulated MPC sensor, where the optimal frequency of both antibodies (546.9 
Hz for NSE and 2148 Hz for S-100β) are displayed. Standard error bars. 
 
Table 4.5: Summary of detection limits based on NSE and S-100β half titer data in the 2-antibody 
MPC system in purified and 12.5% blood solutions. 
Detection Limits 
(pg/mL) 
Purified 546.9 
Hz 
Purified 2148 Hz 
12.5% Blood 
546.9 Hz 
12.5% Blood 
2148 Hz 
NSE -6.43 -6.24 -9.55 -3.85 
S-100β -2.85 -1.84 -12.15 -3.57 
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Fig 4.7: Calibration curve (N = 5) of a half titer of NSE in purified solutions measured by a 3-antibody 
co-encapsulated MPC sensor, where the optimal frequency of both antibodies (546.9 Hz for NSE, 
2148 Hz for S-100β, and 57.44 Hz for TNF-α) are displayed. Standard error bars. 
 
 
Fig 4.8: Calibration curve (N = 5) of a half titer of S-100β in purified solutions measured by a 3-
antibody co-encapsulated MPC sensor, where the optimal frequency of both antibodies (546.9 Hz 
for NSE, 2148 Hz for S-100β, and 57.44 Hz for TNF-α) are displayed. Standard error bars. 
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Fig 4.9: Calibration curve (N = 5) of a half titer of TNF-α in purified solutions measured by a 3-
antibody co-encapsulated MPC sensor, where the optimal frequency of both antibodies (546.9 Hz 
for NSE, 2148 Hz for S-100β, and 57.44 Hz for TNF-α) are displayed. Standard error bars. 
 
 
Fig 4.10: Bar chart showing the raw impedance values measured on high and low combinations of 
NSE, S-100β and TNF-α solutions using a 3-antibody encapsulated MPC at the optimal frequencies 
for NSE (546.9 Hz), S-100β (2148 Hz) and TNF-α (57.44 Hz). Standard error bars. 
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Table 4.6: This table includes a summary of the two-way ANOVA significance of the effects used 
in the models discussed in the 3-antibody MPC section. 
Effect 
Probability in 
57.44 Hz Model 
Probability in 
546.9 Hz Model 
Probability in 
2148 Hz Model 
Model < 0.0001 < 0.0001 < 0.0001 
NSE 0.0015 0.0010 0.0004 
S-100β < 0.0001 < 0.0001 < 0.0001 
TNF-α 0.0280 0.0163 0.0051 
N+S+T 0.2176 0.1851 0.1106 
 
Table 4.7: Summary of detection limits based on NSE, S-100β and TNF-α half titer data in the 3-
antibody MPC system in purified solutions. 
Detection Limits (pg/mL) Purified 57.44 Hz Purified 546.9 Hz Purified 2148 Hz 
NSE -1.60 -1.57 -1.62 
S-100β -1.25 -1.30 -1.42 
TNF-α -4.91 -5.04 -5.23 
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CHAPTER 5 
SUMMARY AND FUTURE WORK 
5.1 Overview and Aims 
The objective of this work was to develop novel electrochemical impedance diagnostic sensors 
and analysis methods to simultaneously quantify multiple TBI biomarkers in the same complex 
sample. Overall, the specific aims listed below were addressed: 
Specific Aim 1:  
Develop impedance and impedance-time models for the four TBI biomarkers of interest (GFAP, 
NSE, S-100β, and TNF-α). 
 
Specific Aim 2: 
Optimize the mesoporous carbon (MPC) protocol to encapsulate individual antibodies and compare 
the filtering ability of MPC to the commercial standard, Nafion. 
 
Specific Aim 3: 
Determine feasibility for simultaneous multiplexed detection of TBI biomarkers using MPC in 
purified and complex solutions. 
 
5.2 Summary of Work 
 
To complete aim 1, the use of EIS and Z-t yielded calibration curves and statistics such as detection 
limits, RSD and standard deviations were conducted. Optimal frequency and general 
electrochemical behavior using these techniques was never before published. While these 
experiments were conducted on gold disk electrodes (not the friendliest regarding test strip design 
and mass manufacturing), these data provided characteristic properties for each of the four TBI 
biomarkers on an ideal electrochemical set up. Successful detection of all four biomarkers was 
achieved in purified (DL = 0.55- 10.32 pg/mL), 5%-90% blood (DL = 3.65 - 67.22 pg/mL), and 
plasma (DL = 5.79 – 50.67 pg/mL) solutions. The CCI injury rat samples had mixed success, but 
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showed promise for biomarker detection in real TBI samples and justifies future work. Moreover, 
the exploration of the Z-t technique proved it might be the best technique for use on a handheld 
TBI diagnostic. 
 
In order to complete aim 2, the MPC protocol was successfully translated to detect each of the 
biomarkers on an individual basis in purified (DL = 1.04 - 26.5 pg/mL) and in 12.5% and 90% blood 
(DL = 9.3 – 23.3 pg/mL) solutions. While the best blood data was detected in 12.5% blood solutions, 
a future device where the sample must be diluted (which may be able to be designed into the end 
device) is a decided improvement over a device which requires separated plasma or serum 
samples. The characteristics found in data for aim 1 were required to be verified and validated due 
to the interesting electrochemical and physical characteristics of MPC (specifically due to diffusion). 
These updated calibration curves will be important for programming a future device so the 
measured impedances of individual biomarkers can be converted to biomarker concentration. And 
if the feasibility of simultaneous detection of multiple biomarkers is not attainable, it would take 
theoretically less than 35 seconds to quantify each of these four biomarkers individually on the 
same test strip using the Z-t technique. Moreover, these MPC data were favorably compared to the 
Nafion commercial coating EIS and Z-t data for NSE detection in purified (DL = 2.8 – 78.9 pg/mL) 
and blood solutions (DL = 2.3 – 1190.9 pg/mL). Both the EIS and Z-t in conjunction with MPC 
provided sensitive and reproducible methods to successfully quantify the four TBI biomarkers using 
the novel, mass manufacturable and cost-effective alternative to Nafion coatings and gold disk 
electrodes. 
 
The feasibility study in aim 3 was meant to explore the possibility of quantifying multiple biomarkers 
simultaneously, and in the same MPC structure. The half titer data in Chapter 5 showed results 
that concluded individual biomarker assessment is possible in a multi-antibody MPC structure. This 
will be very important if the ability to simultaneously detection multiple biomarkers becomes too 
costly or difficult regarding data analysis and handheld device programming. However, the ANOVA 
models presented in Chapter 5 showed promise (especially in the 2-anitbody case) for 
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simultaneous detection of multiple biomarkers. This work has shown that it is possible to detect 
and possibly quantify multiple biomarkers simultaneously, but future work is required to create 
robust models to quantify these biomarkers simultaneously. Furthermore, from a commercial point 
of view, designing one test strip to quantify multiple biomarkers may not be a better business model 
than having one test strip measure one biomarker at a time. 
 
This work has made major efforts towards the development of a novel, safe, and accurate point-of-
care diagnostic device will address the major gap in TBI diagnosis hindering the efficacy of 
treatment, quality of life of TBI survivors, resulting in unnecessary economic burden. In the long 
term, a rigorous assessment of these sensors’ ability to correlate with the severity of TBI, as 
measured via current methods of diagnosis (e.g., Glasgow Scale and MRI), will be addressed in 
preclinical and clinical trials, but was beyond the scope of this project. With the foundation laid by 
this work, the possibility of a handheld blood based TBI diagnostic is feasible and will hopefully 
someday benefit millions of TBI and concussion suffers each year. 
 
5.3 Future Work 
 
Outside of the future work previously mentioned in Chapters 2-4 such as replicating experiments, 
the following considerations may be required to produce a handheld TBI blood diagnostic. 
 
5.3.1 Shaping Protein Signal 
 
As discussed in Chapter 2, the overlapping of potential optimal frequencies can cause issues for 
simultaneously detecting biomarkers. However, a protocol to potentially circumvent this issue has 
been developed: antibodies are labeled with gold, silver or magnetic nanoparticles before the 
antibodies are immobilized to a sensors surface [101] or encapsulated into a mesoporous structure 
(Fig 5.1). The addition of the nanoparticle has been shown by La Belle et al. to change the optimal 
binding frequency, which can be tuned and customized as needed, deepening on the other 
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antibody-antigen pair optimal frequencies. Moreover, the two antibodies are distinguishable in 
absorption and mass spectroscopy. The original antibody-nanoparticle solutions, a mixture of the 
original solutions, and the rinsing water are also typically analyzed to ensure that that two 
antibodies did not aggregate and do enter the mesoporous structure. Next, the same labeled 
antibodies may be encapsulated one after the other to see if encapsulation is more or as effective 
in steps versus all simultaneously. Following this, three antibodies may be encapsulated 
simultaneously or individually in steps, and verified with absorbance and mass spectroscopy. 
Finally, all four antibodies can be quantified using EIS or Z-t. Based on previous BET and BJH 
results on MPC, there are far more pores (2.0E+20 pores/gram) than antibodies, thus saturation is 
not a concern. From a manufacturing standpoint, the next step would be to screen print these mutli-
antibody encapsulated mesoporous carbons onto commercial sensors as described in Aim 2, and 
use these to detect the analytes in purified and complex solutions. 
 
5.3.2 Miniaturization of Electronics to Make a Handheld Diagnostic 
 
The La Belle Lab and colleagues in the electrical engineering department have been working to 
miniaturize the hardware required to perform EIS. So far, this work has focused on dry eye 
diagnosis, but changing out one protein for another is not a very laborious process, especially if 
calibration curves for the new biomarkers are already in hand. Moreover, work is being conducted 
to mass manufacture test strips. This would be essential to the development of a handheld TBI 
diagnostic, to which antibody-encapsulated MPC lends itself well. Furthermore, the Z-t studies in 
this work have shown its quality compared to EIS, and would also be an additional benefit to a 
handheld TBI diagnostic and potentially reduce the amount of hardware required to create the 
handheld device. Once a handheld device is achieved, many of the experiment presented in this 
work would need to be replicated using the new device and compared to the gold standard CH 
instruments electrochemical analyzer (especially for purpose of 510k or PMA FDA submissions). 
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5.3.3 Correlate the Biosensor Data to Imaging Data for Deficit Prediction 
 
As discussed in Chapter 1, a point-of-care diagnostic might be most useful if that information could 
be integrated with imagining data so deficits could be monitored and/or predicted based on severity 
and secondary damage information and location of the brain injury. This would require clinical trials 
(discussed next), but would be the next major step after the development, verification and validation 
of a handheld TBI diagnostic. 
 
5.3.4 Human Samples/Clinical Trials 
 
The purpose of a clinical trial with respect to medical devices, and specifically diagnostics, is to 
fulfill a need to safely and effectively determine the presence of some disease, injury or other 
physiological process [151]–[153]. 
 
If a small feasibility clinical trial for this device were to be conducted, the following would describe 
those efforts. This would naturally occur after more pre-clinical rat data could be obtained. A 
concussion specialist from Mayo Clinic Arizona has expressed interest in aiding the development 
of this TBI diagnostic sensor. Dr. Dodick is willing to provide human TBI whole blood or plasma 
samples with patient consent (and after IRB approval). The data obtained would be compared to 
the experiments described here; the severity would be determined from the biosensors data and 
compared to Dr. Dodick’s assessment of the patient (likely GCS and GOS). The samples of 25 
patients would be obtained at one time point (as close to the same time point after injury as 
possible): 5 uninjured persons, 10 mild TBI and 10 moderate TBI patients. Where each patient 
need only provide a maximum of 15 mL of whole blood. Each patient’s blood test would be 
replicated (N = 5 for mesoporous carbon sensors, N = 3 for GDE sensors). If the multi-encapsulated 
mesoporous carbons prove to be usable, 75 sensors would be required. If the individually 
encapsulated mesoporous carbon sensors must be used, the number of human samples would 
decrease to 3 uninjured persons, 5 mild TBI and 5 moderate TBI patients and only replicated for N 
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= 2, for a total of 104 sensors. These experiments would be double-blinded, so investigators would 
not know about the patient prior to receiving the samples such as name, gender, TBI severity, or 
otherwise. Patient samples would be received two at a time so the manufacturing of the sensors 
can be staggered, each set of two samples would take a maximum of 1 week to run and analyze. 
Therefore, this 25-patient study would last ~12 weeks; if there were 13 patients, it would last 6.5 
weeks. But to incorporate preparation time and the IRB approval, an extra ~3 weeks would be 
factored in. 
 
5.3.4.1 Trial Designs 
 
Ideally, the first pre-pivotal clinical study would assess every protein and biomolecule after all forms 
of TBI would be studied as in the animal studies measuring the same clinical outcomes. It would 
be very large and relatively simple with the sole purpose of collecting as much data as possible. It 
has been recommended that larger more simple trials in TBI studies be implemented to increase 
the likelihood of determining all possible contributing or confounding factors for a biomarkers ability 
to correlate with TBI [154]. On the other hand, too large of a sample size can make effects which 
would not have clinical meaning look significant [151]. 
 
A second pre-pivotal study would be a comparative study on all forms of TBI. This would likely be 
a paired design to test the handheld TBI diagnostic against something like an ELISA and perhaps 
HPLC (high-performance liquid chromatography). This data would probably help in making 
arguments for reimbursement purposes later. This study would likely require fewer subjects since 
only the significant and possibly significant biomarkers from the first pivotal study will be analyzed. 
The same clinical outcomes would be measured which will be helpful to retrospectively verify and 
validate the results of the first pre-pivotal study. 
 
A pivotal clinical study would be a diagnostic performance study which would look at the final set 
of significant and possibly significant biomarkers determined in the previous animal and pre-pivotal 
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studies for comparison to clinical performance measures (clinical outcomes). This would be a larger 
study with as much homogeneity in groupings as possible. 
  
Finally, probably after FDA approval, a longitudinal clinical study of the biomarkers and clinical 
outcomes for all forms of TBI would be most beneficial to the field. 
 
It has been agreed upon that no single clinical trial design is better suited in general. The best trail 
design depends upon the question posed for investigation. For this reason, the FDA has not set 
very many restrictions, and merely asks that the trials are well-designed and reasonable [154]. The 
FDA is not concerned about small treatment effects, or that the treatment/diagnostic cannot be 
applied to every form of TBI; the FDA is concerned about the claims made and that requirements 
of safety and efficacy are supported and met by the clinical evidence collected [154]. Typically, 
non-clinical trials (bench studies) are performed before at least one pre-clinical trial in an animal 
model, followed by the clinical trial designs for humans [152]. For a larger clinical trial for something 
like FDA approval for a TBI diagnostic, the following points have been discovered in literature to 
avoid common pitfalls in clinical trial design: 
 
• Have a large homogenous patient population, but not so large that a clinically insignificant 
effect becomes statistically significant [24], [151] 
• Explicitly categorize patients with consistent injuries using specific criteria [24], [155] 
o Baseline readings on patients before injury would be ideal but unlikely [155] 
• Maintain consistent outcome measures and definitions of critical or transitional values 
throughout the trial[24]  
o Do not use dichotomized possibilities for end points; better resolution will be 
achieved with more than two options (e.g. define outcome in terms of a 5-point 
ordinal scale: death, vegetative state, or severe disability (unfavorable); moderate 
disability or good recovery (favorable)) [155]. However, a baseline prognostic must 
be established as the basis of comparison either for each patient or overall. 
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o Consider the outcome measures, how they will be measured and standardized, 
how these measurements pertain to lifestyle and injury. Six months post-injury is 
the recommended for most clinical trial outcome measurements [154]. 
o Use multiple and different predictors/end points (e.g. Glasgow Coma Motor Score, 
pupillary reactivity, age, hypoxia, hypotension, CT classification, traumatic 
subarachnoid hemorrhage) [24], [155] 
• Statistical analysis should incorporate covariate allowances for predetermined factors 
which may vary in every sample reading (e.g. age of patient, or the amount of time each 
sample spends in the refrigerator) to reduce heterogeneity [155], [156] 
o Attempt to reduce any variation caused in procedures such as data and sample 
collection [154] 
o Design the study to produce potentially significant effect sizes of at least 5-7.5% 
[154]. While this is a small effect size, it is also likely to be reality as so many 
biomarkers lack both sensitivity and specificity [154]. 
• Pre-clinically characterize and model the injuries to be assessed in clinical trials, with 
multiple methods of injury such as fluid percussion and/or CCI [154]. 
 
5.4 Figures 
Fig 5.1: A schematic of nanoparticle labeled antibodies encapsulated within the same mesoporous 
structure. 
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APPENDIX A  
PROTOCOL: SYNTHESIZING MESOPOROUS CARBON 
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Mesoporous Carbon Synthesis (MP-C-46): 9 Days synthesis time 
 
Synthesizing the Resol Polymer Precursor: Day 1 
1. Place the water bath in the hood on a stirring plate 
2. Fill the bath to the physical line in the tank with tap water  
3. Set the bath to 43-45°C (DO NOT TURN ON HEAT FROM STIR PLATE) 
4. Measure 8g of Phenol ≥99% into 250mL round bottom flask and place in fridge 
a. Wear a face mask 
b. Mass of empty 250mL round bottom flask: 
c. Mass of flask cap: 
d. Mass of stir bar: 
e. Combined mass of labware: 
f. Actual mass of measured Phenol:   opened: 
5. In a clean 50mL Erlenmeyer flask, mass out the NaOH needed later 
a. Mass out 0.34g of NaOH pellets into the Erlenmeyer flask 
i. Actual NaOH mass:    opened: 
b. Re-zero the scale and add 1.36g of DI water to the Erlenmeyer flask using a glass 
Pasteur pipette 
i. Actual DI mass: 
c. Carefully mix the solution so the NaOH dissolves 
d. Cover the Erlenmeyer flask with parafilm and set aside in a safe place until needed 
6. In a clean 50mL Erlenmeyer flask, mass out the formaldehyde needed later 
a. Mass out 14.16g of Formaldehyde, 37wt% solution water (should come already as 
37wt% water) 
i. Wear face mask 
ii. Actual mass of formaldehyde:   opened: 
b. Cover the Erlenmeyer flask with parafilm and set aside in a safe place until needed 
7. Set up the water chiller and reflux condenser in the hood 
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8. Fill the crystallization dish halfway with tab water and pace in the fridge 
9. Once the water bath is at 45°C, immerse the phenol inside the capped round bottom flask 
a. Set the stir plate to 150-200 rpm, DO NOT turn on the heat function if it is a stirring 
hotplate 
10. Adding NaOH & H20 to melted phenol 
a. Grab the parafilmed 50mL Erlenmeyer flask with NaOH and DI in it 
b. Add the NaOH and DI mixture to the phenol dropwise over a minute (while still 
stirring in the water bath) and recap the round bottom flask 
c. Raise stir rate to 400rpm and wait 10min  
i. Start:    Stop: 
11. Adding Formaldehyde to Phenol + NaOH + DI mixture 
a. Grab the parafilmed 50mL Erlenmeyer flask with formaldehyde in it 
b.  Add the Formaldehyde to the Phenol + NaOH + DI mixture one glass pipette at a 
time 
i. Wear face mask 
c. Do NOT recap the round bottom flask, CAREFULLY attach the round bottom flask 
to the reflux condenser  
i. Begin a gentle cooled water flow in the reflux condenser 
d. Increase the stir rate to 700rpm and the water bath temperature to 75°C 
i. Once the water bath temperature reaches 75°C, wait 1hr  
1. Start:   Stop: 
e. While waiting, set up the rotovap and vacuum 
12. After the 1hr is up, quickly remove the round bottom flask (Phenol + NaOH + DI + 
formaldehyde mixture) from the heated water 
a. Place the capped round bottom flask in cool water on the stir plate, stir rate = 
200rpm 
b. Drain the reflux condenser carefully and put it away 
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c. Once the round bottom flask and contents have reached room temperature, add 
2M HCl dropwise with a glass pipette until the pH is between 6 & 7 
i. Check pH using pH paper 
13. Place the round bottom flask on the rotary evaporator (rotovap) for 30 minutes  
i. Start:    Stop: 
b. Set water bath to 50°C 
c. Have water running through the condenser must be cooled (use water cooler 
apparatus) 
d. Grease the glass that will interface with the round bottom flask (stir bar still inside) 
e. Clip round bottom flask to rotovap 
f. Close the vent, and make sure everything is sealed, or vacuum won’t work 
g. Turn on vacuum 
h. Start rotation at 50 rpm 
i. Lower the round bottom into water bath so the solution in the round bottom flask 
is submersed 
14. Remove the resol from rotovap: 
a. Turn of the vacuum pump 
b. Turn off the water bath 
c. Turn off the rotation 
d. Release vacuum from vent at side of condenser 
e. Raise the round bottom flask out of the water bath 
f. Carefully unclip and slide off the round bottom flask 
g. Clean grease off of inside of round bottom using chem wipe and ethanol 
h. Color of resol should be a thicker and darker brown/red 
i. Cap the round bottom flask and set aside 
15. Measure the mass of the round bottom flask, resol mixture, stir bar and cap: 
16. Add ethanol to the round bottom flask mixture:  
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a. Actual amount of EtOH added:   opened:  
17. Once the EtOH has been added to the resol mixture, recap and place the round bottom 
flask over a stir plate (no water bath, no heat, the flask does not actually touch the stir 
plate) 
a. Stir at 300 rpm for 5 mins  
i. Start:    Stop: 
18. Centrifuge the Resol and EtOH mixture for 15 mins to remove the NaCl precipitate 
a. If a centrifuge is not available, allow the solution to settle overnight or longer (this 
is not as ideal, it may allow NaCl to remain) 
19. Once the NaCl has precipitated out, use a glass Pasteur pipette to carefully collect the 
resol into a glass bottle without disturbing the NaCl precipitate 
a. Properly label the bottle with the chemical name “Resol Polymer, 20% wt Ethanol” 
and include your name and the date 
i. Parafilm the top of this bottle (to prevent EtOH from escaping over time) 
 
  
This uses the volume = (mass/density) eqn to convert 
grams of EtOH needed into mL; density of EtOH= 0.789 
g/mL 
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Synthesizing MP-CS-46 from the Resol Precursor: Days 2-4 (protocol from Liu, et al 2006 JACS 
DOI: 10.1021/ja0633518) 
** Do not proceed before the watch glasses are clean and ready for use (see Appendix II for 
instructions). 
1. Place the water bath in the hood on a stirring plate and fill the bath to the physical line in 
the tank with tap water  
2. Set the bath to 40°C (DO NOT TURN ON HEAT FROM STIR PLATE) 
3. In the first clean 50mL Erlenmeyer flask: 
a.  Measure 1.6g of the surfactant Pluronic F-127 (first on weigh paper) and pour into 
the Erlenmeyer flask 
i. Actual amount of Pluronic F-127:   opened: 
b. Using a glass Pasteur pipette, add 8g of EtOH to the 50mL Erlenmeyer flask 
i. Actual amount of EtOH:     opened: 
c. Using a glass Pasteur pipette, add 0.1g of 2M HCl to the 50mL Erlenmeyer flask 
i. Actual amount of HCl:     diluted: 
d. Using a glass Pasteur pipette, add 0.9g of DI water to the 50mL Erlenmeyer flask 
i. Actual amount of DI: 
e. Shake the Erlenmeyer until the surfactant dissolves (solution should turn from 
white to clear) 
4. Pour the contents of the Erlenmeyer into a clean 250mL round bottom flask 
5. Add a stir bar to the round bottom flask and cap it 
6. Place the round bottom flask into the 40°C water bath for 1 hour and set the stir rate to 400 
rpm 
a. Start:    Stop: 
7. Before the hour is up: 
a. Using a glass Pasteur pipette, add 2.08g of TEOS to a second clean 50mL 
Erlenmeyer flask 
i. Actual amount of TEOS:    opened: 
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ii. Parafilm and set aside until needed (in the dark) 
b. Using a glass Pasteur pipette, add 5g of Resol to a third clean 50mL Erlenmeyer 
flask 
i. Actual amount of Resol:     made: 
ii. Parafilm and set aside until needed (in the dark) 
8. After the hour is up, add the 2.08g of TEOS dropwise to the round bottom flask still in the 
water bath 
9. Next, add the 5g of Resol dropwise to the round bottom flask still in the water bath 
10. Wait 2 hours for the mixture to mix, still at 40°C, 400 rpm  
a. Start:   Stop: 
11. After the mixing period, transfer the round bottom flask contents into clean 50mL beaker 
and polymer to reach room temperature 
12. Spreading the polymer onto the watch glasses for evaporation 
a. Once at room temperature, use a 10mL plastic syringe (NORM-JET) to draw up 
6mL of the polymer 
b. Place the 0.22µm syringe filter disc on the end of the syringe 
c. Deposit 3mL of polymer onto each 6” watch glass 
d. To re-fill the syringe, remove the filter disc first, then repeat steps 13a-c 
e. Once all the watch glasses have been covered, pick up each watch glass and 
move it in a circular motion to spread the polymer over as much of the glass as 
possible: increases surface area, reduces drying time 
f. Leave the watch glasses in the hood overnight to dry  
i. Make sure you have a sign in the hood to the effect of “Mesoporous 
Carbon Evaporation in progress, please do not disturb.” Add your name 
and the date to the note. 
ii. Start:    Stop: 
13. ***The following day (Day 3), place the dried watch glasses into a conventional oven for 24 
hours at 100°C 
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a. Start:     Stop: 
14. ***The day after that (Day 4), the polymer must be removed from the watch glasses by 
scraping it off 
a. Lay out aluminum foil over the bench top to catch any polymer that falls off of the 
watch glass 
b. Wear goggles and a face mask 
c. Use a spatula with a straight square edge to scrape the polymer off of all the watch 
glasses 
i. Warning- this is tiresome and time-consuming 
d. Place the polymer scraps into a clean alumina boat or crucible that will fit in the 
tube furnace 
i. To clean a boat or crucible, place it in an oven at 500°C 
15. Clean the watch glasses in acid piranha solution (see appendix 2 for protocol). 
 
Carbonizing the Polymer to make MP-CS-46: Day 4 
**Safety Note: If the tube furnace hasn’t been used in the last two weeks (check the furnace log), 
then it needs to run a refractory maintenance heat BEFORE you put anything in it. Failing to do so 
will result in super heating water in the refractory causing catastrophic damage to the furnace. Refer 
for Appendix III for the protocol to remove the water. 
1. Weight of alumina boat (empty):   Weight of boat + Polymer: 
2. Once all the polymer is scraped into a clean alumina boat, open the right side of the tube 
furnace and carefully remove the white refractory cone and set it aside 
3. Using the mesoporous carbon tube furnace stick, carefully slide the alumina boat into the 
tube until the line marked on the stick reaches the edge of the tube 
4. Place the white refractory cone back into the tube (the wider side goes in towards the 
middle of the furnace) using the tube furnace stick until the line on the first piece of yellow 
tape reaches the edge of the tube 
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5. Secure the rubber and metal end plates on both ends by tightening the bolts, the tube 
should now be sealed 
a. Use a set of pliers and 15/32” socket ratchet to tighten the bolts 
6. Purge the system of air (failure to do so = polymer burning = empty boat instead of black 
carbon powder) 
a. Open the N2 gas cylinder until the flow meter near the tank valve reads 1 slpm 
b. Allow the N2 gas to flow at 1 slpm for 30 mins  
i. Start:    Stop: 
ii. If you hear leaking, tighten and do the bubble test to ensure no leaking is 
occurring 
7. Once the purge is complete, reduce the N2 gas flowrate to 0.2 slpm 
8. Tighten the long, skinny nuts from the hanging system to ensure the tube furnace will not 
move vertically 
9. Turn on the oven and input the desired settings (see appendix 3 for a reminder on how to 
enter the settings): 
a. C01: 0°C, t01: 120 min 
b. C02: 600°C, t02: 60 min 
c. C03: 900°C, t03: 180 min (dwell time) 
d. C04: 900°C, t04: 180 min 
e. C05: 0°C, t05: -121 min (ends the program) 
f. Other notes:  
i. Make sure the tube furnace does not heat or cool down faster than 
5°C/min 
ii. This program will take 9 hours to run, but the contents will still be very hot 
for some time after 
10. Press and hold the RUN/HOLD button for the program to start 
a. Start:    Stop: 
11. Other notes: 
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a. Make sure the program has cool down segment (C05 as above) 
b. Max heating rate for alumina tube: 5°C/min 
c. Be in lab at the end of the program to turn the N2 gas off, to remove the boat(s), 
and power off the oven 
 
Removing the Carbonized MP-CS-46 sample: Day 4 
1. Turn off the N2 gas, and turn off the program on the oven 
2. Turn the oven’s power off 
3. Lower the tube by loosening the hanging system 
4. Disconnect the gas inlet at the white & orange joint 
5. Remove the metal ends and rubber piece from the inlet side of the tube 
6. Using tongs and the furnace stick, slowly and carefully pull out the first refractory cone 
and alumina boat 
a. Beware these items may still be hot or warm, use oven mitts 
b. If too hot to handle, leave the boat(s) in the tube, but keep seal and refractory cone 
out 
 
Grinding the Carbonized MP-CS-46 sample: Day 5 
1. Weight of boat + MP-CS-46:    Weight of MP-CS-46: 
2. Place half* of the carbonized powder into the mortar (bowl) and grind using the pestle until 
the size of the particles appear uniform (shiny particles should all be about the same size) 
3. Divide up the grounded powder into two* 15mL centrifuge tubes 
4. Repeat steps 1-2 until all the powder has been ground to a uniform size 
* If doing more than one batch (1 batch = 6 watch glasses), grind ¼ of the product at a time and 
use four 15 mL tubes 
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Etching out the Si in the MP-CS-46 sample: Days 5-8 
1. In a PLASTIC* bottle, put 8g of NaOH pellets + 100mL DI water + 100mL of EtOH = etching 
solution 
a. Use the vortexer to dissolve and mix this solution 
b. Be very careful as this solution has a very high pH and is caustic 
2. Etching out the Si pore template (in etching solution for 72 hours): 
a. Day 5:  Start:    Stop: 
i. Fill the 15mL centrifuge tubes containing the MP-CS-46 to the 15mL mark 
with etching solution 
ii. Vortex each tube for 2 min at a speed of 3000 rpm 
iii. Leave this solution to settle overnight (with a label indicating the contents, 
date and your initials) 
b. On the following day, Day 6:   Start:    Stop: 
i. Centrifuge the tubes containing the MP-CS-46 and the NaOH/DI/EtOH 
solution for 20 mins (at 3200 rpm), make sure any odd solutions are 
counter balanced with a tube of DI 
ii. Using a glass Pasteur pipette, remove the supernatant (and place in the 
strong base waste) 
iii. Refill the centrifuge tubes with the etching solution to the 15mL mark and 
vortex for 1 min 
iv. Leave again overnight to settle 
c. On the following day, Day 7:   Start:    Stop: 
i. Centrifuge the tubes containing the MP-CS-46 and the NaOH/DI/EtOH 
solution for 20 mins 
ii. Using a glass Pasteur pipette, remove the supernatant (and place in the 
strong base waste) 
iii. Refill the centrifuge tubes with the etching solution to the 15mL mark and 
vortex for 1 min 
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iv. Leave again overnight to settle 
d. On the following day, Day 8: 
i. Centrifuge the tubes containing the MP-CS-46 and the NaOH/DI/EtOH 
solution for 20 mins 
ii. Using a glass Pasteur pipette, remove the supernatant (and place in the 
strong base waste) 
3. Rinsing the Mesoporous Carbon: 
a. Continuing on Day 8: 
i. After removing the last etching solution, refill the centrifuge tubes to the 
15mL mark with DI water, then vortex for 1 min 
ii. Centrifuge the tubes containing the MP-C-46 and the DI water for 20 mins 
iii. Using a glass Pasteur pipette, remove the supernatant (and place in the 
strong base waste) 
iv. Immediately (do not wait overnight) repeat steps 3i-3iii two more times (the 
MP-C-46 is rinsed with DI a total of 3 times) 
1. For repeats, centrifuge for 10 mins instead of 20 mins (as in 3aii) 
v. Put the MP-C-46 into a pre-weighed 3” watch glass 
1. Watch glass weight: 
* Lab glassware is made out of borosilicate. Placing the Si etching solution in glassware will destroy 
the glass. 
 
Drying the MP-C-46 sample: Days 8-9 
1. Once the MP-C-46 powder has been rinsed with DI, the powder should be placed onto a 
3” watch glass and placed in the conventional oven at 100°C for 24 hours to dry it. Then 
the powder is ready for use or storage in a labelled glass bottle. 
a. Start:     Stop: 
b. Watch glass weight + dried MP-C-46: 
c. Final weight of MP-C-46 (subtract 1b from 3av1 above): 
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APPENDIX I. Connecting a regulator to a compressed gas cylinder 
1. Remove the cylinder’s cap. 
2. Make sure the regulator is intended for the type of gas inside the cylinder. Different gasses 
have regulators with different shapes and threading. Using a regulator for the wrong gas 
will not properly fit on the cylinder and can result in injury and damage. 
3. Make sure the regulator and cylinder outlet are clean. 
4. Make sure the regulator’s parts all move properly and not damage is visible. 
5. Attach the regulator to the cylinder outlet, never force the threading. 
a. Never use Teflon tape or pipe dope to prevent leaks 
b. Tighten the connection with a smooth-jawed wrench 
6. Turn the regulator’s valve (aka pressure adjusting screw) counterclockwise until it turns 
freely 
7. Slowly open the cylinder valve until the inlet gauge on the regulator reads the cylinder’s 
internal pressure. 
8. Turn the pressure adjusting screw clockwise until the desired pressure on the outlet gauge 
(gauge left of the inlet gauge in the above picture) is the desired pressure. 
9. Now that the regulator’s function has been checked, perform a bubble test to check for 
leaks 
a. Close the cylinder valve 
b. If the inlet gauge’s pressure reading remains stable, there are no leaks 
c. Apply the bubble test solution to the regulator’s inlet and outlet connections, and 
the cylinder’s valve stem connection 
i. If bubbles are visible, tighten the connections 
 
APPENDIX II. Cleaning 6” Pyrex watch glasses using acidic piranha solution  
*** This solution is VERY DANGEROUS. Be extremely cautious and wear the proper PPE 
(including corrosion resistant gloves, acid-safe apron, full face mask, safety goggles and 
yellow over sleeves). 
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The following protocol must be done in a fume hood. 
1. Gather the following labware and be sure these items are very clean, free of water and 
organic material 
a. 3 170 x 90 glass crystallization dishes 
i. Piranha dish 
ii. Water/rinse dish 
iii. Watch glass dish 
b. 1 200mL glass beaker 
c. 1 Pair of stainless steel tweezers 
d. 1 Large squirt bottle of deionized water 
e. 1 Glass funnel 
2. Measure out 150mL of 96% Sulfuric acid using the 200 mL beaker 
3. Pour the measured sulfuric acid into the crystallization dish marked Piranha 
4. In the same, now empty 200mL beaker, measure 50mL of 30% Hydrogen peroxide 
5. Slowly pour the measured hydrogen peroxide into the crystallization dish marked Piranha 
6. Allow the solution to mix and boil before placing anything in the solution (wait ~5 mins) 
7. Take 1 watch glass and carefully submerge it into the piranha crystallization dish 
8. Use the metal tweezers to carefully move the watch glass around in the solution 
9. Once the bubbling has subsided (~5 mins), use the tweezers to carefully move the watch 
glass over the water crystallization dish 
10. While still holding the watch glass with the tweezers, rinse the watch glass very well using 
the DI bottle 
11. Dry the watch glass with two tissues 
12. Place the watch glass into the watch glass into the watch glass crystallization dish 
a. Be sure that there is a tissue between each glass interface (watch glass to 
crystallization dish bottom, and watch glass to watch glass) 
13. Repeat steps 7-12 until all watch glasses are clean 
  150 
14. If the watch glasses are to be stored for future use, parafilm the top of the watch glass 
crystallization dish 
15. Slowly pour the content from the water crystallization dish into the piranha crystallization 
dish 
16. Set this dish aside in a hood, leave uncovered overnight to allow the solution to cool 
a. Make sure you leave out a sign warning anyone who may use the hood that there 
is a dangerous chemical present. Include your name, phone number, the chemical 
details, the date it was made and the date of the next day (when you will pour the 
cooled solution into a hazardous waste bottle). 
17. Using a Clorox wipe, diligently wipe all counter and hood spaces, failing to do so may 
result in a nasty acid burn for yourself or for a fellow lab mate 
18. The next day, carefully pour the cooled piranha and water solution into a properly labeled 
and compatible hazardous waste bottle using the clean glass funnel 
 
APPENDIX III. Removing Condensation from Tube Furnace Refractory 
If the tube furnace hasn’t been used in the last two weeks (check the furnace log), a refractory 
maintenance heat run is required BEFORE you put anything in it. Failing to do so will result in 
super heating water in the refractory causing catastrophic damage to the furnace. 
1. Ensure there is nothing in the tube furnace besides the refractory cones 
2. Ensure both ends of the tube furnace are closed 
3. Power on the furnace and set the following parameters: 
a. Press the                    A/M so the PV (red digits) read C01 
i. Set C01 temperature to 0°C (0 should appear in SV field = green digits) 
using the      button 
1. Press and hold        and        to scroll down to C01 if it is not the 
first to appear 
b. Press the       button, which should show t01 in the PV field 
i. Set t01 to 40mins (time it takes to get to next temperature) 
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c. Press the       button, which should show C02 in the PV field 
i. Set C02 to 200°C 
d. Press the       button, which should show t02 in the PV field 
i. Set t02 to 120mins (dwell time at 200°C) 
e. Continue these steps to set the following values to the specified numbers below: 
i. C03: 200°C, t03: 40 min  
ii. C04: 0°C, t04: -121 min (tells the program to stop running) 
iii. Once the program is set, wait 30 seconds for the display to return to PV: 
(~)21, SV: flashing Stop 
iv. To start heating up the furnace, press and hold the       run/hold button 
(also pauses/hold program when pressed during program run) 
1. Heating red light should flash while the temperature increases, 
and once hot, will remain solid. 
v. If the program needs to be stopped, press and hold the      button  
4. Other notes:  
a. Make sure the tube furnace does not heat or cool down faster than 5°C/min 
b. There is no need to use any gas flow, this process should occur only in air 
c. This program will take 3 hours and 20 min to run 
 
  152 
APPENDIX B  
PROTOCOL: SYNTHESIZING PHBA GLUE  
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Free Radical Polymerization to Synthesize PHBA glue 
 
IMPORTANT INFORMATION: 
* All glassware which will interact with the BENZENE solution should be placed in the convection 
oven at 52°C for 24 hours before beginning this procedure (i.e. graduated cylinder, Schlenk flask, 
round bottom flask, cannula, etc). 
 
*Important general tip: Pull tubing off of reaction vessel before turning off vacuum (especially if the 
vacuum is connected close to the reaction vessel) as vacuum oil can contaminate it is turned off 
before the reaction vessel is removed. 
 
Required items: 
• N2 tank 
• Cannula 
• 4x < 18G Needles connected to 
hoses 
• Graduated Cylinder 
• 3x Septum 
• Ring stand & way to fix the 
BENZENE bottle to the ring stand 
• 2x Bubblers 
• Clear septum bottle tape 
• 1 100mL round bottom flask (RBF) 
• 1 Schlenk flask, mass: 
• Stir bar, mass: 
• Oven mitts 
• Conventional oven 
• Propane torch & lighter 
• Water bath 
• 1 glass Pasteur pipette 
• 10mL glass beaker 
• 10mL syringe & small needle 
• 2 labelled & weighed vials 
 
 
Turning on the N2 gas and vacuum lines: 
1. Make sure all manifold ports are closed. 
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2. Purge the nitrogen gas line for 20 mins (bubbler should have ~2-3 bubbles/second).  
a. When purging is complete, make sure the flow rate is suitable for the reaction. 
Bubbler should have ~1 bubble/second. 
3. While waiting for the nitrogen line to purge, ensure that the cold trap is greased and cold 
finger solution is prepared (dry ice and isopropyl alcohol). 
4. Turn on the vacuum pump and allow it to warm up for 3-5 mins. 
 
Preparing Glassware: 
1. Quickly and carefully (use oven mitts) remove each piece of glassware from the oven (one 
piece at a time), immediately close all the valves or cover holes with rubber septa. 
2. While pulling a vacuum on the Schlenk flask, use the Propane torch to carefully heat the 
glassware. 
3. Each piece of glassware should be purged with N2 (3-5 psi): 
a. Insert 2 needle/hose into the septum. The manifold provides both N2 and vacuum. 
i. 1 needle/hose connected to 2nd bubbler 
ii. 1 needle/hose connected to manifold 
1. N2 tank > bubbler > Drierite canister > manifold > glassware 
2. Vacuum > trap > manifold > glassware 
b. Purge the glassware with N2 by first vacuuming out air, then putting in N2 and 
repeating twice. 
i. Be careful to not turn on gas or vacuum on too suddenly, do it gradually 
and slowly. 
4. Remove all needle/hose lines and set the glassware aside. 
 
BENZENE Extraction Protocol: removing some BENZENE from its original bottle to be used in 
the reaction. 
* When transferring liquid via cannula, it is important to have the receiving flask under closed, 
positive pressure, while the origin flask is under N2 flow. 
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Amount of BENZENE required: 1g of monomer: 10mL BENZENE  Actual mL of 
BENZENE:   Opened: 
1. Make sure all potential fire sources are out and away from the hood. 
2. Clamp the BENZENE bottle to the ring stand in the fume hood and remove the polyethylene 
tape from the bottle’s septum. 
3. Insert 1 needle/hose to the 2nd bubbler into the graduate cylinder septum. 
4. Place another needle/hose (should be already N2 purged) connected to the manifold into 
the RBF septum. 
5. Poke one end of the cannula into the septum of the RBF and allow N2 to flush the cannula 
~2 mins. 
6. Insert another needle/hose from the manifold (N2 should already be flowing to purge the 
line before insertion) into the BENZENE bottle and pressurize with N2 (1-2 psi), requires 
~2 mins. 
7. Insert the free end of the cannula into the BENZENE bottle above the liquid line (do not 
immerse the needle). 
8. The end of the cannula in the RBF should be quickly removed from the RBF septum and 
poked into the septum of the graduated cylinder. 
a. The end of the cannula in the graduated cylinder should be above the level of 
expected liquid (ex: if you want 20mL, the end of the cannula should be above the 
20mL line, ~30mL). 
9. Turn off the manifold valve and remove the N2 needle/hose from the RBF and set aside. 
10. Push the end of the cannula in the BENZENE bottle into the bottle’s liquid, transfer should 
start. 
a. If liquid transfer does not start, flow to the 2nd bubbler may need to be reduced. 
11. When the BENZENE has reached the correct volume, pull the cannula end out of the 
BENZENE bottle, and insert it into the Schlenk flask (cannula height should be above the 
BENZENE liquid height once filled). 
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a. Schlenk flask should be under positive N2 pressure. 
b. Recommended volume of BENZENE: 1 g of monomer = 10 mL of BENZENE. 
12. Remove the needle/hose that connects the graduated cylinder to the 2nd bubbler and insert 
the needle/hose into the Schlenk flask. The 2nd bubbler should now be connected to the 
Schlenk flask. 
13. Keep the manifold valve open to N2 & remove the manifold needle/hose line from the 
BENZENE bottle, then insert that needle/hose into the graduated cylinder. 
14. Push the end of the cannula already in the graduated cylinder to the bottom of the 
graduated cylinder. 
15. Adjust the N2 flow so that the BENZENE slowly drips into the Schlenk flask. 
16. Using the clear Polyethylene tape, cover the BENZENE bottle’s septum. 
17. Once the transfer is complete, turn off the N2 and detach all needle/hose lines from the 
graduated cylinder. 
18. The needle/hose connecting the 2nd bubbler to the Schlenk flask should be removed from 
the 2nd bubbler and placed onto the manifold. 
 
Free Radical Polymerization Protocol: 
*Generally, a reflux condenser is not required unless the reaction mixture will be heated above or 
near the boiling point of any of the solvents used under the vacuum applied. 
 
1. Fill the water bath to the physical line in the tank, set temperature to 40°C. 
2. Place the water bath on the stir plate (200 rpm). 
a. Do not turn on stir plate’s heat function. 
3. Measure out 2.5g of the 4-hydroxybutyl acrylate monomer (4HBA) in beaker using glass 
pipette. 
a. Actual mass of Hydroxybutyl acrylate:   Opened:  
 Added @ : 
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4. Use syringe to add the monomer to the BENZENE solution in the Schlenk flask (under 
position N2 pressure). 
5. Connect the round bottom flask to the manifold and run N2 into it. 
6. Insert one end of the cannula into the RBF, then insert the other end through the top of the 
Schlenk flask and place it into the BENZENE+monomer mixture (do not disturb stir bar 
function). 
a. N2 should be bubbling through the reaction mixture as it heats up to help remove 
oxygen from the reaction solution. 
7. Place the Schlenk flask into the water bath and heat the BENZENE+monomer to 40°C 
before adding the initiator (wait ~10-15 mins). START:    STOP: 
8. Increase the N2 flow so 2-3 bubbles/second are coming out of the bubbler (3-5 psi) and 
quickly remove the septum from the top of the Schlenk flask. 
9. Add required g of the recrystallized AIBN initiator (1g 4HBA : 7.93mg AIBN). 
a. Make sure there is sufficient positive N2 pressure: bubbler = 2-3 bubbles/second 
b. Actual mass of AIBN added:   Opened:  
 Added @ : 
10. Put the rubber septum back on top of the Schlenk flask and reduce the N2 flow back to 1 
bubble/second (1-2 psi). 
11. Close the gray valve near the nitrogen inlet on the manifold and quickly turn off the N2 tank. 
Keep the manifold valve open to the N2 line (and to the bubbler). 
12. Increase the temperature of the hot water bath to 60°C and set timer for 6 hours. 
13. Once complete, turn off N2 tank and remove all connections to the Schlenk flask. 
14. Stop reaction @ :      Notes about product: 
 
Turning off the N2 gas and vacuum lines: 
1. Make sure all glassware connected to the nitrogen line are under N2. 
2. Turn off vacuum pump and remove the cold finger solution. 
3. Vent the vacuum line by opening one of the manifold ports. 
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4. Turn off the N2 gas. 
5. Carefully empty then clean, dry and put back the vacuum trap. 
 
Precipitating PHBA product out of solution: 
Often the product remains dissolved in the reaction mixture. Thus, a solution in which the product 
is not soluble needs to be added to precipitate it out before it can be collected. **Make sure Ether 
is cold! 
1. Place the Schlenk flask in an ice bath and allow to chill for 20 mins. 
2. Next, place the Schlenk flask on the stir plate, 400 rpm. 
3. Use the cannulation method described in the “BENZENE Extraction Protocol” described 
above to cannulate the desired amount of diethyl ether out of the original bottle (1g polymer 
= 100mL of diethyl ether). 
a. Actual volume of diethyl ether:   Opened: 
4. Pour the diethyl ether into a beaker in a cold bath and place a stir bar in the beaker. 
5. Use a pasteur pipette to slowly add the chilled reaction mixture to the cold diethyl ether. 
6. Allow the mixture to stir for ~5 mins. 
7. Pour off the liquid into hazardous waste, the solid remaining at the bottom of the beaker is 
the product. 
8. Before vacuum drying, put some of the product into a small pre-weighed vial and dissolve 
this to 5% wt in EtOH. 
a. Vial weight with label: 
 
Vacuum drying of product: 
Required: filter flask, closed rubber stopper, small vial that fits into the filter flask. 
1. Using a spatula, scrape all of the product into a small pre-weighed vial which fits into the 
filter flask. 
a. Vial weight with label: 
2. Carefully place the vial into the filter flask (the vial should remain uncapped). 
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3. Stopper the filter flask and connect the flask to the vacuum spout in the fume hood using 
reinforced tubing. 
4. Turn on the vacuum and leave on all night. START:    STOP: 
5. The next morning, turn off the vacuum, remove the vacuum tubing from the filter flask and 
cap the vial. 
 
Dissolving the PHBA Glue in DMF: 
Before the glue can be used to make sensors, the dried product must be dissolved in DMF to make 
a 5 wt% PHBA solution. 
1. Determine dry weight of PHBA product = x 
2. Use the following equation to solve for y (x = g of PHBA from previous step, y = g of DMF): 
a.  
3. In a closed bottle, add a stir bar to the 5 % wt solution and set the hot plate to 60°C for 5 
hrs. 
 
Using a syringe to remove up to 50mL of BENZENE: 
Required: gas tight glass syringe and flexible needle (12-24”) 
1. Dry the disassembled syringe and needle in the oven at 52°C for 24 hours before beginning 
this procedure. 
2. Secure the BENZENE bottle to a ring stand in the fume hood. 
3. Immediately upon removal from the oven, flush the needle and syringe with N2 10 times. 
a. A little grease should be used on the outside of the needle which interfaces with 
the Luer-lock connection on the syringe (take care to not contaminate the inner 
part of the needle).  
b. If a hose connection as depicted below is not available, use a rubber septum, dried 
and N2 purged round bottom flask. 
4. Fill the syringe halfway with N2 and insert into a rubber stopper for later use & to avoid 
contamination. 
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5. Insert a needle/hose (connected to the manifold) into the BENZENE bottle. 
6. Begin N2 flow to slightly pressurize the bottle. 
7. Insert the transfer needle/syringe into the bottle, and into the liquid. 
8. Fill up the syringe with slightly more than the required amount of BENZENE. 
a. Allow the N2 to move the syringe’s plunger, try not to pull it yourself (= bubbles). 
9. Next, pull the syringe out of the bottle’s liquid (but still in the bottle); 
10. Turn the syringe upside down and slowly push the plunger to expel gas bubbles and to 
obtain the desired amount of BENZENE. 
11. Holding the syringe in one hand and carefully holding the syringe’s needle with the other, 
pull the syringe needle out of the BENZENE bottle. 
12. Quickly and carefully insert the syringe into the septum of the dried and N2 purged Schlenk 
flask. 
13. Turn off the N2 pressurizing the BENZENE bottle. 
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APPENDIX C  
PROTOCOL: PROTEIN ENCAPSULATION AND MAKING MESOPOROUS CARBON 
SENSORS 
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Mesoporous Carbon Encapsulation Protocol: 4 Days 
Notes:  
• Need ~1mg of MPC powder for each zensor 
• Can’t make more than 5 zensors by hand at one; modify zensors in several batches of 5 if 
more are required 
 
Encapsulating the desired proteins into the MPC structure: Day 1 & 2 
20. Make the desired protein solution 
a. For PNMT enzyme, 250 µL of 1 mg/mL PNMT in PBS is prepared 
i. 200 µL for encapsulating, 50 µL is saved to run ABS in a microplate 
b. Actual mg/mL of Protein: 
c. Microplate: 
i. Place 50 µL each of PBS into 3 microplate wells 
ii. Place 50 µL of the protein solution into one well 
1. If there is enough of the protein solution, it is also recommended 
to do n=3 
iii. Parafilm and label the top of the microplate then store at 4°C until it is 
needed tomorrow 
21. Add the desired amount of MPC powder to the protein solution from step 1 (~1mg for each 
zensor to be made) 
a. For PNMT encapsulation, 4 mg of MP-C-46 was added to the 200 µL PNMT 
solution in a small glass vial 
b. Actual mg of MP-C-46: 
22. Allow the MPC+protein solution to shake in the 4°C environmental room (across the hall 
from the main lab door) for 24 hours using the orbital shaker set to 300rpm  
a. Make sure your vial is well-labelled 
b. Start:   / /  Stop:    / /   
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23. On the second day, 30 mins before the 24 hour shaking period is concluded on the orbital 
shaker, turn on the ultracentrifuge machine and set the chamber to 4°C 
24. Stop the mixing at 4°C and remove 50 µL of the MPC+protein solution supernatant and 
place in the microplate, discard the remaining solution 
25. Add 1 mL of DI water to the MPC+protein mixture and shake well by hand 
26. Divide the well-mixed MPC+protein-PBS solution into tubes for the ultracentrifuge (2 mL 
maximum/tube) 
27. Centrifuge the MPC+protein-PBS solution for 10 mins at 30,000 rpm 
28. Save 50 µL of the new PBS supernatant in the microplate and discard the remainder 
29. Add (1 mL/# of ultracentrifuge tubes used) of DI to each tube 
30. Repeat steps 7-10 so that the MPC+protein mixture is rinsed a total of three times with 
PBS 
a. On the last rinse: leave enough water in the ultracentrifuge tubes so it is easy to 
pour the MPC+protein mixture into a watch glass using a small spatula 
31. Weight of a 3” watch glass:   Weight of watch glass + MPC+protein mixture: 
32. Store the watch glass in the 4°C environmental room overnight (make sure there is a box 
with holes over the watch glass which permits airflow, but minimizes chances of 
contamination) 
a.  Start:     Stop: 
33. Run absorbance on the microplate at 235, 260 and 280 nm (spectra 5 nm steps), or 
alternatively use the BCA colorimetric protocol (separate document). 
a. Don’t use the plate blank; manually subtract the average of the PBS blanks when 
doing data analysis 
b. Calculate the PNMT enzyme (or other) protein concentration. 
i. If all went well, there should be little to no protein after encapsulation 
ii. It is recommended that you make a standard curve of known PNMT 
enzyme concentration (take the original concentration of protein in PBS 
(the pre-encapsulated protein solution) and dilute with PBS) 
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1. [mg protein/mL] @ 280 nm = A280/d (path length) Another Ref 
a. (if you’re not worried about nucleic acid contamination) 
 OR 
2. [mg protein/mL] = 1.55*(ABS280) – 0.76*(ABS260)  OR 
3. [mg protein/mL] = (A235 - A280)/2.51  
a. (J.R. Whitaker and P.E. Granum, Analytical Biochemistry 
109, 156-159(1980)) 
 
Making MPC+protein modified zensors: Days 3-4 
1. On the third day, run CV and EIS on all zensors to be used before modifying (use your 
usual redox probe) 
2. Weigh all zensors 
3. Re-weigh watch glass + MPC+protein mixture:   Weight of MPC+protein 
only: 
a. MPC+protein mixture must appear to be completely dry (scrape with spatula), or 
leave in 4°C for longer 
4. In the small marble mortar, weigh out enough MPC+protein powder to make 1-5 zensors 
(= 1-5 mg) 
a. Actual mg of MPC+protein = 
5. Calculate the mass of PHBA glue/binder required: 
a. Theoretical mg of 5% wt PHBA in ethanol required = 5 * (value from 4a above) = 
6. Using a glass Pasteur pipette, quickly add the required mg of PHBA to the MPC+protein in 
mortar 
a. Actual mg of PHBA: 
7. Using a spatula, quickly mix the glue+MPC+protein substance 
8. Using the same spatula, quickly and carefully deposit the glue+MPC+protein substance 
onto only the working electrode portion of the zensors 
a. Maximum of 5 zensors can be modified before the PHBA glue dries 
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b. If too much glue is used, wait a few seconds until the glue+MPC+protein is not 
extremely runny 
9. Clean the mortar and spatula with ethanol 
10. Repeat steps 4-9 until all the desired zensors are modified 
11. Bake the zensors: 
c. Zensors with glue+MPC, but no protein 
i. Bake at 90°C for 1.5 hours  Start:    Stop: 
a. Zensors with glue+MPC+protein: bake at 40°C for 2 hours, then place in 4°C 
overnight 
ii. Bake at 40°C    Start:    Stop: 
iii. Overnight 4°C storage   Start:    Stop: 
12. On the fourth day, re-weigh all zensors (post-bake weight)  
13. Quickly take pictures of the modified zensors (use LOTS of flash and a macro lens) 
14. Visual inspection: only keep zensors which do not have any MPC touching the counter or 
reference electrodes 
a. If all zensors are usable, keep ones which appear to have the same amount of 
MPC on them, or have similar geometries and sizes 
 
The modified zensors are now ready to run target concentration gradients and impedance 
measurements on.  
 
Recommendations for taking measurements: 
• Do not run CVs on glue+MPC+protein sensors; it is too risky to possibly fry your protein 
• As a rule of thumb, you can use the formal potential determined from Day 1’s CVs, or run 
Impedance-potential on a blank solution (50% ferricyanide, 50% PBS) 
Run at least 3 blanks before starting the target concentration gradient 
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APPENDIX D  
BCA COLORIMETRIC PROTEIN QUANTIFICATION ASSAY 
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BCA Protocol with TBI Antibodies 
 
Day 1- Prep & antibody encapsulation 
1. Mass out required MPC into eppendorfs 
2. Create antibody solutions 
a. See Appendix A 
3. On the microplates to be used and 3 cuvettes run ABS while empty, all containing DI, and 
all containing PBS 
a. For BCA: run 562, 900 & 975 nm 
b. For regular ABS: run 235-280 nm (in 5 nm steps) & at 900 & 975 nm 
c. 3 cuvettes: 562, 900 & 975 nm, 235-280 nm (in 5 nm steps) to use as baseline 
4. Determine amount of working solution required 
150uL sample minimum per well 
   
 
solutions to be tested for each marker: 
 
   450 uL after shake, before rinse 
     (rinse with 1 mL DI) 
   450 uL rinse 1 
   450 uL rinse 2 
   450 uL rinse 3 
      
   450 uL Antibody D1 
   450 uL Antibody D2 
   450 uL Antibody D3 
   450 uL Antibody D4 
   450 uL Antibody D5 
      
   4050 uL for each biomarker 
   
1620
0 uL for all biomarkers 
   4050 uL for 9 albumin standards (n=3) 
   
22.27
5 
m
L 
total req'd (incl. 10% fudge 
factor) 
22.
5 
mL of working solution 
needed  
Day 2- MPC encapsulation 
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1. Mix MPC with antibody solutions mixed yesterday 
2. Place the MPC+antibody solutions on the orbital shaker @ 300 rpm for 24 hrs in the 4°C 
room 
a. START =      STOP = 
3. Determine mixing quantities for working solution (this is stable for 24 hrs at room temp, 
so don’t make the solution too early) 
22.5 mL  of working solution needed 
     
Working soln = 25 MA: 24 MB: 1MC  
MA 11.250 mL 11250 uL 
MB 10.800 mL 10800 uL 
MC 0.450 mL 450 uL 
 
Day 3- Rinsing MPC and running ABS 
1. Turn oven on to 37°C 
2. Turn on ultracentrifuge (set to 4°C) 
3. Rinse MPC using 1 mL of DI according to the protein encapsulation protocol 
a. Save 3x 150 µL of each rinse and place into microplate as shown in Appendix B 
4. While waiting throughout rinsing protocol: 
a. Prepare the working solution 
b. Add antibody gradients to the microplates as shown in Appendix B 
5. When the microplates for the BCA protocol are filed, place them in the 37°C oven for 2 
hours (covered) 
a. START =    STOP = 
6. Run absorbance on all microplates after the plates have reached room temperature 
a. BCA plates at 562, 900 & 975 nm 
b. Regular ABS plates at 235-180 nm (in 5 nm steps), 900 & 975 nm 
7. Perform data analysis 
a. For BCA solutions, first create standard curves for the BSA and other antibody 
gradients, then use these to determine the protein concentrations in the rinses 
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b. For regular ABS, several techniques to analyze data are in the protein 
encapsulation protocol 
c. The PBS and DI solutions are for blank subtration 
d. The purpose of measuring at 900 and 975 nm is to determine path length (which 
changes based on the solution and its contents): 
i.  
ii. If cuvette is 1 cm (10 mm) 
iii. From Fischer Scientific: 
https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&
cad=rja&uact=8&ved=0ahUKEwju_NbIttnTAhVLxVQKHVcRA5cQFggjM
AA&url=https%3A%2F%2Fstatic.thermoscientific.com%2Fimages%2FD
20827~.pdf&usg=AFQjCNEdtmkRjjrEzGePtvH4_khNliCE9A&sig2=SyyO
QgmZqoJ5sBBfPwQ_2Q 
 
 APPENDIX A- Antibody Solns 
BSA (from BCA kit) 
Stock: 1mL @ 2 mg/mL= 2000 ug/mL 
Dilution Desired [BSA] (ug/mL) From previous Dilution (uL) PBS (uL) 
1 0 -- 600 
2 0.5 475 475 
3 1 380 570 
4 2.5 475 475 
5 5 475 475 
6 10 475 475 
7 20 475 475 
8 40 190 760 
9 200 95 855 
450 uL for plates +   
500 uL for next dilution = 950 
 
Anti-GFAP for antibody gradient 
 ug/mL From previous soln PBS 915 uL 
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Stock: 15 uL: uL: 455 uL needed for 3x @ 150 uL 
D5 5 305.00 610.00 460 uL to make next dilution 
D4 2.5 457.50 457.50   
D3 1.25 457.50 457.50   
D2 0.625 457.50 457.50   
D1 0.313 177.73 737.27   
Anti-GFAP for MPC 
495 uL of 5 ug/mL Anti-GFAP + 5mg MPC 
      
Stock: 15 ug/mL From stock PBS 
 
   165.00 330.00 
 
 
Anti-NSE for antibody gradient 
 ug/mL From previous soln PBS 610 uL 
Stock: 20 uL: uL: 455 uL needed for 3x @ 150 uL 
D5 20 610.00 0.00 155 uL to make next dilution 
D4 5 152.50 457.50   
D3 1.25 152.50 457.50   
D2 0.313 152.50 457.50   
D1 0.078 113.75 496.25   
Anti-NSE for MPC 
495 uL of 20 ug/mL Anti-NSE + 5mg MPC 
     
Stock: 20 ug/mL From stock PBS 
   495.00 0.00 
Anti-NSE for MPC (Regular method, not BCA) 
495 uL of 200 ug/mL anti-NSE + 5 mg MPC 
     
Stock 2100 ug/mL from stock PBS 
   47.14 447.86 
 
Anti-S-100B for antibody gradient 
 
ug/m
L 
From 
previou
s soln 
PBS 
 
45
5 
uL 
Stock
: 500 
uL: uL: 
 
45
5 
uL needed for 3x @ 150 
uL 
D5 2.5 
2.28 
452.7
3 from 500 ug/mL 0 uL to make next dilution 
D4 1.429 
65.00 
390.0
0 make from 10 ug/mL   
D3 0.816 
49.52 
405.4
8 
make from 7.5 
ug/mL   
D2 0.466 
84.90 
370.1
0 
make from 2.5 
ug/mL   
D1 0.267 
48.51 
406.4
9 
make from 2.5 
ug/mL   
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Anti-S-100B for MPC 
495 uL of 2.5 ug/mL Anti-S-100B + 5mg MPC 
      
Stock: 500 ug/mL From stock PBS 
 
   2.48 492.53 
 
 
Anti-TNF-a for antibody gradient 
 
ug/m
L 
From 
previou
s soln 
PBS 
 
45
5 
uL 
Stock
:  
uL: uL: 
 
45
5 
uL needed for 3x @ 150 
uL 
D5 5 
151.67 
303.3
3 
make from old 15 
ug/mL 0 uL to make next dilution 
D4 2.5 
227.50 
227.5
0 make from old 5 ug/mL   
D3 1.25 
113.75 
341.2
5 make from old 5 ug/mL   
D2 0.625 
56.88 
398.1
3 make from old 5 ug/mL   
D1 
0.312
5 
28.44 
426.5
6 make from old 5 ug/mL   
 
Anti-TNF-a for MPC 
495 uL of 5 ug/mL Anti-TNF-a + 5mg MPC 
      
Stock: 500 ug/mL From stock PBS 
 
   4.95 490.05 
 
 
APPENDIX B- Microplate Design 
 
 
Plate 1- BCA
1 2 3 4 5 6 7 8 9 10 11 12
A PBS PBS PBS DI DI DI
DI w/Working 
soln
DI w/Working 
soln
DI w/Working 
soln
Anti-NSE D1 Anti-NSE D1
B BSA D0 BSA D1 BSA D2 BSA D3 BSA D4 BSA D5 BSA D6 BSA D7 BSA D8 BSA D9 Anti-NSE D2 Anti-NSE D2
C BSA D0 BSA D1 BSA D2 BSA D3 BSA D4 BSA D5 BSA D6 BSA D7 BSA D8 BSA D9 Anti-NSE D3 Anti-NSE D3
D Anti-NSE D1 Anti-NSE D2 Anti-NSE D3 Anti-NSE D4 Anti-NSE D5 Anti-S-100B D1 Anti-S-100B D2 Anti-S-100B D3 Anti-S-100B D4 Anti-S-100B D5 Anti-NSE D4 Anti-NSE D4
E Anti-S-100B D1 Anti-S-100B D2 Anti-S-100B D3 Anti-S-100B D4 Anti-S-100B D5 Anti-S-100B D1 Anti-S-100B D2 Anti-S-100B D3 Anti-S-100B D4 Anti-S-100B D5 Anti-NSE D5 Anti-NSE D5
F NSE Soln1 NSE Soln1 NSE Soln1 NSE Soln2 NSE Soln2 NSE Soln2 NSE Soln3 NSE Soln3 NSE Soln3 NSE Soln4 NSE Soln4 NSE Soln4
G S-100B Soln1 S-100B Soln1 S-100B Soln1 S-100B Soln2 S-100B Soln2 S-100B Soln2 S-100B Soln3 S-100B Soln3 S-100B Soln3 S-100B Soln4 S-100B Soln4 S-100B Soln4
H
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Soln1= After shaking, before centrifuge; Soln2= Rinse 1, Soln3= Rinse 2; Soln4= Rinse 3 
 
Plate 2- BCA
1 2 3 4 5 6 7 8 9 10 11 12
A PBS PBS PBS DI DI DI Anti-GFAP D1 Anti-GFAP D1
B BSA D0 BSA D1 BSA D2 BSA D3 BSA D4 BSA D5 BSA D6 BSA D7 BSA D8 BSA D9 Anti-GFAP D2 Anti-GFAP D2
C Anti-GFAP D1 Anti-GFAP D2 Anti-GFAP D3 Anti-GFAP D4 Anti-GFAP D5 Anti-TNFa D1 Anti-TNFa D2 Anti-TNFa D3 Anti-TNFa D4 Anti-TNFa D5 Anti-GFAP D3 Anti-GFAP D3
D Anti-TNFa D1 Anti-TNFa D2 Anti-TNFa D3 Anti-TNFa D4 Anti-TNFa D5 Anti-TNFa D1 Anti-TNFa D2 Anti-TNFa D3 Anti-TNFa D4 Anti-TNFa D5 Anti-GFAP D4 Anti-GFAP D4
E Anti-GFAP D5 Anti-GFAP D5
F GFAP Soln1 GFAP Soln1 GFAP Soln1 GFAP Soln2 GFAP Soln2 GFAP Soln2 GFAP Soln3 GFAP Soln3 GFAP Soln3 GFAP Soln4 GFAP Soln4 GFAP Soln4
G TNFa Soln1 TNFa Soln1 TNFa Soln1 TNFa Soln2 TNFa Soln2 TNFa Soln2 TNFa Soln3 TNFa Soln3 TNFa Soln3 TNFa Soln4 TNFa Soln4 TNFa Soln4
H
Plate 3- Reg ABS
1 2 3 4 5 6 7 8 9 10 11 12
A PBS PBS PBS DI DI DI
B NSE Soln1 NSE Soln1 NSE Soln1 NSE Soln2 NSE Soln2 NSE Soln2 NSE Soln3 NSE Soln3 NSE Soln3 NSE Soln4 NSE Soln4 NSE Soln4
C
D
E
F
G
H
